PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23213321-7	2012	In prostate cancer, PPARgamma ligands such as troglitazone and 15d-PGJ(2) have also shown to inhibit tumor growth.	15d-pgj	63-70	peroxisome proliferator activated receptor gamma	Homo sapiens	20-29
24337644-8	2014	Furthermore, 15d-PGJ(2) and CV3988 enhanced the PAF-AH activity.	15d-pgj	13-20	phospholipase A2 group VII	Homo sapiens	48-54
24337644-9	2014	Additionally, 15d-PGJ(2) inhibited the phosphorylation of the extracellular signal-regulated kinase (ERK) and the activation of nuclear transcription factor-kappaB (NF-kappaB).	15d-pgj	14-21	mitogen-activated protein kinase 1	Homo sapiens	62-99
24337644-5	2014	The activity of PAF-acetylhydrolase (PAF-AH) was assayed by treatment with 15d-PGJ(2) and CV3988 in the presence of LPS.	15d-pgj	75-82	phospholipase A2 group VII	Homo sapiens	16-35
24337644-5	2014	The activity of PAF-acetylhydrolase (PAF-AH) was assayed by treatment with 15d-PGJ(2) and CV3988 in the presence of LPS.	15d-pgj	75-82	phospholipase A2 group VII	Homo sapiens	37-43
24337644-6	2014	15d-PGJ(2) and CV3988 inhibited the LPS-induced mRNA expression and protein production of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) in ARPE19 cells.	15d-pgj	0-7	interleukin 6	Homo sapiens	90-103
24337644-9	2014	Additionally, 15d-PGJ(2) inhibited the phosphorylation of the extracellular signal-regulated kinase (ERK) and the activation of nuclear transcription factor-kappaB (NF-kappaB).	15d-pgj	14-21	mitogen-activated protein kinase 1	Homo sapiens	101-104
24337644-6	2014	15d-PGJ(2) and CV3988 inhibited the LPS-induced mRNA expression and protein production of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) in ARPE19 cells.	15d-pgj	0-7	interleukin 6	Homo sapiens	105-109
24337644-9	2014	Additionally, 15d-PGJ(2) inhibited the phosphorylation of the extracellular signal-regulated kinase (ERK) and the activation of nuclear transcription factor-kappaB (NF-kappaB).	15d-pgj	14-21	nuclear factor kappa B subunit 1	Homo sapiens	128-163
24337644-9	2014	Additionally, 15d-PGJ(2) inhibited the phosphorylation of the extracellular signal-regulated kinase (ERK) and the activation of nuclear transcription factor-kappaB (NF-kappaB).	15d-pgj	14-21	nuclear factor kappa B subunit 1	Homo sapiens	165-174
23333326-3	2013	We determined the effects of 15d-PGJ(2) on IL-13 expression in the Jurkat E6.1 T-cell line and in peripheral blood mononuclear cells.	15d-pgj	29-36	interleukin 13	Homo sapiens	43-48
24337644-6	2014	15d-PGJ(2) and CV3988 inhibited the LPS-induced mRNA expression and protein production of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) in ARPE19 cells.	15d-pgj	0-7	C-C motif chemokine ligand 2	Homo sapiens	112-146
24337644-6	2014	15d-PGJ(2) and CV3988 inhibited the LPS-induced mRNA expression and protein production of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) in ARPE19 cells.	15d-pgj	0-7	C-C motif chemokine ligand 2	Homo sapiens	148-153
24337644-6	2014	15d-PGJ(2) and CV3988 inhibited the LPS-induced mRNA expression and protein production of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) in ARPE19 cells.	15d-pgj	0-7	intercellular adhesion molecule 1	Homo sapiens	160-193
24337644-6	2014	15d-PGJ(2) and CV3988 inhibited the LPS-induced mRNA expression and protein production of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) in ARPE19 cells.	15d-pgj	0-7	intercellular adhesion molecule 1	Homo sapiens	195-201
23333326-7	2013	Collectively, these results demonstrate the potential of 15d-PGJ(2) in attenuating expression and production of IL-13 in activated T cells.	15d-pgj	57-64	interleukin 13	Homo sapiens	112-117
22481026-8	2012	CFTR(inh172) also altered the release of inflammation mediators PGE(2) and IL-8, and this effect was blunted by exogenous 15d-PGJ(2).	15d-pgj	122-129	CF transmembrane conductance regulator	Homo sapiens	0-4
22564409-6	2012	Pretreatment with 15d-PGJ(2)-NC (100 and 1000 pg/TMJ), but not unloaded 15d-PGJ(2), was found to significantly decrease the release of IL-1beta cytokine and the animals" nociceptive behavioral response induced by intra-TMJ injection of formalin.	15d-pgj	18-25	interleukin 1 beta	Rattus norvegicus	135-143
23192983-5	2013	However, exposure of prostate cancer cells to 15d-PGJ(2) does not simply evoke a general inhibition of nuclear receptor activity or transcription because under the same conditions, peroxisome proliferator-activated receptor-gamma is activated by 15d-PGJ(2).	15d-pgj	46-53	peroxisome proliferator activated receptor gamma	Homo sapiens	181-229
23192983-5	2013	However, exposure of prostate cancer cells to 15d-PGJ(2) does not simply evoke a general inhibition of nuclear receptor activity or transcription because under the same conditions, peroxisome proliferator-activated receptor-gamma is activated by 15d-PGJ(2).	15d-pgj	246-253	peroxisome proliferator activated receptor gamma	Homo sapiens	181-229
23192983-6	2013	Moreover, 15d-PGJ(2) rapidly triggers modifications of AR by small ubiquitin-related modifier-2/3 (SUMO-2/3), which may modulate the repressing effect of 15d-PGJ(2) on AR-dependent transcription.	15d-pgj	10-17	androgen receptor	Homo sapiens	55-57
23192983-6	2013	Moreover, 15d-PGJ(2) rapidly triggers modifications of AR by small ubiquitin-related modifier-2/3 (SUMO-2/3), which may modulate the repressing effect of 15d-PGJ(2) on AR-dependent transcription.	15d-pgj	10-17	small ubiquitin like modifier 2	Homo sapiens	61-97
23192983-6	2013	Moreover, 15d-PGJ(2) rapidly triggers modifications of AR by small ubiquitin-related modifier-2/3 (SUMO-2/3), which may modulate the repressing effect of 15d-PGJ(2) on AR-dependent transcription.	15d-pgj	10-17	small ubiquitin like modifier 2	Homo sapiens	99-107
23192983-6	2013	Moreover, 15d-PGJ(2) rapidly triggers modifications of AR by small ubiquitin-related modifier-2/3 (SUMO-2/3), which may modulate the repressing effect of 15d-PGJ(2) on AR-dependent transcription.	15d-pgj	10-17	androgen receptor	Homo sapiens	168-170
23192983-6	2013	Moreover, 15d-PGJ(2) rapidly triggers modifications of AR by small ubiquitin-related modifier-2/3 (SUMO-2/3), which may modulate the repressing effect of 15d-PGJ(2) on AR-dependent transcription.	15d-pgj	154-161	androgen receptor	Homo sapiens	55-57
23192983-6	2013	Moreover, 15d-PGJ(2) rapidly triggers modifications of AR by small ubiquitin-related modifier-2/3 (SUMO-2/3), which may modulate the repressing effect of 15d-PGJ(2) on AR-dependent transcription.	15d-pgj	154-161	small ubiquitin like modifier 2	Homo sapiens	61-97
23192983-6	2013	Moreover, 15d-PGJ(2) rapidly triggers modifications of AR by small ubiquitin-related modifier-2/3 (SUMO-2/3), which may modulate the repressing effect of 15d-PGJ(2) on AR-dependent transcription.	15d-pgj	154-161	small ubiquitin like modifier 2	Homo sapiens	99-107
23192983-6	2013	Moreover, 15d-PGJ(2) rapidly triggers modifications of AR by small ubiquitin-related modifier-2/3 (SUMO-2/3), which may modulate the repressing effect of 15d-PGJ(2) on AR-dependent transcription.	15d-pgj	154-161	androgen receptor	Homo sapiens	168-170
23192983-7	2013	Chromatin immunoprecipitation assays indicate that the inhibitory effect of 15d-PGJ(2) on FKBP51 and TMPRSS2 expression occurs in parallel with the inhibition of the AR binding to the regulatory regions of these genes.	15d-pgj	76-83	transmembrane serine protease 2	Homo sapiens	101-108
23192983-7	2013	Chromatin immunoprecipitation assays indicate that the inhibitory effect of 15d-PGJ(2) on FKBP51 and TMPRSS2 expression occurs in parallel with the inhibition of the AR binding to the regulatory regions of these genes.	15d-pgj	76-83	androgen receptor	Homo sapiens	166-168
23192983-9	2013	In conclusion, our results identify 15d-PGJ(2) as a potent and direct inhibitor of androgen signaling, suggesting novel possibilities in restricting the AR activity in prostate cancer cells.	15d-pgj	36-43	androgen receptor	Homo sapiens	153-155
23372817-6	2013	Treatment with PPAR-gamma agonist 15d-PGJ(2) decreased not only autophagic-related protein expression in ischemic cortex, but also immunoreactivity of LC3 and cathepsin-B in neurons.	15d-pgj	34-41	peroxisome proliferator activated receptor gamma	Homo sapiens	15-25
23372817-6	2013	Treatment with PPAR-gamma agonist 15d-PGJ(2) decreased not only autophagic-related protein expression in ischemic cortex, but also immunoreactivity of LC3 and cathepsin-B in neurons.	15d-pgj	34-41	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	151-154
23372817-6	2013	Treatment with PPAR-gamma agonist 15d-PGJ(2) decreased not only autophagic-related protein expression in ischemic cortex, but also immunoreactivity of LC3 and cathepsin-B in neurons.	15d-pgj	34-41	cathepsin B	Homo sapiens	159-170
23372817-8	2013	These results indicate that PPAR-gamma agonist 15d-PGJ(2) exerts neuroprotection by inhibiting neuronal autophagy after cerebral I/R injury.	15d-pgj	47-54	peroxisome proliferator activated receptor gamma	Homo sapiens	28-38
22560326-5	2012	Our results showed that 15d-PGJ(2) inhibited the phagocytic activity and cell proliferation in a dose-dependent manner, and suppressed proinflammatory cytokines expression, such as tumor necrosis factor-alpha, transforming growth factor-beta1, interleukin-6, and monocyte chemotactic protein-1.	15d-pgj	24-31	tumor necrosis factor	Mus musculus	181-242
22560326-5	2012	Our results showed that 15d-PGJ(2) inhibited the phagocytic activity and cell proliferation in a dose-dependent manner, and suppressed proinflammatory cytokines expression, such as tumor necrosis factor-alpha, transforming growth factor-beta1, interleukin-6, and monocyte chemotactic protein-1.	15d-pgj	24-31	interleukin 6	Mus musculus	244-257
22560326-5	2012	Our results showed that 15d-PGJ(2) inhibited the phagocytic activity and cell proliferation in a dose-dependent manner, and suppressed proinflammatory cytokines expression, such as tumor necrosis factor-alpha, transforming growth factor-beta1, interleukin-6, and monocyte chemotactic protein-1.	15d-pgj	24-31	chemokine (C-C motif) ligand 2	Mus musculus	263-293
22481026-11	2012	In Calu-3 cells, 15d-PGJ(2) production resulted from COX-2-regulated COX-1 activation, while CFTR(inh172)-induced alteration of 15d-PGJ(2) synthesis involved both decreased expression of PGD synthase and disturbed relationships between both COXs.	15d-pgj	17-24	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	53-58
22481026-11	2012	In Calu-3 cells, 15d-PGJ(2) production resulted from COX-2-regulated COX-1 activation, while CFTR(inh172)-induced alteration of 15d-PGJ(2) synthesis involved both decreased expression of PGD synthase and disturbed relationships between both COXs.	15d-pgj	17-24	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	69-74
22481026-11	2012	In Calu-3 cells, 15d-PGJ(2) production resulted from COX-2-regulated COX-1 activation, while CFTR(inh172)-induced alteration of 15d-PGJ(2) synthesis involved both decreased expression of PGD synthase and disturbed relationships between both COXs.	15d-pgj	128-135	CF transmembrane conductance regulator	Homo sapiens	93-97
22481026-8	2012	CFTR(inh172) also altered the release of inflammation mediators PGE(2) and IL-8, and this effect was blunted by exogenous 15d-PGJ(2).	15d-pgj	122-129	C-X-C motif chemokine ligand 8	Homo sapiens	75-79
22219346-9	2012	Interestingly, pretreatment of mice with a peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist before 15d-PGJ(2) administration completely abrogated its protective effect against influenza infection.	15d-pgj	122-129	peroxisome proliferator activated receptor gamma	Mus musculus	43-91
22444276-11	2012	However, the cyclooxygenase (COX)-2 inhibitor NS-398 blocked the production of 15d-PGJ(2) in OGD-exposed neurons with HBO preconditioning.	15d-pgj	79-86	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-35
22444276-13	2012	These results demonstrate that HBO preconditioning has directly beneficial effects on ODG-exposed cortical neurons by the activation of PPAR gamma subsequent to the production of 15d-PGJ(2), which in turn increases the downstream antioxidant enzymatic activities.	15d-pgj	179-186	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	136-146
22387200-9	2012	15d-PGJ(2) was observed to induce p65 glutathionylation and is suppressed by a GSH synthesis inhibitor, buthionine sulfoximine, by catalase, and by Nrf2 siRNA molecules.	15d-pgj	0-7	RELA proto-oncogene, NF-kB subunit	Homo sapiens	34-37
22387200-9	2012	15d-PGJ(2) was observed to induce p65 glutathionylation and is suppressed by a GSH synthesis inhibitor, buthionine sulfoximine, by catalase, and by Nrf2 siRNA molecules.	15d-pgj	0-7	NFE2 like bZIP transcription factor 2	Homo sapiens	148-152
22387200-10	2012	Our results thus indicate that the GSH/ROS-dependent glutathionylation of p65 is likely to be responsible for 15d-PGJ(2)-mediated NF-kappaB inactivation and for the enhanced inhibitory effects of 15d-PGJ(2) on TNFalpha-treated ECs.	15d-pgj	110-117	RELA proto-oncogene, NF-kB subunit	Homo sapiens	74-77
22387200-10	2012	Our results thus indicate that the GSH/ROS-dependent glutathionylation of p65 is likely to be responsible for 15d-PGJ(2)-mediated NF-kappaB inactivation and for the enhanced inhibitory effects of 15d-PGJ(2) on TNFalpha-treated ECs.	15d-pgj	110-117	tumor necrosis factor	Homo sapiens	210-218
22387200-10	2012	Our results thus indicate that the GSH/ROS-dependent glutathionylation of p65 is likely to be responsible for 15d-PGJ(2)-mediated NF-kappaB inactivation and for the enhanced inhibitory effects of 15d-PGJ(2) on TNFalpha-treated ECs.	15d-pgj	196-203	RELA proto-oncogene, NF-kB subunit	Homo sapiens	74-77
22387200-10	2012	Our results thus indicate that the GSH/ROS-dependent glutathionylation of p65 is likely to be responsible for 15d-PGJ(2)-mediated NF-kappaB inactivation and for the enhanced inhibitory effects of 15d-PGJ(2) on TNFalpha-treated ECs.	15d-pgj	196-203	tumor necrosis factor	Homo sapiens	210-218
22293191-5	2012	Nevertheless, the addition of 15d-PGJ(2) to NaBut-stimulated cells significantly upregulated MDR1 mRNA expression and P-gp expression and functionality, leading to an important diminution of saquinavir accumulation by these cells.	15d-pgj	30-37	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
22219346-9	2012	Interestingly, pretreatment of mice with a peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist before 15d-PGJ(2) administration completely abrogated its protective effect against influenza infection.	15d-pgj	122-129	peroxisome proliferator activated receptor gamma	Mus musculus	93-102
21745193-10	2012	In human monocyte/macrophages, MPs as well as rosiglitazone and 15d-PGJ(2) induced PPARgamma protein expression.	15d-pgj	64-71	peroxisome proliferator activated receptor gamma	Homo sapiens	83-92
21924248-5	2011	Knockdown of peroxisome proliferator-activated receptor-gamma (PPARgamma) with siRNA abolished pioglitazone- and 15d-PGJ(2)-induced VLDLR expression and simultaneously reduced VLDL uptake in adipocytes.	15d-pgj	113-120	peroxisome proliferator activated receptor gamma	Mus musculus	13-61
22192475-1	2012	We evaluate the immunomodulation of Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists 15d-PGJ(2) and rosiglitazone (RGZ) in a model of chronic eosinophilia.	15d-pgj	107-114	peroxisome proliferator activated receptor gamma	Mus musculus	86-96
22192475-3	2012	The synthesis of IL-5 was decreased after the treatment with 15d-PGJ(2) and RGZ corroborating with the eosinophil migration inhibition.	15d-pgj	61-68	interleukin 5	Mus musculus	17-21
22178289-9	2012	Both electrophilic PPARgamma ligands (CDDO-Me and 15d-PGJ(2)) potently inhibited TGFbeta-induced myofibroblast differentiation, but PPARgamma was only partially required for inhibition of myofibroblast differentiation by either agent.	15d-pgj	50-57	peroxisome proliferator activated receptor gamma	Homo sapiens	19-28
22178289-9	2012	Both electrophilic PPARgamma ligands (CDDO-Me and 15d-PGJ(2)) potently inhibited TGFbeta-induced myofibroblast differentiation, but PPARgamma was only partially required for inhibition of myofibroblast differentiation by either agent.	15d-pgj	50-57	transforming growth factor beta 1	Homo sapiens	81-88
22178289-11	2012	CDDO-Me and 15d-PGJ(2) are strong inhibitors of TGFbeta-induced corneal fibroblast to myofibroblast differentiation in vitro, suggesting this class of agents as potential novel therapies for corneal scarring warranting further study in pre-clinical animal models.	15d-pgj	12-19	transforming growth factor beta 1	Homo sapiens	48-55
22309084-4	2012	Interestingly, the switch from stimulatory to inhibitory actions occurred within a narrow concentration range and correlated with the ability of 15d-PGJ(2) to induce heme oxygenase 1 and gamma-GCSm expression.	15d-pgj	145-152	heme oxygenase 1	Homo sapiens	166-182
22309084-6	2012	Indeed, the levels of the master regulator of the antioxidant response Nrf2 increased upon treatment with concentrations of 15d-PGJ(2) above 5 muM, an effect that could not be mimicked by 9,10-dihydro-15d-PGJ(2).	15d-pgj	124-131	NFE2 like bZIP transcription factor 2	Homo sapiens	71-75
22192475-0	2012	PPAR-gamma agonists, mainly 15d-PGJ(2), reduce eosinophil recruitment following allergen challenge.	15d-pgj	28-35	peroxisome proliferator activated receptor gamma	Mus musculus	0-10
22192475-1	2012	We evaluate the immunomodulation of Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists 15d-PGJ(2) and rosiglitazone (RGZ) in a model of chronic eosinophilia.	15d-pgj	107-114	peroxisome proliferator activated receptor gamma	Mus musculus	36-84
22991494-7	2012	15d-PGJ(2) induced chromatin-condensation and elevated caspase-3 activity, and the cell viability was restored by co-treatment with a pan-caspase inhibitor, Z-VAD-FMK, indicating the involvement of caspase-dependent apoptosis.	15d-pgj	0-7	caspase 3	Homo sapiens	55-64
22991494-8	2012	The cytotoxicity was not impaired by a PPARgamma inhibitor, GW9662, suggesting that 15d-PGJ(2) exerted the cytotoxicity in a PPARgamma-independent manner.	15d-pgj	84-91	peroxisome proliferator activated receptor gamma	Homo sapiens	125-134
22991494-10	2012	15d-PGJ(2) also increased the expression levels of phospho-c-Jun N terminal kinase (JNK) in Caki-2 cells, and decreased those of phospho-Akt in 786-O cells, indicating that the JNK MAPK and the Akt pathways participated in the anticancer effects of 15d-PGJ(2) in some cell lines.	15d-pgj	0-7	mitogen-activated protein kinase 8	Homo sapiens	51-82
22991494-10	2012	15d-PGJ(2) also increased the expression levels of phospho-c-Jun N terminal kinase (JNK) in Caki-2 cells, and decreased those of phospho-Akt in 786-O cells, indicating that the JNK MAPK and the Akt pathways participated in the anticancer effects of 15d-PGJ(2) in some cell lines.	15d-pgj	0-7	mitogen-activated protein kinase 8	Homo sapiens	84-87
22991494-10	2012	15d-PGJ(2) also increased the expression levels of phospho-c-Jun N terminal kinase (JNK) in Caki-2 cells, and decreased those of phospho-Akt in 786-O cells, indicating that the JNK MAPK and the Akt pathways participated in the anticancer effects of 15d-PGJ(2) in some cell lines.	15d-pgj	0-7	AKT serine/threonine kinase 1	Homo sapiens	137-140
22991494-10	2012	15d-PGJ(2) also increased the expression levels of phospho-c-Jun N terminal kinase (JNK) in Caki-2 cells, and decreased those of phospho-Akt in 786-O cells, indicating that the JNK MAPK and the Akt pathways participated in the anticancer effects of 15d-PGJ(2) in some cell lines.	15d-pgj	0-7	mitogen-activated protein kinase 8	Homo sapiens	177-180
22991494-10	2012	15d-PGJ(2) also increased the expression levels of phospho-c-Jun N terminal kinase (JNK) in Caki-2 cells, and decreased those of phospho-Akt in 786-O cells, indicating that the JNK MAPK and the Akt pathways participated in the anticancer effects of 15d-PGJ(2) in some cell lines.	15d-pgj	0-7	AKT serine/threonine kinase 1	Homo sapiens	194-197
22991494-10	2012	15d-PGJ(2) also increased the expression levels of phospho-c-Jun N terminal kinase (JNK) in Caki-2 cells, and decreased those of phospho-Akt in 786-O cells, indicating that the JNK MAPK and the Akt pathways participated in the anticancer effects of 15d-PGJ(2) in some cell lines.	15d-pgj	249-256	mitogen-activated protein kinase 8	Homo sapiens	177-180
22991494-11	2012	CONCLUSION: 15d-PGJ(2) exerted cytotoxic effects accompanying caspase-dependent apoptosis, and this effect was elicited in a PPARgamma-independent manner in three cell lines.	15d-pgj	12-19	peroxisome proliferator activated receptor gamma	Homo sapiens	125-134
22991494-12	2012	In addition, the JNK MAPK and Akt pathway was involved in the cytotoxicity of 15d-PGJ(2) to some extent in some cell line.	15d-pgj	78-85	mitogen-activated protein kinase 8	Homo sapiens	17-20
22991494-12	2012	In addition, the JNK MAPK and Akt pathway was involved in the cytotoxicity of 15d-PGJ(2) to some extent in some cell line.	15d-pgj	78-85	AKT serine/threonine kinase 1	Homo sapiens	30-33
21924248-5	2011	Knockdown of peroxisome proliferator-activated receptor-gamma (PPARgamma) with siRNA abolished pioglitazone- and 15d-PGJ(2)-induced VLDLR expression and simultaneously reduced VLDL uptake in adipocytes.	15d-pgj	113-120	peroxisome proliferator activated receptor gamma	Mus musculus	63-72
21924248-5	2011	Knockdown of peroxisome proliferator-activated receptor-gamma (PPARgamma) with siRNA abolished pioglitazone- and 15d-PGJ(2)-induced VLDLR expression and simultaneously reduced VLDL uptake in adipocytes.	15d-pgj	113-120	very low density lipoprotein receptor	Mus musculus	132-137
21924248-8	2011	Sequence analysis revealed the presence of a putative PPARgamma responsive sequence (PPRE) within the vldlr promoter, which is responsive to natural (15d-PGJ(2)) and synthetic (pioglitazone) PPARgamma agonists.	15d-pgj	150-157	peroxisome proliferator activated receptor gamma	Mus musculus	54-63
21924248-8	2011	Sequence analysis revealed the presence of a putative PPARgamma responsive sequence (PPRE) within the vldlr promoter, which is responsive to natural (15d-PGJ(2)) and synthetic (pioglitazone) PPARgamma agonists.	15d-pgj	150-157	very low density lipoprotein receptor	Mus musculus	102-107
21728338-7	2011	Pharmacologic inhibition or siRNA knockdown of Akt, the target of phosphoinositide 3-kinase (PI3-K), attenuated 15d-PGJ(2)-induced Nrf2 activation and GCLC expression, and NAC treatment inhibited phosphorylation of Akt, and subsequently Nrf2 activation and GCLC upregulation.	15d-pgj	112-119	AKT serine/threonine kinase 1	Homo sapiens	215-218
21780947-6	2011	Thirty-eight PPARgamma direct target genes were found to be involved in prostate cancer and two key (hub) PPARgamma direct target genes, PRKCZ and PGK1, were experimentally validated to be repressed upon PPARgamma activation by its natural ligand, 15d-PGJ(2) in three prostrate cancer cell lines.	15d-pgj	248-255	peroxisome proliferator activated receptor gamma	Homo sapiens	106-115
21780947-6	2011	Thirty-eight PPARgamma direct target genes were found to be involved in prostate cancer and two key (hub) PPARgamma direct target genes, PRKCZ and PGK1, were experimentally validated to be repressed upon PPARgamma activation by its natural ligand, 15d-PGJ(2) in three prostrate cancer cell lines.	15d-pgj	248-255	protein kinase C zeta	Homo sapiens	137-142
21780947-6	2011	Thirty-eight PPARgamma direct target genes were found to be involved in prostate cancer and two key (hub) PPARgamma direct target genes, PRKCZ and PGK1, were experimentally validated to be repressed upon PPARgamma activation by its natural ligand, 15d-PGJ(2) in three prostrate cancer cell lines.	15d-pgj	248-255	phosphoglycerate kinase 1	Homo sapiens	147-151
21780947-6	2011	Thirty-eight PPARgamma direct target genes were found to be involved in prostate cancer and two key (hub) PPARgamma direct target genes, PRKCZ and PGK1, were experimentally validated to be repressed upon PPARgamma activation by its natural ligand, 15d-PGJ(2) in three prostrate cancer cell lines.	15d-pgj	248-255	peroxisome proliferator activated receptor gamma	Homo sapiens	106-115
21728338-3	2011	15d-PGJ(2) treatment caused nuclear translocation and transactivation of Nrf2, a redox-sensitive transcription factor responsible for induced expression of antioxidant and other cytoprotective genes.	15d-pgj	0-7	NFE2 like bZIP transcription factor 2	Homo sapiens	73-77
21728338-7	2011	Pharmacologic inhibition or siRNA knockdown of Akt, the target of phosphoinositide 3-kinase (PI3-K), attenuated 15d-PGJ(2)-induced Nrf2 activation and GCLC expression, and NAC treatment inhibited phosphorylation of Akt, and subsequently Nrf2 activation and GCLC upregulation.	15d-pgj	112-119	AKT serine/threonine kinase 1	Homo sapiens	47-50
21728338-7	2011	Pharmacologic inhibition or siRNA knockdown of Akt, the target of phosphoinositide 3-kinase (PI3-K), attenuated 15d-PGJ(2)-induced Nrf2 activation and GCLC expression, and NAC treatment inhibited phosphorylation of Akt, and subsequently Nrf2 activation and GCLC upregulation.	15d-pgj	112-119	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	66-91
21728338-7	2011	Pharmacologic inhibition or siRNA knockdown of Akt, the target of phosphoinositide 3-kinase (PI3-K), attenuated 15d-PGJ(2)-induced Nrf2 activation and GCLC expression, and NAC treatment inhibited phosphorylation of Akt, and subsequently Nrf2 activation and GCLC upregulation.	15d-pgj	112-119	NFE2 like bZIP transcription factor 2	Homo sapiens	131-135
21728338-14	2011	In conclusion, MRP1 mediates Nrf2-dependent up-regulation of GCLC in 15d-PGJ(2)-treated MCF-7 cells, possibly via a putative recycling loop of 15d-PGJ(2)-GSH conjugation.	15d-pgj	143-150	ATP binding cassette subfamily C member 1	Homo sapiens	15-19
21728338-14	2011	In conclusion, MRP1 mediates Nrf2-dependent up-regulation of GCLC in 15d-PGJ(2)-treated MCF-7 cells, possibly via a putative recycling loop of 15d-PGJ(2)-GSH conjugation.	15d-pgj	143-150	NFE2 like bZIP transcription factor 2	Homo sapiens	29-33
21728338-7	2011	Pharmacologic inhibition or siRNA knockdown of Akt, the target of phosphoinositide 3-kinase (PI3-K), attenuated 15d-PGJ(2)-induced Nrf2 activation and GCLC expression, and NAC treatment inhibited phosphorylation of Akt, and subsequently Nrf2 activation and GCLC upregulation.	15d-pgj	112-119	NFE2 like bZIP transcription factor 2	Homo sapiens	237-241
21728338-7	2011	Pharmacologic inhibition or siRNA knockdown of Akt, the target of phosphoinositide 3-kinase (PI3-K), attenuated 15d-PGJ(2)-induced Nrf2 activation and GCLC expression, and NAC treatment inhibited phosphorylation of Akt, and subsequently Nrf2 activation and GCLC upregulation.	15d-pgj	112-119	glutamate-cysteine ligase catalytic subunit	Homo sapiens	257-261
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	10-17	glutamate-cysteine ligase catalytic subunit	Homo sapiens	29-33
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	10-17	ATP binding cassette subfamily C member 1	Homo sapiens	104-108
21728338-14	2011	In conclusion, MRP1 mediates Nrf2-dependent up-regulation of GCLC in 15d-PGJ(2)-treated MCF-7 cells, possibly via a putative recycling loop of 15d-PGJ(2)-GSH conjugation.	15d-pgj	143-150	glutamate-cysteine ligase catalytic subunit	Homo sapiens	61-65
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	10-17	ATP binding cassette subfamily C member 1	Homo sapiens	126-130
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	10-17	glutamate-cysteine ligase catalytic subunit	Homo sapiens	183-187
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	146-153	glutamate-cysteine ligase catalytic subunit	Homo sapiens	29-33
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	146-153	ATP binding cassette subfamily C member 1	Homo sapiens	104-108
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	146-153	ATP binding cassette subfamily C member 1	Homo sapiens	126-130
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	146-153	glutamate-cysteine ligase catalytic subunit	Homo sapiens	183-187
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	146-153	glutamate-cysteine ligase catalytic subunit	Homo sapiens	29-33
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	146-153	ATP binding cassette subfamily C member 1	Homo sapiens	104-108
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	146-153	ATP binding cassette subfamily C member 1	Homo sapiens	126-130
21728338-12	2011	Moreover, 15d-PGJ(2)-induced GCLC expression was attenuated by the MK571 and also by siRNA knockdown of MRP1, suggesting that MRP1 contributes to 15d-PGJ(2)-mediated up-regulation of GCLC by pumping out the 15d-PGJ(2)-GSH conjugate.	15d-pgj	146-153	glutamate-cysteine ligase catalytic subunit	Homo sapiens	183-187
21728338-13	2011	It is speculated that 15d-PGJ(2), once effluxed through MRP, liberates from the GSH conjugate, and the free 15d-PGJ(2) re-enters the cell and forms the GSH conjugate again.	15d-pgj	22-29	ATP binding cassette subfamily C member 1	Homo sapiens	56-59
21728338-14	2011	In conclusion, MRP1 mediates Nrf2-dependent up-regulation of GCLC in 15d-PGJ(2)-treated MCF-7 cells, possibly via a putative recycling loop of 15d-PGJ(2)-GSH conjugation.	15d-pgj	69-76	ATP binding cassette subfamily C member 1	Homo sapiens	15-19
21728338-14	2011	In conclusion, MRP1 mediates Nrf2-dependent up-regulation of GCLC in 15d-PGJ(2)-treated MCF-7 cells, possibly via a putative recycling loop of 15d-PGJ(2)-GSH conjugation.	15d-pgj	69-76	NFE2 like bZIP transcription factor 2	Homo sapiens	29-33
21728338-14	2011	In conclusion, MRP1 mediates Nrf2-dependent up-regulation of GCLC in 15d-PGJ(2)-treated MCF-7 cells, possibly via a putative recycling loop of 15d-PGJ(2)-GSH conjugation.	15d-pgj	69-76	glutamate-cysteine ligase catalytic subunit	Homo sapiens	61-65
21236332-4	2011	15d-PGJ(2) induced the accumulation of reactive oxygen species (ROS) that in turn may lead to upregulation of Cox-2 via two different routes in a PPARgamma-independent manner.	15d-pgj	0-7	prostaglandin-endoperoxide synthase 2	Homo sapiens	110-115
21699992-3	2011	15d-PGJ(2) interfered significantly the endogenous synthesis of those PGs in response to cell stimuli by suppressing the induction of COX-2 following the attenuation of NF-kappaB activation.	15d-pgj	0-7	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	134-139
21683069-9	2011	The treatment of CPT combined with 15d-PGJ(2) activated caspase-3 more than the separate treatment.	15d-pgj	35-42	caspase 3	Homo sapiens	56-65
20174873-6	2011	15d-PGJ(2) decreased TLR2 mRNA, increased IL-8 production, and suppressed NF-kappaB activity.	15d-pgj	0-7	toll like receptor 2	Homo sapiens	21-25
20174873-6	2011	15d-PGJ(2) decreased TLR2 mRNA, increased IL-8 production, and suppressed NF-kappaB activity.	15d-pgj	0-7	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
20174873-6	2011	15d-PGJ(2) decreased TLR2 mRNA, increased IL-8 production, and suppressed NF-kappaB activity.	15d-pgj	0-7	nuclear factor kappa B subunit 1	Homo sapiens	74-83
20174873-10	2011	Thus, 15d-PGJ(2) can have both anti- and pro-inflammatory effects, and 15d-PGJ(2)-mediated IL-8 up-regulation is related to the mitogen-activated protein kinase (MAPK) and NF-kappaB signaling pathways.	15d-pgj	71-78	C-X-C motif chemokine ligand 8	Homo sapiens	91-95
20174873-10	2011	Thus, 15d-PGJ(2) can have both anti- and pro-inflammatory effects, and 15d-PGJ(2)-mediated IL-8 up-regulation is related to the mitogen-activated protein kinase (MAPK) and NF-kappaB signaling pathways.	15d-pgj	71-78	nuclear factor kappa B subunit 1	Homo sapiens	172-181
21338579-3	2011	The early transcription factor EGR1 (Early Growth Response gene 1) mRNA and protein levels peaked after 3h of incubation with 25muM TGZ, CGZ or 15d-PGJ(2) and then gradually decreased.	15d-pgj	144-151	early growth response 1	Homo sapiens	31-35
21338579-3	2011	The early transcription factor EGR1 (Early Growth Response gene 1) mRNA and protein levels peaked after 3h of incubation with 25muM TGZ, CGZ or 15d-PGJ(2) and then gradually decreased.	15d-pgj	144-151	early growth response 1	Homo sapiens	37-65
21236332-4	2011	15d-PGJ(2) induced the accumulation of reactive oxygen species (ROS) that in turn may lead to upregulation of Cox-2 via two different routes in a PPARgamma-independent manner.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	146-155
21236332-6	2011	Second, 15d-PGJ(2) induces activation of epidermal growth factor receptors and downstream activation of Cox-2 via phosphorylation of p42/44 MAPK.	15d-pgj	8-15	prostaglandin-endoperoxide synthase 2	Homo sapiens	104-109
21236332-6	2011	Second, 15d-PGJ(2) induces activation of epidermal growth factor receptors and downstream activation of Cox-2 via phosphorylation of p42/44 MAPK.	15d-pgj	8-15	erythrocyte membrane protein band 4.2	Homo sapiens	133-136
20933087-4	2011	15d-PGJ(2) covalently modifies UCH-L1 and inhibits its hydrolase activity.	15d-pgj	0-7	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	31-37
21445266-3	2011	Previously, we reported that the cytotoxicity of 15d-PGJ(2) was independent of DP2 and PPARgamma, and suggested that 15d-PGJ(2) induced apoptosis through the novel specific binding sites of 15d-PGJ(2) different from DP2 and PPARgamma.	15d-pgj	49-56	transcription factor Dp-2	Homo sapiens	216-219
21445266-3	2011	Previously, we reported that the cytotoxicity of 15d-PGJ(2) was independent of DP2 and PPARgamma, and suggested that 15d-PGJ(2) induced apoptosis through the novel specific binding sites of 15d-PGJ(2) different from DP2 and PPARgamma.	15d-pgj	49-56	peroxisome proliferator activated receptor gamma	Homo sapiens	224-233
21445266-3	2011	Previously, we reported that the cytotoxicity of 15d-PGJ(2) was independent of DP2 and PPARgamma, and suggested that 15d-PGJ(2) induced apoptosis through the novel specific binding sites of 15d-PGJ(2) different from DP2 and PPARgamma.	15d-pgj	117-124	transcription factor Dp-2	Homo sapiens	216-219
21445266-3	2011	Previously, we reported that the cytotoxicity of 15d-PGJ(2) was independent of DP2 and PPARgamma, and suggested that 15d-PGJ(2) induced apoptosis through the novel specific binding sites of 15d-PGJ(2) different from DP2 and PPARgamma.	15d-pgj	117-124	peroxisome proliferator activated receptor gamma	Homo sapiens	224-233
21445266-3	2011	Previously, we reported that the cytotoxicity of 15d-PGJ(2) was independent of DP2 and PPARgamma, and suggested that 15d-PGJ(2) induced apoptosis through the novel specific binding sites of 15d-PGJ(2) different from DP2 and PPARgamma.	15d-pgj	117-124	transcription factor Dp-2	Homo sapiens	216-219
21445266-3	2011	Previously, we reported that the cytotoxicity of 15d-PGJ(2) was independent of DP2 and PPARgamma, and suggested that 15d-PGJ(2) induced apoptosis through the novel specific binding sites of 15d-PGJ(2) different from DP2 and PPARgamma.	15d-pgj	117-124	peroxisome proliferator activated receptor gamma	Homo sapiens	224-233
21164107-4	2011	METHODS AND RESULTS: Proteomic screening with biotinylated 15d-PGJ(2) identified novel vascular targets to which it adducts, most notably soluble epoxide hydrolase (sEH).	15d-pgj	59-66	epoxide hydrolase 2, cytoplasmic	Mus musculus	138-163
21164107-4	2011	METHODS AND RESULTS: Proteomic screening with biotinylated 15d-PGJ(2) identified novel vascular targets to which it adducts, most notably soluble epoxide hydrolase (sEH).	15d-pgj	59-66	epoxide hydrolase 2, cytoplasmic	Mus musculus	165-168
21164107-7	2011	15d-PGJ(2) dilated coronary vessels and a role for hydrolase inhibition was supported by 2 structurally different sEH antagonists each independently inducing vasorelaxation.	15d-pgj	0-7	epoxide hydrolase 2, cytoplasmic	Mus musculus	114-117
21364986-3	2011	We therefore found that ectopic overexpression in HeLa cells of human Sprouty2, or human Spred1 or 2, inhibits ERK1/2 and Elk-1 activation triggered by the cyclopentenone prostanoids PGA(1) and 15d-PGJ(2).	15d-pgj	194-201	sprouty related EVH1 domain containing 1	Homo sapiens	89-95
21957481-1	2011	15-Deoxy-delta-12,14-prostaglandin-J(2) (15d-PGJ(2)), an arachidonic metabolite and a natural PPARgamma agonist, is known to induce apoptosis in tumor cells.	15d-pgj	41-48	peroxisome proliferator activated receptor gamma	Homo sapiens	94-103
22096605-3	2011	However, the effects of PGD(2) and 15d-PGJ(2) in the absence or presence of PGE(2) on IL-6 synthesis in human chondrocytes have yet to be determined.	15d-pgj	35-42	interleukin 6	Homo sapiens	86-90
22096605-8	2011	PGD(2) or 15d-PGJ(2) concurrently downregulates TLR4 and upregulates caveolin-1, which in turn inhibit the PGE(2)-dependent ERK1/2, PI3-K and PKA activation, and ultimately with NF-kappaB-dependent IL-6 synthesis in chondrocytes.	15d-pgj	10-17	toll like receptor 4	Homo sapiens	48-52
22096605-8	2011	PGD(2) or 15d-PGJ(2) concurrently downregulates TLR4 and upregulates caveolin-1, which in turn inhibit the PGE(2)-dependent ERK1/2, PI3-K and PKA activation, and ultimately with NF-kappaB-dependent IL-6 synthesis in chondrocytes.	15d-pgj	10-17	caveolin 1	Homo sapiens	69-79
22096605-8	2011	PGD(2) or 15d-PGJ(2) concurrently downregulates TLR4 and upregulates caveolin-1, which in turn inhibit the PGE(2)-dependent ERK1/2, PI3-K and PKA activation, and ultimately with NF-kappaB-dependent IL-6 synthesis in chondrocytes.	15d-pgj	10-17	mitogen-activated protein kinase 3	Homo sapiens	124-130
22096605-8	2011	PGD(2) or 15d-PGJ(2) concurrently downregulates TLR4 and upregulates caveolin-1, which in turn inhibit the PGE(2)-dependent ERK1/2, PI3-K and PKA activation, and ultimately with NF-kappaB-dependent IL-6 synthesis in chondrocytes.	15d-pgj	10-17	interleukin 6	Homo sapiens	198-202
22096605-9	2011	CONCLUSIONS/SIGNIFICANCE: We have delineated the signaling cascade by which PGE(2) and PGD(2)/15d-PGJ(2) exert opposing effects on IL-6 synthesis in human chondrocytes.	15d-pgj	94-101	interleukin 6	Homo sapiens	131-135
20854809-7	2011	Furthermore, TSIIA reduced the mRNA expression of CD36 in macrophages treated with PPARgamma agonist 15d-PGJ(2) (2muM) or troglitazone (50muM), whereas both 15d-PGJ(2) (0.5-1.5muM) and troglitazone (5-20muM) dose-dependently abolished the down-regulation of CD36 expression by TSIIA in oxLDL treated macrophages.	15d-pgj	101-108	peroxisome proliferator activated receptor gamma	Mus musculus	83-92
21957481-5	2011	15d-PGJ(2) also was able to reduce the doxorubicin resistance of A2780/AD cells at low doses as confirmed by the inhibition of gene expression of MDR1 (p-glycoprotein) and SIRT1 (a drug senescence gene).	15d-pgj	0-7	ATP binding cassette subfamily B member 1	Homo sapiens	146-150
21957481-5	2011	15d-PGJ(2) also was able to reduce the doxorubicin resistance of A2780/AD cells at low doses as confirmed by the inhibition of gene expression of MDR1 (p-glycoprotein) and SIRT1 (a drug senescence gene).	15d-pgj	0-7	ATP binding cassette subfamily B member 1	Homo sapiens	152-166
21957481-5	2011	15d-PGJ(2) also was able to reduce the doxorubicin resistance of A2780/AD cells at low doses as confirmed by the inhibition of gene expression of MDR1 (p-glycoprotein) and SIRT1 (a drug senescence gene).	15d-pgj	0-7	sirtuin 1	Homo sapiens	172-177
21957481-7	2011	We found that 15d-PGJ(2) inhibited migration most likely due to NF-kappaB inhibition and induced transformation of the round-shape A2780/AD cells into elongated epithelial cells due to HDAC1 inhibition.	15d-pgj	14-21	histone deacetylase 1	Homo sapiens	185-190
21957481-8	2011	Using a 15d-PGJ(2) analog, we found the mechanism of action of these new activities of 15d-PGJ(2) on SIRT1 and HDAC1 gene expressions and enzyme activities.	15d-pgj	8-15	sirtuin 1	Homo sapiens	101-106
21957481-8	2011	Using a 15d-PGJ(2) analog, we found the mechanism of action of these new activities of 15d-PGJ(2) on SIRT1 and HDAC1 gene expressions and enzyme activities.	15d-pgj	8-15	histone deacetylase 1	Homo sapiens	111-116
21957481-8	2011	Using a 15d-PGJ(2) analog, we found the mechanism of action of these new activities of 15d-PGJ(2) on SIRT1 and HDAC1 gene expressions and enzyme activities.	15d-pgj	87-94	sirtuin 1	Homo sapiens	101-106
21957481-8	2011	Using a 15d-PGJ(2) analog, we found the mechanism of action of these new activities of 15d-PGJ(2) on SIRT1 and HDAC1 gene expressions and enzyme activities.	15d-pgj	87-94	histone deacetylase 1	Homo sapiens	111-116
21957481-9	2011	In conclusion, the present study demonstrates that 15d-PGJ(2) has a high therapeutic potential to kill drug-resistant tumor cells and, the newly described inhibitory effects of this cyclo-oxygenase product on SIRT1 and HDAC will provide new opportunities for cancer therapeutics.	15d-pgj	51-58	sirtuin 1	Homo sapiens	209-214
21957481-9	2011	In conclusion, the present study demonstrates that 15d-PGJ(2) has a high therapeutic potential to kill drug-resistant tumor cells and, the newly described inhibitory effects of this cyclo-oxygenase product on SIRT1 and HDAC will provide new opportunities for cancer therapeutics.	15d-pgj	51-58	histone deacetylase 9	Homo sapiens	219-223
19891980-7	2010	ICV administration of structurally dissimilar PPARgamma antagonists (either GW9662 or BADGE) reversed the anti-inflammatory and anti-hyperalgesic actions of both rosiglitazone and 15d-PGJ(2).	15d-pgj	180-187	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	46-55
20631055-8	2010	It is noteworthy that 15d-PGJ(2) elicited GSTP1-1 cross-linking in vitro, a process that could be mimicked by other dienone cyclopentenone PG, such as Delta(12)-PGJ(2), and by the bifunctional thiol reagent dibromobimane, suggesting that cyclopentenone PG may be directly involved in oligomer formation.	15d-pgj	22-29	glutathione S-transferase pi 1	Homo sapiens	42-49
20457605-3	2010	Like leptomycin B (LMB), an established fungal CRM1-inhibitor, 15d-PGJ(2) reacts with a conserved cysteine residue in the CRM1 sequence.	15d-pgj	63-70	exportin 1	Homo sapiens	47-51
20457605-3	2010	Like leptomycin B (LMB), an established fungal CRM1-inhibitor, 15d-PGJ(2) reacts with a conserved cysteine residue in the CRM1 sequence.	15d-pgj	63-70	exportin 1	Homo sapiens	122-126
20457605-5	2010	Cells that are transfected with mutant CRM1 (C528S) are resistant to the inhibitory effects of LMB and 15d-PGJ(2), demonstrating that the same single amino acid is targeted by the two compounds.	15d-pgj	103-110	exportin 1	Homo sapiens	39-43
20457605-6	2010	Inhibition of the CRM1 pathway by endogenously produced prostaglandin and/or exogenously applied 15d-PGJ(2) may contribute to its anti-inflammatory, anti-proliferative, and anti-viral effects.	15d-pgj	97-104	exportin 1	Homo sapiens	18-22
20385560-5	2010	We report that alpha,beta-unsaturated carbonyl compounds, e.g. the cyclopentenone prostaglandin, 15-deoxy-Delta12,14-PGJ(2) (15d-PGJ(2)), and 4-hydroxy-2-nonenal (4HNE), alkylate (carbonylate), a subset of class I HDACs including HDAC1, -2, and -3, but not HDAC8.	15d-pgj	125-132	histone deacetylase 1	Homo sapiens	230-247
20385560-5	2010	We report that alpha,beta-unsaturated carbonyl compounds, e.g. the cyclopentenone prostaglandin, 15-deoxy-Delta12,14-PGJ(2) (15d-PGJ(2)), and 4-hydroxy-2-nonenal (4HNE), alkylate (carbonylate), a subset of class I HDACs including HDAC1, -2, and -3, but not HDAC8.	15d-pgj	125-132	histone deacetylase 8	Homo sapiens	257-262
19712722-6	2010	Relaxin increased both the baseline activity and the response to the PPARgamma agonists rosiglitazone and 15d-PGJ(2), but not to agonists of PPARalpha or PPARdelta.	15d-pgj	106-113	peroxisome proliferator activated receptor gamma	Homo sapiens	69-78
20457605-2	2010	Here we show that substrates of the nuclear export receptor CRM1 accumulate in the nucleus in the presence of 15d-PGJ(2), identifying this prostaglandin as a regulator of CRM1-dependent nuclear protein export that can be produced endogenously.	15d-pgj	110-117	exportin 1	Homo sapiens	60-64
20457605-2	2010	Here we show that substrates of the nuclear export receptor CRM1 accumulate in the nucleus in the presence of 15d-PGJ(2), identifying this prostaglandin as a regulator of CRM1-dependent nuclear protein export that can be produced endogenously.	15d-pgj	110-117	exportin 1	Homo sapiens	171-175
20208557-2	2010	In this study, treatment of human breast cancer cells (MCF-7) with 15d-PGJ(2) led to accumulation of p53 protein.	15d-pgj	67-74	tumor protein p53	Homo sapiens	101-104
20208557-4	2010	15d-PGJ(2) directly modified p53 as verified by reacting recombinant p53 with biotinylated 15d-PGJ(2).	15d-pgj	0-7	tumor protein p53	Homo sapiens	29-32
20208557-4	2010	15d-PGJ(2) directly modified p53 as verified by reacting recombinant p53 with biotinylated 15d-PGJ(2).	15d-pgj	0-7	tumor protein p53	Homo sapiens	69-72
20208557-4	2010	15d-PGJ(2) directly modified p53 as verified by reacting recombinant p53 with biotinylated 15d-PGJ(2).	15d-pgj	91-98	tumor protein p53	Homo sapiens	29-32
20208557-4	2010	15d-PGJ(2) directly modified p53 as verified by reacting recombinant p53 with biotinylated 15d-PGJ(2).	15d-pgj	91-98	tumor protein p53	Homo sapiens	69-72
20208557-6	2010	Moreover, by conducting an in vitro [(35)S]-labeled p53 translation assay, we identified cysteine 277 as a putative site of p53 modification by 15d-PGJ(2).	15d-pgj	144-151	tumor protein p53	Homo sapiens	52-55
20208557-6	2010	Moreover, by conducting an in vitro [(35)S]-labeled p53 translation assay, we identified cysteine 277 as a putative site of p53 modification by 15d-PGJ(2).	15d-pgj	144-151	tumor protein p53	Homo sapiens	124-127
20208557-8	2010	Likewise, p53 binding activity of biotinylated 15d-PGJ(2) was abolished in mutant cells.	15d-pgj	47-54	tumor protein p53	Homo sapiens	10-13
20150631-8	2010	TWEAK induced nuclear factor-kappa B activation, which was attenuated by 15d-PGJ(2).	15d-pgj	73-80	TNF superfamily member 12	Homo sapiens	0-5
20438519-1	2010	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) is an endogenous peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that suppresses progressive matrix deposition; however, little is known about the effects of 15d-PGJ(2) on human peritoneal mesothelial cells (HPMCs).	15d-pgj	233-240	peroxisome proliferator activated receptor gamma	Homo sapiens	121-130
20438519-4	2010	15d-PGJ(2) inhibited Ang II-induced FN expression and increased HGF expression, even in the presence of Ang II.	15d-pgj	0-7	angiotensinogen	Homo sapiens	21-27
20438519-4	2010	15d-PGJ(2) inhibited Ang II-induced FN expression and increased HGF expression, even in the presence of Ang II.	15d-pgj	0-7	fibronectin 1	Homo sapiens	36-38
20438519-4	2010	15d-PGJ(2) inhibited Ang II-induced FN expression and increased HGF expression, even in the presence of Ang II.	15d-pgj	0-7	hepatocyte growth factor	Homo sapiens	64-67
20438519-6	2010	Additionally, upregulation of HGF secretion induced by 15d-PGJ(2) and HGF production induced by pioglitazone was revealed.	15d-pgj	55-62	hepatocyte growth factor	Homo sapiens	30-33
20438519-1	2010	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) is an endogenous peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that suppresses progressive matrix deposition; however, little is known about the effects of 15d-PGJ(2) on human peritoneal mesothelial cells (HPMCs).	15d-pgj	42-49	peroxisome proliferator activated receptor gamma	Homo sapiens	71-119
20438519-1	2010	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) is an endogenous peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that suppresses progressive matrix deposition; however, little is known about the effects of 15d-PGJ(2) on human peritoneal mesothelial cells (HPMCs).	15d-pgj	42-49	peroxisome proliferator activated receptor gamma	Homo sapiens	121-130
19942298-6	2010	These results suggest that PPAR-gamma agonists, 15d-PGJ(2) and pioglitazone, had the anti-inflammatory effects.	15d-pgj	48-55	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	27-37
19690198-6	2009	RESULTS: 15d-PGJ(2) induced apoptosis in leukemia and colorectal cancer cells in a dose-dependent manner and led to generation of reactive oxygen species (ROS) through mitochondria and NADPH oxidase activation, activation of JNK, and inactivation of Akt, a serine/threonine-specific protein kinase.	15d-pgj	9-16	AKT serine/threonine kinase 1	Homo sapiens	250-253
20064636-5	2010	15d-PGJ(2) potently induced HO-1 protein expression in normal and malignant B cells.	15d-pgj	0-7	heme oxygenase 1	Homo sapiens	28-32
20064636-7	2010	Using siRNA directed against the transcription factor Nrf2 and B cells isolated from Nrf2-deficient mice, we show that HO-1 induction by 15d-PGJ(2) is dependent on Nrf2.	15d-pgj	137-144	nuclear factor, erythroid derived 2, like 2	Mus musculus	54-58
20064636-7	2010	Using siRNA directed against the transcription factor Nrf2 and B cells isolated from Nrf2-deficient mice, we show that HO-1 induction by 15d-PGJ(2) is dependent on Nrf2.	15d-pgj	137-144	nuclear factor, erythroid derived 2, like 2	Mus musculus	85-89
20064636-7	2010	Using siRNA directed against the transcription factor Nrf2 and B cells isolated from Nrf2-deficient mice, we show that HO-1 induction by 15d-PGJ(2) is dependent on Nrf2.	15d-pgj	137-144	heme oxygenase 1	Mus musculus	119-123
20064636-7	2010	Using siRNA directed against the transcription factor Nrf2 and B cells isolated from Nrf2-deficient mice, we show that HO-1 induction by 15d-PGJ(2) is dependent on Nrf2.	15d-pgj	137-144	nuclear factor, erythroid derived 2, like 2	Mus musculus	85-89
19760394-6	2010	Patients with resolved sepsis had increased levels of the endogenous PPARgamma ligand, 15d-PGJ(2), compared with patients with systemic inflammatory response syndrome (SIRS) and septic shock (77.7 +/- 21.7 versus 58 +/- 16.5 pg/ml; p = 0.03).	15d-pgj	87-94	peroxisome proliferator activated receptor gamma	Homo sapiens	69-78
19647045-3	2009	This antinociceptive effect is dependent on peroxisome proliferator-activated receptors-gamma (PPAR-gamma) since pre-treatment with GW9662 (PPAR-gamma receptor antagonist) blocked the antinociceptive effect of 15d-PGJ(2) in the TMJ.	15d-pgj	210-217	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	95-105
19647045-3	2009	This antinociceptive effect is dependent on peroxisome proliferator-activated receptors-gamma (PPAR-gamma) since pre-treatment with GW9662 (PPAR-gamma receptor antagonist) blocked the antinociceptive effect of 15d-PGJ(2) in the TMJ.	15d-pgj	210-217	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	140-150
19647045-9	2009	Taken together, these results demonstrate that 15d-PGJ(2) has a potential peripheral antinociceptive and anti-inflammatory effect in the TMJ via PPAR-gamma activation.	15d-pgj	47-54	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	145-155
19647045-11	2009	The pharmacological properties of the peripheral administration of 15d-PGJ(2) highlight the potential use of this PPAR-gamma agonist on TMJ inflammatory pain conditions.	15d-pgj	67-74	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	114-124
19573595-3	2009	One of the signaling pathways potently activated by 15d-PGJ(2) is the Keap1-Nrf2-ARE system, which has a well-appreciated role in protecting cells from endogenous and exogenous stresses as well as anti-inflammatory effects.	15d-pgj	52-59	kelch like ECH associated protein 1	Homo sapiens	70-75
19573595-3	2009	One of the signaling pathways potently activated by 15d-PGJ(2) is the Keap1-Nrf2-ARE system, which has a well-appreciated role in protecting cells from endogenous and exogenous stresses as well as anti-inflammatory effects.	15d-pgj	52-59	NFE2 like bZIP transcription factor 2	Homo sapiens	76-80
19573595-5	2009	In addition, the Nrf2-dependent anti-inflammatory and cytoprotective effects of 15d-PGJ(2) are discussed.	15d-pgj	80-87	NFE2 like bZIP transcription factor 2	Homo sapiens	17-21
20424389-2	2010	We examined the mechanism by which 15d-PGJ(2) enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells.	15d-pgj	35-42	nerve growth factor	Rattus norvegicus	55-74
20424389-2	2010	We examined the mechanism by which 15d-PGJ(2) enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells.	15d-pgj	35-42	nerve growth factor	Rattus norvegicus	76-79
20019843-1	2009	15-Deoxy-Delta(12,14)-prostaglandin-J(2) (15d-PGJ(2)), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, induces cell death in tumor cells in vitro; however, no study showed its in vivo effect on tumors.	15d-pgj	42-49	peroxisome proliferator activated receptor gamma	Mus musculus	57-105
20019843-1	2009	15-Deoxy-Delta(12,14)-prostaglandin-J(2) (15d-PGJ(2)), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, induces cell death in tumor cells in vitro; however, no study showed its in vivo effect on tumors.	15d-pgj	42-49	peroxisome proliferator activated receptor gamma	Mus musculus	107-116
19690198-9	2009	Moreover, 15d-PGJ(2) markedly reduced growth of mouse CT-26 s.c. tumors and HL-60 xenograft tumors and down-regulated p-Akt and Akt expression in vivo.	15d-pgj	10-17	AKT serine/threonine kinase 1	Homo sapiens	120-123
19690198-9	2009	Moreover, 15d-PGJ(2) markedly reduced growth of mouse CT-26 s.c. tumors and HL-60 xenograft tumors and down-regulated p-Akt and Akt expression in vivo.	15d-pgj	10-17	thymoma viral proto-oncogene 1	Mus musculus	128-131
19690198-10	2009	CONCLUSIONS: These results suggest that Akt inactivation through ROS production may contribute to 15d-PGJ(2)-induced apoptosis in leukemia and colorectal cancer cell lines and that 15d-PGJ(2) may have therapeutic relevance in the treatment of human leukemia and colorectal cancer.	15d-pgj	98-105	AKT serine/threonine kinase 1	Homo sapiens	40-43
19690198-10	2009	CONCLUSIONS: These results suggest that Akt inactivation through ROS production may contribute to 15d-PGJ(2)-induced apoptosis in leukemia and colorectal cancer cell lines and that 15d-PGJ(2) may have therapeutic relevance in the treatment of human leukemia and colorectal cancer.	15d-pgj	181-188	AKT serine/threonine kinase 1	Homo sapiens	40-43
19723057-3	2009	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a representative cyPG of the J series, has been reported to directly inhibit the activity of redox-sensitive transcription factors, such as activator protein-1 and nuclear factor-kappaB.	15d-pgj	42-49	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	195-214
19723057-4	2009	In the present study, we examined the effects of 15d-PGJ(2) on activation of p53 tumor suppressor in human breast cancer (MCF-7) cells.	15d-pgj	49-56	tumor protein p53	Homo sapiens	77-80
19723057-5	2009	MCF-7 cells treated with 15d-PGJ(2) exhibited elevated p53 protein expression in time- and concentration-related manners, whereas prostaglandin A(2) (PGA(2)) and the nonprostaglandin derivative 2-cyclopenten-1-one exerted an effect to a lesser extent than did 15d-PGJ(2).	15d-pgj	25-32	tumor protein p53	Homo sapiens	55-58
19723058-5	2009	In the present study we have found that 15d-PGJ(2) induces the expression of MRP1, one of the phase 3 efflux transporters, in human breast cancer cells (MCF-7).	15d-pgj	40-47	ATP binding cassette subfamily C member 1	Homo sapiens	77-81
19723058-6	2009	In addition, treatment of MCF-7 cells with 15d-PGJ(2) resulted in nuclear translocation and DNA binding of Nrf2.	15d-pgj	43-50	NFE2 like bZIP transcription factor 2	Homo sapiens	107-111
19409914-5	2009	To further examine the mechanism responsible for the inhibition of IL-6 production by 15d-PGJ(2), we examined the effect of 15d-PGJ(2) on nuclear factor-kappaB (NF-kappaB) activation and the phosphorylation of protein kinase B (Akt).	15d-pgj	86-93	interleukin 6	Homo sapiens	67-71
19299483-5	2009	Our studies indicate that 15d-PGJ(2) treatment of cells inhibits Tat-dependent transcription and replication of HIV-1, while 9,10-dihydro-15d-PGJ(2), PGE(2), PGF(2alpha), or PGD(2) that lack the reactive alpha,beta-unsaturated ketone were ineffective.	15d-pgj	26-33	Tat	Human immunodeficiency virus 1	65-68
19299483-6	2009	The inhibition of Tat activity by 15d-PGJ(2) was dose-dependent, with an IC(50) of 1.2 microM and independent of NF-kappaB pathway.	15d-pgj	34-41	Tat	Human immunodeficiency virus 1	18-21
19299483-7	2009	Furthermore, using a biotinylated derivative of 15d-PGJ(2), we demonstrate that 15d-PGJ(2) modifies free Cys-thiols in Tat to form covalent Michael adducts and that the interaction was further increased on reduction of Tat.	15d-pgj	48-55	Tat	Human immunodeficiency virus 1	119-122
19299483-7	2009	Furthermore, using a biotinylated derivative of 15d-PGJ(2), we demonstrate that 15d-PGJ(2) modifies free Cys-thiols in Tat to form covalent Michael adducts and that the interaction was further increased on reduction of Tat.	15d-pgj	48-55	Tat	Human immunodeficiency virus 1	219-222
19299483-7	2009	Furthermore, using a biotinylated derivative of 15d-PGJ(2), we demonstrate that 15d-PGJ(2) modifies free Cys-thiols in Tat to form covalent Michael adducts and that the interaction was further increased on reduction of Tat.	15d-pgj	80-87	Tat	Human immunodeficiency virus 1	119-122
19299483-7	2009	Furthermore, using a biotinylated derivative of 15d-PGJ(2), we demonstrate that 15d-PGJ(2) modifies free Cys-thiols in Tat to form covalent Michael adducts and that the interaction was further increased on reduction of Tat.	15d-pgj	80-87	Tat	Human immunodeficiency virus 1	219-222
19299483-8	2009	15d-PGJ(2)-modified Tat was unable to transactivate the HIV long terminal repeat in U937 human macrophages.	15d-pgj	0-7	Tat	Human immunodeficiency virus 1	20-23
19409914-7	2009	In addition, 15d-PGJ(2) attenuated the LPS-mediated Akt pathway.	15d-pgj	13-20	AKT serine/threonine kinase 1	Homo sapiens	52-55
19409914-8	2009	These effects of 15d-PGJ(2) were not abrogated by the PPARgamma antagonist, GW9662, indicating that they are PPARgamma-independent actions.	15d-pgj	17-24	peroxisome proliferator activated receptor gamma	Homo sapiens	109-118
19458911-4	2009	We found that 15d-PGJ(2) induced an over-accumulation of HIF-1alpha in RCC4 cells, which lack pVHL and in HK-2 cells treated with inhibitors of the pVHL-proteasome pathway.	15d-pgj	14-21	hypoxia inducible factor 1 subunit alpha	Homo sapiens	57-67
19458911-4	2009	We found that 15d-PGJ(2) induced an over-accumulation of HIF-1alpha in RCC4 cells, which lack pVHL and in HK-2 cells treated with inhibitors of the pVHL-proteasome pathway.	15d-pgj	14-21	von Hippel-Lindau tumor suppressor	Homo sapiens	94-98
19458911-4	2009	We found that 15d-PGJ(2) induced an over-accumulation of HIF-1alpha in RCC4 cells, which lack pVHL and in HK-2 cells treated with inhibitors of the pVHL-proteasome pathway.	15d-pgj	14-21	von Hippel-Lindau tumor suppressor	Homo sapiens	148-152
19429239-4	2009	15d-PGJ(2) significantly inhibited TGF-beta-induced CTGF protein and mRNA expressions, and promoter activity in hepatoma cells.	15d-pgj	0-7	transforming growth factor beta 1	Homo sapiens	35-43
19346435-7	2009	The PPARgamma antagonist GW-9662 did not inhibit any biological responses, but it reversed the effect of 15d-PGJ(2) on cell growth.	15d-pgj	105-112	peroxisome proliferator activated receptor gamma	Homo sapiens	4-13
19429239-7	2009	The results suggest that 15d-PGJ(2) inhibits TGF-beta-induced CTGF expression by inhibiting the phosphorylation of Smad2, which is independent of PPAR, and 15d-PGJ(2) might also act through a PPAR-dependent mechanism in human hepatoma cells.	15d-pgj	25-32	transforming growth factor beta 1	Homo sapiens	45-53
19429239-4	2009	15d-PGJ(2) significantly inhibited TGF-beta-induced CTGF protein and mRNA expressions, and promoter activity in hepatoma cells.	15d-pgj	0-7	cellular communication network factor 2	Homo sapiens	52-56
19429239-7	2009	The results suggest that 15d-PGJ(2) inhibits TGF-beta-induced CTGF expression by inhibiting the phosphorylation of Smad2, which is independent of PPAR, and 15d-PGJ(2) might also act through a PPAR-dependent mechanism in human hepatoma cells.	15d-pgj	25-32	cellular communication network factor 2	Homo sapiens	62-66
19429239-5	2009	15d-PGJ(2) suppressed TGF-beta-induced Smad2 phosphorylation, however enhancing the phosphorylation of ERK, c-Jun N-terminal kinase (JNK), and p38 in TGF-beta-treated Hep3B cells.	15d-pgj	0-7	transforming growth factor beta 1	Homo sapiens	22-30
19429239-7	2009	The results suggest that 15d-PGJ(2) inhibits TGF-beta-induced CTGF expression by inhibiting the phosphorylation of Smad2, which is independent of PPAR, and 15d-PGJ(2) might also act through a PPAR-dependent mechanism in human hepatoma cells.	15d-pgj	25-32	SMAD family member 2	Homo sapiens	115-120
19429239-5	2009	15d-PGJ(2) suppressed TGF-beta-induced Smad2 phosphorylation, however enhancing the phosphorylation of ERK, c-Jun N-terminal kinase (JNK), and p38 in TGF-beta-treated Hep3B cells.	15d-pgj	0-7	SMAD family member 2	Homo sapiens	39-44
19429239-7	2009	The results suggest that 15d-PGJ(2) inhibits TGF-beta-induced CTGF expression by inhibiting the phosphorylation of Smad2, which is independent of PPAR, and 15d-PGJ(2) might also act through a PPAR-dependent mechanism in human hepatoma cells.	15d-pgj	25-32	peroxisome proliferator activated receptor alpha	Homo sapiens	146-150
19429239-7	2009	The results suggest that 15d-PGJ(2) inhibits TGF-beta-induced CTGF expression by inhibiting the phosphorylation of Smad2, which is independent of PPAR, and 15d-PGJ(2) might also act through a PPAR-dependent mechanism in human hepatoma cells.	15d-pgj	25-32	peroxisome proliferator activated receptor alpha	Homo sapiens	192-196
19429239-7	2009	The results suggest that 15d-PGJ(2) inhibits TGF-beta-induced CTGF expression by inhibiting the phosphorylation of Smad2, which is independent of PPAR, and 15d-PGJ(2) might also act through a PPAR-dependent mechanism in human hepatoma cells.	15d-pgj	156-163	transforming growth factor beta 1	Homo sapiens	45-53
19429239-5	2009	15d-PGJ(2) suppressed TGF-beta-induced Smad2 phosphorylation, however enhancing the phosphorylation of ERK, c-Jun N-terminal kinase (JNK), and p38 in TGF-beta-treated Hep3B cells.	15d-pgj	0-7	mitogen-activated protein kinase 1	Homo sapiens	103-106
19429239-5	2009	15d-PGJ(2) suppressed TGF-beta-induced Smad2 phosphorylation, however enhancing the phosphorylation of ERK, c-Jun N-terminal kinase (JNK), and p38 in TGF-beta-treated Hep3B cells.	15d-pgj	0-7	mitogen-activated protein kinase 8	Homo sapiens	108-131
19429239-5	2009	15d-PGJ(2) suppressed TGF-beta-induced Smad2 phosphorylation, however enhancing the phosphorylation of ERK, c-Jun N-terminal kinase (JNK), and p38 in TGF-beta-treated Hep3B cells.	15d-pgj	0-7	mitogen-activated protein kinase 8	Homo sapiens	133-136
19429239-5	2009	15d-PGJ(2) suppressed TGF-beta-induced Smad2 phosphorylation, however enhancing the phosphorylation of ERK, c-Jun N-terminal kinase (JNK), and p38 in TGF-beta-treated Hep3B cells.	15d-pgj	0-7	mitogen-activated protein kinase 14	Homo sapiens	143-146
19429239-5	2009	15d-PGJ(2) suppressed TGF-beta-induced Smad2 phosphorylation, however enhancing the phosphorylation of ERK, c-Jun N-terminal kinase (JNK), and p38 in TGF-beta-treated Hep3B cells.	15d-pgj	0-7	transforming growth factor beta 1	Homo sapiens	150-158
19114032-6	2009	Pretreatment with PPAR-gamma agonist, 15d-PGJ(2), attenuated intestinal NF-kappaB response and I/R-induced gut injury.	15d-pgj	38-45	peroxisome proliferator activated receptor gamma	Homo sapiens	18-28
19167456-3	2009	In the present study, we determined whether NF-kappaB inhibition induces cell death through the mitochondrial apoptotic pathway and whether protein kinase A (PKA) functions upstream of NF-kappaB inhibition by 15d-PGJ(2).	15d-pgj	209-216	nuclear factor kappa B subunit 1	Homo sapiens	185-194
19167456-5	2009	15d-PGJ(2) induced cell death by a PPARgamma-independent mechanism and the cell death was prevented by NF-kappaB p65 transfection.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	35-44
19167456-5	2009	15d-PGJ(2) induced cell death by a PPARgamma-independent mechanism and the cell death was prevented by NF-kappaB p65 transfection.	15d-pgj	0-7	nuclear factor kappa B subunit 1	Homo sapiens	103-112
19167456-6	2009	15d-PGJ(2) treatment caused disruption of mitochondrial membrane potential, cytochrome c release, and caspase-3 activation, suggesting that 15d-PGJ(2) induces cell death through a mitochondria-dependent apoptotic mechanism.	15d-pgj	0-7	cytochrome c, somatic	Homo sapiens	76-88
19167456-6	2009	15d-PGJ(2) treatment caused disruption of mitochondrial membrane potential, cytochrome c release, and caspase-3 activation, suggesting that 15d-PGJ(2) induces cell death through a mitochondria-dependent apoptotic mechanism.	15d-pgj	0-7	caspase 3	Homo sapiens	102-111
19167456-6	2009	15d-PGJ(2) treatment caused disruption of mitochondrial membrane potential, cytochrome c release, and caspase-3 activation, suggesting that 15d-PGJ(2) induces cell death through a mitochondria-dependent apoptotic mechanism.	15d-pgj	140-147	caspase 3	Homo sapiens	102-111
19167456-8	2009	15d-PGJ(2) treatment resulted in an increase in Bax expression, which were blocked by NF-kappaB p65 transfection.	15d-pgj	0-7	BCL2 associated X, apoptosis regulator	Homo sapiens	48-51
19167456-8	2009	15d-PGJ(2) treatment resulted in an increase in Bax expression, which were blocked by NF-kappaB p65 transfection.	15d-pgj	0-7	nuclear factor kappa B subunit 1	Homo sapiens	86-95
19167456-10	2009	Inhibition of NF-kappaB by 15d-PGJ(2) was prevented by addition of forskolin, a PKA activator.	15d-pgj	27-34	nuclear factor kappa B subunit 1	Homo sapiens	14-23
20107546-5	2009	The upregulatory effect of 15d-PGJ(2) in SHR VSMCs was mediated through PPARgamma, and dependent on NF-kappaB activation and ERK phosphorylation.	15d-pgj	27-34	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	72-81
20107546-5	2009	The upregulatory effect of 15d-PGJ(2) in SHR VSMCs was mediated through PPARgamma, and dependent on NF-kappaB activation and ERK phosphorylation.	15d-pgj	27-34	Eph receptor B1	Rattus norvegicus	125-128
20107546-6	2009	However, inhibition of the p38 signaling pathway augmented the upregulatory effect of 15d-PGJ(2) on LPS-induced IL-8/CXCL8 mRNA.	15d-pgj	86-93	mitogen activated protein kinase 14	Rattus norvegicus	27-30
20107546-8	2009	CONCLUSION: Our results indicate that the upregulatory effect of 15d-PGJ(2) on LPS-induced IL-8/CXCL8 expression in SHR VSMCs is mediated through the PPARgamma and ERK pathway, and may be related to NAD(P)H oxidase activity.	15d-pgj	65-72	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	150-159
20107546-8	2009	CONCLUSION: Our results indicate that the upregulatory effect of 15d-PGJ(2) on LPS-induced IL-8/CXCL8 expression in SHR VSMCs is mediated through the PPARgamma and ERK pathway, and may be related to NAD(P)H oxidase activity.	15d-pgj	65-72	Eph receptor B1	Rattus norvegicus	164-167
19114032-6	2009	Pretreatment with PPAR-gamma agonist, 15d-PGJ(2), attenuated intestinal NF-kappaB response and I/R-induced gut injury.	15d-pgj	38-45	nuclear factor kappa B subunit 1	Homo sapiens	72-81
19152448-9	2009	Expression of vascular endothelial growth factor (VEGF) mRNA in PANC-1 cells, which were treated with 15d-PGJ(2) or 9-cis-RA at various concentrations or different duration, was detected by semi-quantitative RT-PCR.	15d-pgj	102-109	vascular endothelial growth factor A	Homo sapiens	14-48
18977231-4	2009	Point mutations of these repositioned residues on the loop and helix H3 almost completely abolished PPARgamma activation by 15d-PGJ(2), indicating that the observed structural alteration may be crucial for PPARgamma activation by the endogenous fatty acid.	15d-pgj	124-131	peroxisome proliferator activated receptor gamma	Homo sapiens	100-109
18977231-4	2009	Point mutations of these repositioned residues on the loop and helix H3 almost completely abolished PPARgamma activation by 15d-PGJ(2), indicating that the observed structural alteration may be crucial for PPARgamma activation by the endogenous fatty acid.	15d-pgj	124-131	peroxisome proliferator activated receptor gamma	Homo sapiens	206-215
19152448-9	2009	Expression of vascular endothelial growth factor (VEGF) mRNA in PANC-1 cells, which were treated with 15d-PGJ(2) or 9-cis-RA at various concentrations or different duration, was detected by semi-quantitative RT-PCR.	15d-pgj	102-109	vascular endothelial growth factor A	Homo sapiens	50-54
18771658-6	2008	15d-PGJ(2) inhibits angiogenesis via suppression of pro-inflammatory enzymes and cytokines, while it also stimulates angiogenesis via induction of heme oxygenase-1, endothelial nitric-oxide synthase, and hypoxia inducible factor-1alpha.	15d-pgj	0-7	hypoxia inducible factor 1 subunit alpha	Homo sapiens	204-235
18983509-10	2009	15d-PGJ(2)-induced HO-1 was independent of PPARgamma, but could be replicated using other electrophilic prostaglandins, suggesting that the electrophilic properties of 15d-PGJ(2) were important for HO-1 induction.	15d-pgj	0-7	heme oxygenase 1	Homo sapiens	19-23
18983509-10	2009	15d-PGJ(2)-induced HO-1 was independent of PPARgamma, but could be replicated using other electrophilic prostaglandins, suggesting that the electrophilic properties of 15d-PGJ(2) were important for HO-1 induction.	15d-pgj	0-7	heme oxygenase 1	Homo sapiens	198-202
18983509-10	2009	15d-PGJ(2)-induced HO-1 was independent of PPARgamma, but could be replicated using other electrophilic prostaglandins, suggesting that the electrophilic properties of 15d-PGJ(2) were important for HO-1 induction.	15d-pgj	168-175	heme oxygenase 1	Homo sapiens	19-23
18775681-9	2008	Taken together, these findings suggest that 15d-PGJ(2) augments cellular antioxidant defense capacity through activation of Akt and ERK signal pathways that leads to Nrf2 activation, and subsequently HO-1 induction, thereby protecting the PC12 cells from H2O2-induced oxidative cell death.	15d-pgj	44-51	AKT serine/threonine kinase 1	Rattus norvegicus	124-127
18775681-9	2008	Taken together, these findings suggest that 15d-PGJ(2) augments cellular antioxidant defense capacity through activation of Akt and ERK signal pathways that leads to Nrf2 activation, and subsequently HO-1 induction, thereby protecting the PC12 cells from H2O2-induced oxidative cell death.	15d-pgj	44-51	mitogen activated protein kinase 3	Rattus norvegicus	132-135
18775681-9	2008	Taken together, these findings suggest that 15d-PGJ(2) augments cellular antioxidant defense capacity through activation of Akt and ERK signal pathways that leads to Nrf2 activation, and subsequently HO-1 induction, thereby protecting the PC12 cells from H2O2-induced oxidative cell death.	15d-pgj	44-51	NFE2 like bZIP transcription factor 2	Rattus norvegicus	166-170
18775681-9	2008	Taken together, these findings suggest that 15d-PGJ(2) augments cellular antioxidant defense capacity through activation of Akt and ERK signal pathways that leads to Nrf2 activation, and subsequently HO-1 induction, thereby protecting the PC12 cells from H2O2-induced oxidative cell death.	15d-pgj	44-51	heme oxygenase 1	Rattus norvegicus	200-204
19050284-4	2008	In the present study, we focused on the inhibitory action of 15d-PGJ(2) on the chemokine MCP-1, which plays a key role in the initiation and progression of inflammation by recruiting inflammatory cells to lesion sites.	15d-pgj	61-68	C-C motif chemokine ligand 2	Homo sapiens	89-94
19050284-6	2008	The inhibitory effects of 15d-PGJ(2) on MCP-1 resulted from its actions on the transcription factors, AP-1 and specificity protein-1, which play key roles in IFN-gamma-induced MCP-1 expression in astrocytes.	15d-pgj	26-33	C-C motif chemokine ligand 2	Homo sapiens	40-45
19050284-6	2008	The inhibitory effects of 15d-PGJ(2) on MCP-1 resulted from its actions on the transcription factors, AP-1 and specificity protein-1, which play key roles in IFN-gamma-induced MCP-1 expression in astrocytes.	15d-pgj	26-33	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	102-132
19050284-6	2008	The inhibitory effects of 15d-PGJ(2) on MCP-1 resulted from its actions on the transcription factors, AP-1 and specificity protein-1, which play key roles in IFN-gamma-induced MCP-1 expression in astrocytes.	15d-pgj	26-33	interferon gamma	Homo sapiens	158-167
19050284-6	2008	The inhibitory effects of 15d-PGJ(2) on MCP-1 resulted from its actions on the transcription factors, AP-1 and specificity protein-1, which play key roles in IFN-gamma-induced MCP-1 expression in astrocytes.	15d-pgj	26-33	C-C motif chemokine ligand 2	Homo sapiens	176-181
19050284-7	2008	Of interest, the negative effects of 15d-PGJ(2) on AP-1/specificity protein-1 signaling and the resulting inhibition of MCP-1 expression were mediated by MAPK phosphatase (MKP)-1 activity, which was induced by 15d-PGJ(2) in a peroxisome proliferator-activated receptor-independent manner.	15d-pgj	37-44	Sp1 transcription factor	Homo sapiens	56-77
19050284-7	2008	Of interest, the negative effects of 15d-PGJ(2) on AP-1/specificity protein-1 signaling and the resulting inhibition of MCP-1 expression were mediated by MAPK phosphatase (MKP)-1 activity, which was induced by 15d-PGJ(2) in a peroxisome proliferator-activated receptor-independent manner.	15d-pgj	37-44	C-C motif chemokine ligand 2	Homo sapiens	120-125
19050284-7	2008	Of interest, the negative effects of 15d-PGJ(2) on AP-1/specificity protein-1 signaling and the resulting inhibition of MCP-1 expression were mediated by MAPK phosphatase (MKP)-1 activity, which was induced by 15d-PGJ(2) in a peroxisome proliferator-activated receptor-independent manner.	15d-pgj	37-44	dual specificity phosphatase 1	Homo sapiens	154-178
19050284-7	2008	Of interest, the negative effects of 15d-PGJ(2) on AP-1/specificity protein-1 signaling and the resulting inhibition of MCP-1 expression were mediated by MAPK phosphatase (MKP)-1 activity, which was induced by 15d-PGJ(2) in a peroxisome proliferator-activated receptor-independent manner.	15d-pgj	210-217	Sp1 transcription factor	Homo sapiens	56-77
19050284-7	2008	Of interest, the negative effects of 15d-PGJ(2) on AP-1/specificity protein-1 signaling and the resulting inhibition of MCP-1 expression were mediated by MAPK phosphatase (MKP)-1 activity, which was induced by 15d-PGJ(2) in a peroxisome proliferator-activated receptor-independent manner.	15d-pgj	210-217	C-C motif chemokine ligand 2	Homo sapiens	120-125
19050284-7	2008	Of interest, the negative effects of 15d-PGJ(2) on AP-1/specificity protein-1 signaling and the resulting inhibition of MCP-1 expression were mediated by MAPK phosphatase (MKP)-1 activity, which was induced by 15d-PGJ(2) in a peroxisome proliferator-activated receptor-independent manner.	15d-pgj	210-217	dual specificity phosphatase 1	Homo sapiens	154-178
19050284-9	2008	Considering the importance of MCP-1 in inflammatory processes, our results suggest that 15d-PGJ(2) analogues may have therapeutic potential to attenuate inflammatory brain diseases by inducing MKP-1 expression.	15d-pgj	88-95	C-C motif chemokine ligand 2	Homo sapiens	30-35
19050284-9	2008	Considering the importance of MCP-1 in inflammatory processes, our results suggest that 15d-PGJ(2) analogues may have therapeutic potential to attenuate inflammatory brain diseases by inducing MKP-1 expression.	15d-pgj	88-95	dual specificity phosphatase 1	Homo sapiens	193-198
18665800-2	2008	It has been demonstrated that 15d-PGJ(2) potently increases the generation of interleukin-8 (IL-8) in human microvascular endothelial cells (HMEC-1s); however, the mechanism of this induction is not known.	15d-pgj	30-37	C-X-C motif chemokine ligand 8	Homo sapiens	78-91
18665800-2	2008	It has been demonstrated that 15d-PGJ(2) potently increases the generation of interleukin-8 (IL-8) in human microvascular endothelial cells (HMEC-1s); however, the mechanism of this induction is not known.	15d-pgj	30-37	C-X-C motif chemokine ligand 8	Homo sapiens	93-97
18778734-10	2008	While induction of heme oxygenase-1 was implicated in the cytoprotection by 15d-PGJ(2) under some experimental conditions, additional experiments indicated that this enzyme was not involved in the cytoprotection observed in this system.	15d-pgj	76-83	heme oxygenase 1	Homo sapiens	19-35
18204896-4	2008	In both of them, TGZ, CGZ and 15d-PGJ(2) induced an inhibition of ERalpha signalling associated with the proteasomal degradation of ERalpha.	15d-pgj	30-37	estrogen receptor 1	Homo sapiens	66-73
18204896-4	2008	In both of them, TGZ, CGZ and 15d-PGJ(2) induced an inhibition of ERalpha signalling associated with the proteasomal degradation of ERalpha.	15d-pgj	30-37	estrogen receptor 1	Homo sapiens	132-139
18596134-6	2008	Combined results from EMSA and western blot analysis revealed the inhibitory ability of 15d-PGJ(2), but not of synthetic PPARgamma ligands, on IFN-gamma-induced tyrosine phosphorylation of JAK1, JAK2, STAT1 and nuclear STAT1 translocation and DNA binding.	15d-pgj	88-95	interferon gamma	Homo sapiens	143-152
18596134-6	2008	Combined results from EMSA and western blot analysis revealed the inhibitory ability of 15d-PGJ(2), but not of synthetic PPARgamma ligands, on IFN-gamma-induced tyrosine phosphorylation of JAK1, JAK2, STAT1 and nuclear STAT1 translocation and DNA binding.	15d-pgj	88-95	Janus kinase 1	Homo sapiens	189-193
18596134-6	2008	Combined results from EMSA and western blot analysis revealed the inhibitory ability of 15d-PGJ(2), but not of synthetic PPARgamma ligands, on IFN-gamma-induced tyrosine phosphorylation of JAK1, JAK2, STAT1 and nuclear STAT1 translocation and DNA binding.	15d-pgj	88-95	Janus kinase 2	Homo sapiens	195-199
18596134-6	2008	Combined results from EMSA and western blot analysis revealed the inhibitory ability of 15d-PGJ(2), but not of synthetic PPARgamma ligands, on IFN-gamma-induced tyrosine phosphorylation of JAK1, JAK2, STAT1 and nuclear STAT1 translocation and DNA binding.	15d-pgj	88-95	signal transducer and activator of transcription 1	Homo sapiens	201-206
18596134-6	2008	Combined results from EMSA and western blot analysis revealed the inhibitory ability of 15d-PGJ(2), but not of synthetic PPARgamma ligands, on IFN-gamma-induced tyrosine phosphorylation of JAK1, JAK2, STAT1 and nuclear STAT1 translocation and DNA binding.	15d-pgj	88-95	signal transducer and activator of transcription 1	Homo sapiens	219-224
18596134-7	2008	CONCLUSIONS: Our results demonstrate that 15d-PGJ(2) inhibits INF-gamma-induced chemokine expression in mesangial cells by targeting the JAK/STAT signalling pathway.	15d-pgj	42-49	signal transducer and activator of transcription 1	Homo sapiens	141-145
18718914-4	2008	Moreover, 15d-PGJ(2) activated JNK and p38 MAPK while inducing p53 phosphorylation at sites responsible for p53 activity.	15d-pgj	10-17	mitogen-activated protein kinase 8	Homo sapiens	31-34
18718914-4	2008	Moreover, 15d-PGJ(2) activated JNK and p38 MAPK while inducing p53 phosphorylation at sites responsible for p53 activity.	15d-pgj	10-17	mitogen-activated protein kinase 14	Homo sapiens	39-42
18718914-5	2008	JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) pretreatment attenuated 15d-PGJ(2)-mediated apoptosis and suppressed the p21(Waf1) and Bax expressions without affecting p53 protein accumulation.	15d-pgj	82-89	mitogen-activated protein kinase 8	Homo sapiens	0-3
18718914-4	2008	Moreover, 15d-PGJ(2) activated JNK and p38 MAPK while inducing p53 phosphorylation at sites responsible for p53 activity.	15d-pgj	10-17	tumor protein p53	Homo sapiens	63-66
18718914-5	2008	JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) pretreatment attenuated 15d-PGJ(2)-mediated apoptosis and suppressed the p21(Waf1) and Bax expressions without affecting p53 protein accumulation.	15d-pgj	82-89	mitogen-activated protein kinase 14	Homo sapiens	28-31
18718914-4	2008	Moreover, 15d-PGJ(2) activated JNK and p38 MAPK while inducing p53 phosphorylation at sites responsible for p53 activity.	15d-pgj	10-17	tumor protein p53	Homo sapiens	108-111
18718914-6	2008	Pretreatment with SP600125 partially prevented the phosphorylation of p53 at serines 33 and 392 induced by 15d-PGJ(2).	15d-pgj	107-114	tumor protein p53	Homo sapiens	70-73
18523308-6	2008	We further revealed that certain 15d-PGJ(2)-related PGs such as 15d-PGD(2) and PGD(2) also suppressed the ligand-stimulated increase of TLR2 expression, whereas PGE(2) and arachidonic acids did not.	15d-pgj	33-40	toll like receptor 2	Homo sapiens	136-140
18718914-9	2008	Using a mouse model of corneal neovascularization, it was demonstrated in vivo that 15d-PGJ(2) induced reactive oxygen species generation, activated JNK and p38 MAPK, induced p53 accumulation/phosphorylation, and induced vascular endothelial cell apoptosis, which could be abolished by N-acetylcysteine, SP600125, SB203580, or a virus-derived amphipathic peptides-based p53 small interfering RNA.	15d-pgj	84-91	mitogen-activated protein kinase 8	Mus musculus	149-152
18718914-9	2008	Using a mouse model of corneal neovascularization, it was demonstrated in vivo that 15d-PGJ(2) induced reactive oxygen species generation, activated JNK and p38 MAPK, induced p53 accumulation/phosphorylation, and induced vascular endothelial cell apoptosis, which could be abolished by N-acetylcysteine, SP600125, SB203580, or a virus-derived amphipathic peptides-based p53 small interfering RNA.	15d-pgj	84-91	mitogen-activated protein kinase 14	Mus musculus	157-165
18718914-9	2008	Using a mouse model of corneal neovascularization, it was demonstrated in vivo that 15d-PGJ(2) induced reactive oxygen species generation, activated JNK and p38 MAPK, induced p53 accumulation/phosphorylation, and induced vascular endothelial cell apoptosis, which could be abolished by N-acetylcysteine, SP600125, SB203580, or a virus-derived amphipathic peptides-based p53 small interfering RNA.	15d-pgj	84-91	transformation related protein 53, pseudogene	Mus musculus	175-178
18718914-9	2008	Using a mouse model of corneal neovascularization, it was demonstrated in vivo that 15d-PGJ(2) induced reactive oxygen species generation, activated JNK and p38 MAPK, induced p53 accumulation/phosphorylation, and induced vascular endothelial cell apoptosis, which could be abolished by N-acetylcysteine, SP600125, SB203580, or a virus-derived amphipathic peptides-based p53 small interfering RNA.	15d-pgj	84-91	transformation related protein 53, pseudogene	Mus musculus	370-373
18718914-10	2008	This is the first study that 15d-PGJ(2) induces vascular endothelial cell apoptosis through the signaling of JNK and p38 MAPK-mediated p53 activation both in vitro and in vivo, further establishing the potential of 15d-PGJ(2) as an anti-angiogenesis agent.	15d-pgj	29-36	mitogen-activated protein kinase 8	Homo sapiens	109-112
18718914-10	2008	This is the first study that 15d-PGJ(2) induces vascular endothelial cell apoptosis through the signaling of JNK and p38 MAPK-mediated p53 activation both in vitro and in vivo, further establishing the potential of 15d-PGJ(2) as an anti-angiogenesis agent.	15d-pgj	29-36	mitogen-activated protein kinase 14	Homo sapiens	117-120
18718914-10	2008	This is the first study that 15d-PGJ(2) induces vascular endothelial cell apoptosis through the signaling of JNK and p38 MAPK-mediated p53 activation both in vitro and in vivo, further establishing the potential of 15d-PGJ(2) as an anti-angiogenesis agent.	15d-pgj	29-36	tumor protein p53	Homo sapiens	135-138
18718914-10	2008	This is the first study that 15d-PGJ(2) induces vascular endothelial cell apoptosis through the signaling of JNK and p38 MAPK-mediated p53 activation both in vitro and in vivo, further establishing the potential of 15d-PGJ(2) as an anti-angiogenesis agent.	15d-pgj	215-222	tumor protein p53	Homo sapiens	135-138
18641309-9	2008	Indeed, Bid cleavage and cytochrome c release following 15d-PGJ(2) but not MEHP treatment was profoundly inhibited by Z-VAD-FMK, suggesting that 15d-PGJ(2) activates apoptosis via two pathways, Bax mobilization and protease-dependent Bid cleavage.	15d-pgj	56-63	BH3 interacting domain death agonist	Homo sapiens	8-11
18641309-9	2008	Indeed, Bid cleavage and cytochrome c release following 15d-PGJ(2) but not MEHP treatment was profoundly inhibited by Z-VAD-FMK, suggesting that 15d-PGJ(2) activates apoptosis via two pathways, Bax mobilization and protease-dependent Bid cleavage.	15d-pgj	56-63	cytochrome c, somatic	Homo sapiens	25-37
18641309-9	2008	Indeed, Bid cleavage and cytochrome c release following 15d-PGJ(2) but not MEHP treatment was profoundly inhibited by Z-VAD-FMK, suggesting that 15d-PGJ(2) activates apoptosis via two pathways, Bax mobilization and protease-dependent Bid cleavage.	15d-pgj	56-63	BCL2 associated X, apoptosis regulator	Homo sapiens	194-197
18641309-9	2008	Indeed, Bid cleavage and cytochrome c release following 15d-PGJ(2) but not MEHP treatment was profoundly inhibited by Z-VAD-FMK, suggesting that 15d-PGJ(2) activates apoptosis via two pathways, Bax mobilization and protease-dependent Bid cleavage.	15d-pgj	56-63	BH3 interacting domain death agonist	Homo sapiens	234-237
18641309-9	2008	Indeed, Bid cleavage and cytochrome c release following 15d-PGJ(2) but not MEHP treatment was profoundly inhibited by Z-VAD-FMK, suggesting that 15d-PGJ(2) activates apoptosis via two pathways, Bax mobilization and protease-dependent Bid cleavage.	15d-pgj	145-152	BH3 interacting domain death agonist	Homo sapiens	8-11
18641309-9	2008	Indeed, Bid cleavage and cytochrome c release following 15d-PGJ(2) but not MEHP treatment was profoundly inhibited by Z-VAD-FMK, suggesting that 15d-PGJ(2) activates apoptosis via two pathways, Bax mobilization and protease-dependent Bid cleavage.	15d-pgj	145-152	cytochrome c, somatic	Homo sapiens	25-37
18641309-9	2008	Indeed, Bid cleavage and cytochrome c release following 15d-PGJ(2) but not MEHP treatment was profoundly inhibited by Z-VAD-FMK, suggesting that 15d-PGJ(2) activates apoptosis via two pathways, Bax mobilization and protease-dependent Bid cleavage.	15d-pgj	145-152	BCL2 associated X, apoptosis regulator	Homo sapiens	194-197
18641309-9	2008	Indeed, Bid cleavage and cytochrome c release following 15d-PGJ(2) but not MEHP treatment was profoundly inhibited by Z-VAD-FMK, suggesting that 15d-PGJ(2) activates apoptosis via two pathways, Bax mobilization and protease-dependent Bid cleavage.	15d-pgj	145-152	BH3 interacting domain death agonist	Homo sapiens	234-237
18523308-9	2008	Taken together, our results suggest that 15d-PGJ(2), 15d-PGD(2), and PGD(2) may play notable roles as modulators of the TLR2-mediated inflammatory events, and provide new insight into the resolution of inflammation in the brain.	15d-pgj	41-48	toll like receptor 2	Homo sapiens	120-124
18456507-5	2008	N-acetylcysteine (NAC), a thiol reducing agent, but not reactive oxygen species scavengers, prevented 15d-PGJ(2)-induced COX-2 up-regulation.	15d-pgj	102-109	synuclein alpha	Homo sapiens	18-21
18456507-5	2008	N-acetylcysteine (NAC), a thiol reducing agent, but not reactive oxygen species scavengers, prevented 15d-PGJ(2)-induced COX-2 up-regulation.	15d-pgj	102-109	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	121-126
18456507-4	2008	15d-PGJ(2) induced an increase in the reduced glutathione (GSH) content and up-regulated COX-2 protein expression, but not COX-1, in a manner which was unaffected by selective peroxisome proliferator-activated receptor gamma (PPARgamma) blockade nor mimicked by ciglitazone, a PPARgamma agonist.	15d-pgj	0-7	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	89-94
18456507-4	2008	15d-PGJ(2) induced an increase in the reduced glutathione (GSH) content and up-regulated COX-2 protein expression, but not COX-1, in a manner which was unaffected by selective peroxisome proliferator-activated receptor gamma (PPARgamma) blockade nor mimicked by ciglitazone, a PPARgamma agonist.	15d-pgj	0-7	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	123-128
18456507-6	2008	Depletion of GSH by buthionine sulfoximine, which diminishes thiol antioxidant activity, cooperated with 15d-PGJ(2) to accumulate COX-2.	15d-pgj	105-112	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	130-135
18456507-4	2008	15d-PGJ(2) induced an increase in the reduced glutathione (GSH) content and up-regulated COX-2 protein expression, but not COX-1, in a manner which was unaffected by selective peroxisome proliferator-activated receptor gamma (PPARgamma) blockade nor mimicked by ciglitazone, a PPARgamma agonist.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	226-235
18456507-4	2008	15d-PGJ(2) induced an increase in the reduced glutathione (GSH) content and up-regulated COX-2 protein expression, but not COX-1, in a manner which was unaffected by selective peroxisome proliferator-activated receptor gamma (PPARgamma) blockade nor mimicked by ciglitazone, a PPARgamma agonist.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	277-286
18456507-9	2008	Up-regulation of COX-2 by 15d-PGJ(2) did not result in increased PGE(2) production.	15d-pgj	26-33	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	17-22
18456507-10	2008	Furthermore, preincubation with 15d-PGJ(2) inhibited IL-1beta-induced PGE(2) production although IL-1beta-induced COX-2 expression remained unaffected by the treatment with 15d-PGJ(2).	15d-pgj	32-39	interleukin 1 beta	Homo sapiens	53-61
18192694-6	2008	Furthermore, 15d-PGJ(2) formed reactive oxygen species, which led to increased phosphorylation of Akt, DNA binding of AP-1 and expression of COX-2.	15d-pgj	13-20	prostaglandin-endoperoxide synthase 2	Homo sapiens	141-146
18208815-9	2008	Moreover, 15d-PGJ(2) induced both PPARalpha and PPARgamma activation.	15d-pgj	10-17	peroxisome proliferator activated receptor alpha	Mus musculus	34-43
18208815-9	2008	Moreover, 15d-PGJ(2) induced both PPARalpha and PPARgamma activation.	15d-pgj	10-17	peroxisome proliferator activated receptor gamma	Mus musculus	48-57
18192694-6	2008	Furthermore, 15d-PGJ(2) formed reactive oxygen species, which led to increased phosphorylation of Akt, DNA binding of AP-1 and expression of COX-2.	15d-pgj	13-20	AKT serine/threonine kinase 1	Homo sapiens	98-101
18192694-8	2008	Taken together, these observations suggest that 15d-PGJ(2) produced by COX-2 overexpression may function as a positive regulator of COX-2 in human breast cancer MCF-7 cells.	15d-pgj	48-55	prostaglandin-endoperoxide synthase 2	Homo sapiens	71-76
18192694-6	2008	Furthermore, 15d-PGJ(2) formed reactive oxygen species, which led to increased phosphorylation of Akt, DNA binding of AP-1 and expression of COX-2.	15d-pgj	13-20	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	118-122
18192694-8	2008	Taken together, these observations suggest that 15d-PGJ(2) produced by COX-2 overexpression may function as a positive regulator of COX-2 in human breast cancer MCF-7 cells.	15d-pgj	48-55	prostaglandin-endoperoxide synthase 2	Homo sapiens	132-137
18079203-6	2008	Pharmacological inhibition (predominantly through beta-adrenergic receptor) of the stress-released catecholamines in the central nervous system regulates 15d-PGJ(2) and PGE(2) synthesis, by reducing COX-2 overexpression, and reduces PPARgamma activation.	15d-pgj	154-161	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	199-204
18079203-6	2008	Pharmacological inhibition (predominantly through beta-adrenergic receptor) of the stress-released catecholamines in the central nervous system regulates 15d-PGJ(2) and PGE(2) synthesis, by reducing COX-2 overexpression, and reduces PPARgamma activation.	15d-pgj	154-161	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	233-242
18079203-9	2008	Finally, the selective blockade of the N-methyl-d-aspartate type of glutamate receptor after stress also negatively regulates 15d-PGJ(2) and PGE(2) production by COX-2 down-regulation and decrease in PPARgamma transcriptional activity and expression.	15d-pgj	126-133	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	162-167
18382621-5	2008	This is followed by a detailed review on those reports that examine the protective effect of the natural PPARgamma ligand, 15d-PGJ(2), against RPE oxidative stress.	15d-pgj	123-130	peroxisome proliferator activated receptor gamma	Homo sapiens	105-114
18725985-5	2008	The treatment of OUMS-27 by 15d-PGJ(2), the most potent endogenous ligand for PPARgamma, downregulated expression of Bcl-xL and induced transient upregulation of proapoptotic Bax, which could accelerate cytochrome c release from mitochondria to the cytosol, followed by induction of caspase-dependent apoptosis.	15d-pgj	28-35	peroxisome proliferator activated receptor gamma	Homo sapiens	78-87
18725985-5	2008	The treatment of OUMS-27 by 15d-PGJ(2), the most potent endogenous ligand for PPARgamma, downregulated expression of Bcl-xL and induced transient upregulation of proapoptotic Bax, which could accelerate cytochrome c release from mitochondria to the cytosol, followed by induction of caspase-dependent apoptosis.	15d-pgj	28-35	BCL2 like 1	Homo sapiens	117-123
18725985-5	2008	The treatment of OUMS-27 by 15d-PGJ(2), the most potent endogenous ligand for PPARgamma, downregulated expression of Bcl-xL and induced transient upregulation of proapoptotic Bax, which could accelerate cytochrome c release from mitochondria to the cytosol, followed by induction of caspase-dependent apoptosis.	15d-pgj	28-35	BCL2 associated X, apoptosis regulator	Homo sapiens	175-178
18725985-5	2008	The treatment of OUMS-27 by 15d-PGJ(2), the most potent endogenous ligand for PPARgamma, downregulated expression of Bcl-xL and induced transient upregulation of proapoptotic Bax, which could accelerate cytochrome c release from mitochondria to the cytosol, followed by induction of caspase-dependent apoptosis.	15d-pgj	28-35	cytochrome c, somatic	Homo sapiens	203-215
18725985-6	2008	15d-PGJ(2) induced the expression of CDK inhibitor p21 protein in human chondrosarcoma cells, which appears to be involved in the mechanism of inhibition of cell proliferation.	15d-pgj	0-7	H3 histone pseudogene 16	Homo sapiens	51-54
18231633-2	2008	We previously reported that 15d-PGJ(2) can suppress interleukin (IL)-1beta-induced prostaglandin E(2) (PGE(2)) synthesis in synoviocytes of rheumatoid arthritis (RA).	15d-pgj	28-35	interleukin 1 beta	Mus musculus	52-74
18231633-5	2008	Treatment with 15d-PGJ(2) led to a significant increase in IL-1alpha-induced COX-2 expression and PGE(2) production in a dose dependent manner.	15d-pgj	15-22	interleukin 1 alpha	Mus musculus	59-68
18231633-5	2008	Treatment with 15d-PGJ(2) led to a significant increase in IL-1alpha-induced COX-2 expression and PGE(2) production in a dose dependent manner.	15d-pgj	15-22	cytochrome c oxidase II, mitochondrial	Mus musculus	77-82
17928570-8	2008	Moreover, the antinociceptive effect of 15d-PGJ(2) was also blocked by naloxone and by the PPAR-gamma antagonist 2-chloro-5-nitro-N-phenylbenzamide (GW9662), suggesting the involvement of peripheral opioids and PPAR-gamma receptor in the process.	15d-pgj	40-47	peroxisome proliferator activated receptor gamma	Homo sapiens	91-101
17928570-8	2008	Moreover, the antinociceptive effect of 15d-PGJ(2) was also blocked by naloxone and by the PPAR-gamma antagonist 2-chloro-5-nitro-N-phenylbenzamide (GW9662), suggesting the involvement of peripheral opioids and PPAR-gamma receptor in the process.	15d-pgj	40-47	peroxisome proliferator activated receptor gamma	Homo sapiens	211-221
17928570-10	2008	Taken together, these results demonstrate for the first time that 15d-PGJ(2) inhibits inflammatory hypernociception via PPAR-gamma activation.	15d-pgj	66-73	peroxisome proliferator activated receptor gamma	Homo sapiens	120-130
18584038-6	2008	For example, 15d-PGJ(2) and pioglitazone were both effective at reducing IL-12 p40 release by TLR ligand-activated glia, whereas CXCL2 expression was either augmented or inhibited by 15d-PGJ(2), effects that were dependent on the TLR ligand examined.	15d-pgj	183-190	C-X-C motif chemokine ligand 2	Homo sapiens	129-134
17697048-4	2007	Pre-treatment with 15d-PGJ(2) increased the intracellular glutathione (GSH) as well as the gene expression of glutamate-cysteine ligase (GCL), the rate-limiting enzyme of GSH synthesis.	15d-pgj	19-26	glutamate-cysteine ligase catalytic subunit	Homo sapiens	110-135
18162716-2	2007	In this study, we investigated the effects of 15d-PGJ(2), a high-affinity ligand of PPAR-gamma, on dedifferentiation and on inflammatory responses such as COX-2 expression and PGE(2) production in rabbit articular chondrocytes with a focus on ERK-1/-2, p38 kinase, and PPAR-gamma activation.	15d-pgj	46-53	peroxisome proliferator-activated receptor gamma	Oryctolagus cuniculus	84-94
18162716-3	2007	We report here that 15d-PGJ(2) induced dedifferentiation and/or COX-2 expression and subsequent PGE(2) production.	15d-pgj	20-27	cytochrome c oxidase subunit II	Oryctolagus cuniculus	64-69
18162716-4	2007	15d-PGJ(2) treatment stimulated activation of ERK-1/-2, p38 kinase, and PPAR-gamma.	15d-pgj	0-7	peroxisome proliferator-activated receptor gamma	Oryctolagus cuniculus	72-82
17673570-5	2007	Our data indicate that both the chemically reactive cyclopentenone moiety of 15d-PGJ(2) and the activation of PPARgamma may be involved in this repressive mechanism.	15d-pgj	77-84	peroxisome proliferator activated receptor gamma	Homo sapiens	110-119
17673570-8	2007	Moreover, 15d-PGJ(2)-mediated activation of the transcription factor heat shock factor-1 may contribute to inhibit trail promoter activity in transfected Jurkat T cells.	15d-pgj	10-17	TNF superfamily member 10	Homo sapiens	115-120
17658243-3	2007	15d-PGJ(2) induced stabilization of HIF-1alpha protein, without affecting HIF-1alpha mRNA levels or proteasome activity, leading to its nuclear accumulation and activation of HIF-induced transcription.	15d-pgj	0-7	hypoxia inducible factor 1 subunit alpha	Homo sapiens	36-46
17551094-9	2007	These results indicate that 15d-PGJ(2) sensitizes TRAIL-resistant cells to TRAIL in a PPAR gamma-independent manner and that the use of 15d-PGJ(2) or its inducers, such as FCB, is a new strategy for cancer therapy.	15d-pgj	28-35	TNF superfamily member 10	Homo sapiens	50-55
17551094-9	2007	These results indicate that 15d-PGJ(2) sensitizes TRAIL-resistant cells to TRAIL in a PPAR gamma-independent manner and that the use of 15d-PGJ(2) or its inducers, such as FCB, is a new strategy for cancer therapy.	15d-pgj	28-35	TNF superfamily member 10	Homo sapiens	75-80
17706193-6	2007	We found that 15d-PGJ(2) induced apoptosis in the MIAPaCa-2 pancreatic cancer cells and dose-dependently decreased hTERT mRNA and protein expression.	15d-pgj	14-21	telomerase reverse transcriptase	Homo sapiens	115-120
17706193-12	2007	Furthermore, 15d-PGJ(2) inhibits ERbeta-mediated hTERT gene transcription by suppressing ERbeta phosphorylation via the inhibition of MAP kinase signaling.	15d-pgj	13-20	estrogen receptor 2	Homo sapiens	33-39
17706193-12	2007	Furthermore, 15d-PGJ(2) inhibits ERbeta-mediated hTERT gene transcription by suppressing ERbeta phosphorylation via the inhibition of MAP kinase signaling.	15d-pgj	13-20	telomerase reverse transcriptase	Homo sapiens	49-54
17706193-12	2007	Furthermore, 15d-PGJ(2) inhibits ERbeta-mediated hTERT gene transcription by suppressing ERbeta phosphorylation via the inhibition of MAP kinase signaling.	15d-pgj	13-20	estrogen receptor 2	Homo sapiens	89-95
17697048-4	2007	Pre-treatment with 15d-PGJ(2) increased the intracellular glutathione (GSH) as well as the gene expression of glutamate-cysteine ligase (GCL), the rate-limiting enzyme of GSH synthesis.	15d-pgj	19-26	glutamate-cysteine ligase catalytic subunit	Homo sapiens	137-140
17418102-2	2007	Here we found that 15d-PGJ(2)-induced eNOS reduction is inversely associated with heat shock protein 70 (HSP70) induction in endothelial cells.	15d-pgj	19-26	nitric oxide synthase 3	Homo sapiens	38-42
17418102-2	2007	Here we found that 15d-PGJ(2)-induced eNOS reduction is inversely associated with heat shock protein 70 (HSP70) induction in endothelial cells.	15d-pgj	19-26	heat shock protein family A (Hsp70) member 4	Homo sapiens	82-103
17418102-2	2007	Here we found that 15d-PGJ(2)-induced eNOS reduction is inversely associated with heat shock protein 70 (HSP70) induction in endothelial cells.	15d-pgj	19-26	heat shock protein family A (Hsp70) member 4	Homo sapiens	105-110
17418102-5	2007	Interestingly, we observed that 15d-PGJ(2) induced HSP70 in a dose-dependent manner.	15d-pgj	32-39	heat shock protein family A (Hsp70) member 4	Homo sapiens	51-56
17418102-7	2007	Cellular fractionation revealed that treatment with 15d-PGJ(2) increased eNOS distribution 2.5-fold from soluble to insoluble fractions.	15d-pgj	52-59	nitric oxide synthase 3	Homo sapiens	73-77
17028981-10	2007	Thus, 15d-PGJ(2) induced cell cycle arrest at the G(2)-M phase via inhibition of cyclin B1 expression and aurora-B kinase activity.	15d-pgj	6-13	cyclin B1	Homo sapiens	81-90
17363578-4	2007	In addition, 15d-PGJ(2) directly modifies ERalpha protein via its reactive cyclopentenone moiety, evidenced by incorporation of biotinylated 15d-PGJ(2) into ERalpha, both in vitro and in vivo.	15d-pgj	13-20	estrogen receptor 1	Homo sapiens	42-49
17484875-9	2007	Pretreatment with PPARgamma agonists 15d-PGJ(2) and rosiglitazone prevented colonic inflammation and barrier dysfunction as well as the decrease of IgA production induced after acute stress; PPARgamma specific antagonist T0070907 reverted these effects.	15d-pgj	37-44	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	18-27
17484875-9	2007	Pretreatment with PPARgamma agonists 15d-PGJ(2) and rosiglitazone prevented colonic inflammation and barrier dysfunction as well as the decrease of IgA production induced after acute stress; PPARgamma specific antagonist T0070907 reverted these effects.	15d-pgj	37-44	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	191-200
17371958-7	2007	We show that 15d-PGJ(2) inhibits rankl mRNA expression, protein, and rankl promoter activity by mechanisms mediated by its chemically reactive cyclopentenone moiety.	15d-pgj	13-20	TNF superfamily member 11	Homo sapiens	33-38
17371958-7	2007	We show that 15d-PGJ(2) inhibits rankl mRNA expression, protein, and rankl promoter activity by mechanisms mediated by its chemically reactive cyclopentenone moiety.	15d-pgj	13-20	TNF superfamily member 11	Homo sapiens	69-74
17363578-4	2007	In addition, 15d-PGJ(2) directly modifies ERalpha protein via its reactive cyclopentenone moiety, evidenced by incorporation of biotinylated 15d-PGJ(2) into ERalpha, both in vitro and in vivo.	15d-pgj	13-20	estrogen receptor 1	Homo sapiens	157-164
17363578-4	2007	In addition, 15d-PGJ(2) directly modifies ERalpha protein via its reactive cyclopentenone moiety, evidenced by incorporation of biotinylated 15d-PGJ(2) into ERalpha, both in vitro and in vivo.	15d-pgj	141-148	estrogen receptor 1	Homo sapiens	42-49
17363578-4	2007	In addition, 15d-PGJ(2) directly modifies ERalpha protein via its reactive cyclopentenone moiety, evidenced by incorporation of biotinylated 15d-PGJ(2) into ERalpha, both in vitro and in vivo.	15d-pgj	141-148	estrogen receptor 1	Homo sapiens	157-164
17130903-7	2007	Although the synergistic effect of 15d-PGJ(2) on LPS-induced MIP-2 (CXCL2) mRNA expression was remarkable, the production of MIP-2 (CXCL2) in cells treated with 15d-PGJ(2) and LPS did not increase compared to the production in cells treated with LPS alone.	15d-pgj	161-168	chemokine (C-X-C motif) ligand 2	Mus musculus	132-137
17130903-8	2007	The synergistic action of 15d-PGJ(2) on LPS-induced MIP-2 (CXCL2) mRNA expression was dependent on the activation of nuclear factor-kappaB (NF-kappaB), and 15d-PGJ(2) increased the phosphorylation of p38 and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in cells stimulated with LPS.	15d-pgj	26-33	chemokine (C-X-C motif) ligand 2	Mus musculus	59-64
17130903-7	2007	Although the synergistic effect of 15d-PGJ(2) on LPS-induced MIP-2 (CXCL2) mRNA expression was remarkable, the production of MIP-2 (CXCL2) in cells treated with 15d-PGJ(2) and LPS did not increase compared to the production in cells treated with LPS alone.	15d-pgj	35-42	chemokine (C-X-C motif) ligand 2	Mus musculus	68-73
17130903-8	2007	The synergistic action of 15d-PGJ(2) on LPS-induced MIP-2 (CXCL2) mRNA expression was dependent on the activation of nuclear factor-kappaB (NF-kappaB), and 15d-PGJ(2) increased the phosphorylation of p38 and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in cells stimulated with LPS.	15d-pgj	26-33	mitogen-activated protein kinase 14	Mus musculus	200-203
17130903-9	2007	These results suggest that the synergistic effect of 15d-PGJ(2) on LPS-induced MIP-2 (CXCL2) expression is PPARgamma-independent, and is mediated by the p38 and SAPK/JNK pathway in mitogen-activated protein kinase signaling pathways, which activates NF-kappaB.	15d-pgj	53-60	chemokine (C-X-C motif) ligand 2	Mus musculus	86-91
17130903-9	2007	These results suggest that the synergistic effect of 15d-PGJ(2) on LPS-induced MIP-2 (CXCL2) expression is PPARgamma-independent, and is mediated by the p38 and SAPK/JNK pathway in mitogen-activated protein kinase signaling pathways, which activates NF-kappaB.	15d-pgj	53-60	peroxisome proliferator activated receptor gamma	Mus musculus	107-116
17130903-9	2007	These results suggest that the synergistic effect of 15d-PGJ(2) on LPS-induced MIP-2 (CXCL2) expression is PPARgamma-independent, and is mediated by the p38 and SAPK/JNK pathway in mitogen-activated protein kinase signaling pathways, which activates NF-kappaB.	15d-pgj	53-60	mitogen-activated protein kinase 14	Mus musculus	153-156
16987499-6	2006	15d-PGJ(2) is also well known as an endogenous ligand of peroxisome proliferator-activated receptor gamma (PPARgamma).	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	57-105
17541271-4	2007	For instance, at low concentrations, 15d-PGJ(2) enhances eotaxin-induced chemotaxis, shape change, and actin reorganization in eosinophils through its ligation with PPARgamma.	15d-pgj	37-44	C-C motif chemokine ligand 11	Homo sapiens	57-64
17541271-4	2007	For instance, at low concentrations, 15d-PGJ(2) enhances eotaxin-induced chemotaxis, shape change, and actin reorganization in eosinophils through its ligation with PPARgamma.	15d-pgj	37-44	peroxisome proliferator activated receptor gamma	Homo sapiens	165-174
17541271-6	2007	Conversely, at high concentrations, 15d-PGJ(2) inhibits eosinophil survival by inducing apoptosis in a PPARgamma-independent manner.	15d-pgj	36-43	peroxisome proliferator activated receptor gamma	Homo sapiens	103-112
16987499-6	2006	15d-PGJ(2) is also well known as an endogenous ligand of peroxisome proliferator-activated receptor gamma (PPARgamma).	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	107-116
16818793-7	2006	We found that COX-2 inhibitors (celecoxib and NS398) suppressed the death of microglia induced by a combination of LPS and IL-13 and that exogenous addition of PGE(2) and 15d-PGJ(2) induced microglial death.	15d-pgj	171-178	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	14-19
16412567-2	2006	We showed that treatment with 15d-PGJ(2), a PPARgamma ligand, downregulate the expressions of angiopoietin-1 (Ang-1) in gastric cancer cells MKN45.	15d-pgj	30-37	peroxisome proliferator activated receptor gamma	Homo sapiens	44-53
16412567-2	2006	We showed that treatment with 15d-PGJ(2), a PPARgamma ligand, downregulate the expressions of angiopoietin-1 (Ang-1) in gastric cancer cells MKN45.	15d-pgj	30-37	angiopoietin 1	Homo sapiens	94-108
16412567-2	2006	We showed that treatment with 15d-PGJ(2), a PPARgamma ligand, downregulate the expressions of angiopoietin-1 (Ang-1) in gastric cancer cells MKN45.	15d-pgj	30-37	angiopoietin 1	Homo sapiens	110-115
16412567-6	2006	Our findings supported that 15d-PGJ(2) suppressed angiogenesis of gastric cancer cells by downregulation of Ang-1.	15d-pgj	28-35	angiopoietin 1	Homo sapiens	108-113
16908599-5	2006	15d-PGJ(2)-induced inhibition of NF-kappaB function is rapidly followed by down-regulation of NF-kappaB-dependent antiapoptotic proteins cIAPs 1/2, Bcl-X(L), and cellular FLICE-inhibitory protein, leading to caspase activation and induction of apoptosis in breast cancer cells resistant to treatment with paclitaxel and doxorubicin.	15d-pgj	0-7	baculoviral IAP repeat containing 2	Homo sapiens	137-146
16908599-5	2006	15d-PGJ(2)-induced inhibition of NF-kappaB function is rapidly followed by down-regulation of NF-kappaB-dependent antiapoptotic proteins cIAPs 1/2, Bcl-X(L), and cellular FLICE-inhibitory protein, leading to caspase activation and induction of apoptosis in breast cancer cells resistant to treatment with paclitaxel and doxorubicin.	15d-pgj	0-7	BCL2 like 1	Homo sapiens	148-156
16908599-5	2006	15d-PGJ(2)-induced inhibition of NF-kappaB function is rapidly followed by down-regulation of NF-kappaB-dependent antiapoptotic proteins cIAPs 1/2, Bcl-X(L), and cellular FLICE-inhibitory protein, leading to caspase activation and induction of apoptosis in breast cancer cells resistant to treatment with paclitaxel and doxorubicin.	15d-pgj	0-7	caspase 8	Homo sapiens	171-176
16434095-5	2006	Treatment of placenta, amnion and choriodecidua with both 15d-PGJ(2) and troglitazone decreased basal and LPS-stimulated IL-1beta, IL-6, IL-10 and TNF-alpha release.	15d-pgj	58-65	interleukin 1 beta	Homo sapiens	121-129
16434095-5	2006	Treatment of placenta, amnion and choriodecidua with both 15d-PGJ(2) and troglitazone decreased basal and LPS-stimulated IL-1beta, IL-6, IL-10 and TNF-alpha release.	15d-pgj	58-65	interleukin 6	Homo sapiens	131-135
16434095-5	2006	Treatment of placenta, amnion and choriodecidua with both 15d-PGJ(2) and troglitazone decreased basal and LPS-stimulated IL-1beta, IL-6, IL-10 and TNF-alpha release.	15d-pgj	58-65	interleukin 10	Homo sapiens	137-142
16434095-5	2006	Treatment of placenta, amnion and choriodecidua with both 15d-PGJ(2) and troglitazone decreased basal and LPS-stimulated IL-1beta, IL-6, IL-10 and TNF-alpha release.	15d-pgj	58-65	tumor necrosis factor	Homo sapiens	147-156
16434095-10	2006	15d-PGJ(2) and troglitazone inhibited MMP-9 release from human amnion.	15d-pgj	0-7	matrix metallopeptidase 9	Homo sapiens	38-43
16434095-11	2006	NF-kappaB DNA binding activity and NF-kappaB p65 protein expression was inhibited by treatment with 15d-PGJ(2) in human amnion.	15d-pgj	100-107	RELA proto-oncogene, NF-kB subunit	Homo sapiens	45-48
16818793-11	2006	Furthermore, COX-2 products, PGE(2) and 15d-PGJ(2), caused microglial death, which terminates brain inflammation.	15d-pgj	40-47	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	13-18
16725118-4	2006	Intraventricular injection of 15d-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a proposed endogenous PPARgamma agonist, into the ischemic rat brains significantly increased the PPARgamma-DNA-binding activity and reduced infarction volume at 24 h after reperfusion.	15d-pgj	67-74	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	102-111
16891469-3	2006	Here, we report that 15d-PGJ(2) induces DR5 expression at both mRNA and protein levels, resulting in the synergistic sensitization of TRAIL-induced apoptosis in human neoplastic cells, such as Jurkat human leukemia cells or PC3 human prostate cancer cells.	15d-pgj	21-28	TNF receptor superfamily member 10b	Homo sapiens	40-43
16891469-3	2006	Here, we report that 15d-PGJ(2) induces DR5 expression at both mRNA and protein levels, resulting in the synergistic sensitization of TRAIL-induced apoptosis in human neoplastic cells, such as Jurkat human leukemia cells or PC3 human prostate cancer cells.	15d-pgj	21-28	TNF superfamily member 10	Homo sapiens	134-139
16891469-7	2006	DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 inhibitor efficiently blocked the activation of these apoptotic signal mediators and the induction of apoptotic cell death enhanced by cotreatment with 15d-PGJ(2) and TRAIL.	15d-pgj	221-228	TNF receptor superfamily member 10b	Homo sapiens	0-3
16891469-7	2006	DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 inhibitor efficiently blocked the activation of these apoptotic signal mediators and the induction of apoptotic cell death enhanced by cotreatment with 15d-PGJ(2) and TRAIL.	15d-pgj	221-228	caspase 8	Homo sapiens	59-68
16891469-7	2006	DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 inhibitor efficiently blocked the activation of these apoptotic signal mediators and the induction of apoptotic cell death enhanced by cotreatment with 15d-PGJ(2) and TRAIL.	15d-pgj	221-228	TNF superfamily member 10	Homo sapiens	236-241
16891469-8	2006	Moreover, a double-stranded small interfering RNA targeting DR5 gene, which suppressed DR5 up-regulation by 15d-PGJ(2), significantly attenuated apoptosis induced by cotreatment with 15d-PGJ(2) and TRAIL.	15d-pgj	108-115	TNF receptor superfamily member 10b	Homo sapiens	60-63
16891469-8	2006	Moreover, a double-stranded small interfering RNA targeting DR5 gene, which suppressed DR5 up-regulation by 15d-PGJ(2), significantly attenuated apoptosis induced by cotreatment with 15d-PGJ(2) and TRAIL.	15d-pgj	108-115	TNF receptor superfamily member 10b	Homo sapiens	87-90
16891469-8	2006	Moreover, a double-stranded small interfering RNA targeting DR5 gene, which suppressed DR5 up-regulation by 15d-PGJ(2), significantly attenuated apoptosis induced by cotreatment with 15d-PGJ(2) and TRAIL.	15d-pgj	108-115	TNF superfamily member 10	Homo sapiens	198-203
16891469-8	2006	Moreover, a double-stranded small interfering RNA targeting DR5 gene, which suppressed DR5 up-regulation by 15d-PGJ(2), significantly attenuated apoptosis induced by cotreatment with 15d-PGJ(2) and TRAIL.	15d-pgj	183-190	TNF receptor superfamily member 10b	Homo sapiens	60-63
16891469-8	2006	Moreover, a double-stranded small interfering RNA targeting DR5 gene, which suppressed DR5 up-regulation by 15d-PGJ(2), significantly attenuated apoptosis induced by cotreatment with 15d-PGJ(2) and TRAIL.	15d-pgj	183-190	TNF receptor superfamily member 10b	Homo sapiens	87-90
16725118-4	2006	Intraventricular injection of 15d-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a proposed endogenous PPARgamma agonist, into the ischemic rat brains significantly increased the PPARgamma-DNA-binding activity and reduced infarction volume at 24 h after reperfusion.	15d-pgj	67-74	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	178-187
16547141-6	2006	Lymphocytes isolated from inguinal lymph nodes of hPGD(2)S(-/-) animals showed hyperproliferation and increased IL-2 synthesis effects that were rescued by 15d-PGJ(2), but not PGD(2), working through either of its receptors.	15d-pgj	156-163	interleukin 2	Mus musculus	112-116
16413037-1	2006	In this study, the effects of 15d-PGJ(2) were investigated in IL-6-activated endothelial cells (ECs).	15d-pgj	30-37	interleukin 6	Homo sapiens	62-66
16413037-2	2006	15d-PGJ(2) was found to abrogate phosphorylation on tyr705 of STAT3 in IL-6-treated ECs, in a dose- and time-dependent manner, but did not inhibit serine phosphorylation of STAT3 and the upperstream JAK2 phosphorylation.	15d-pgj	0-7	signal transducer and activator of transcription 3	Homo sapiens	62-67
16413037-2	2006	15d-PGJ(2) was found to abrogate phosphorylation on tyr705 of STAT3 in IL-6-treated ECs, in a dose- and time-dependent manner, but did not inhibit serine phosphorylation of STAT3 and the upperstream JAK2 phosphorylation.	15d-pgj	0-7	interleukin 6	Homo sapiens	71-75
16413037-2	2006	15d-PGJ(2) was found to abrogate phosphorylation on tyr705 of STAT3 in IL-6-treated ECs, in a dose- and time-dependent manner, but did not inhibit serine phosphorylation of STAT3 and the upperstream JAK2 phosphorylation.	15d-pgj	0-7	signal transducer and activator of transcription 3	Homo sapiens	173-178
16413037-2	2006	15d-PGJ(2) was found to abrogate phosphorylation on tyr705 of STAT3 in IL-6-treated ECs, in a dose- and time-dependent manner, but did not inhibit serine phosphorylation of STAT3 and the upperstream JAK2 phosphorylation.	15d-pgj	0-7	Janus kinase 2	Homo sapiens	199-203
16413037-8	2006	Among the antioxidants, only NAC and glutathione reversed the effects of 15d-PGJ(2).	15d-pgj	73-80	X-linked Kx blood group	Homo sapiens	29-32
16413037-9	2006	NAC, glutathione and DTT all reversed the inhibition of STAT3 phosphorylation when preincubated with 15d-PGJ(2).	15d-pgj	101-108	X-linked Kx blood group	Homo sapiens	0-3
16413037-9	2006	NAC, glutathione and DTT all reversed the inhibition of STAT3 phosphorylation when preincubated with 15d-PGJ(2).	15d-pgj	101-108	signal transducer and activator of transcription 3	Homo sapiens	56-61
16413037-10	2006	The inhibition of ICAM-1 gene expression by 15d-PGJ(2) was abrogated by NAC and glutathione in IL-6-treated ECs.	15d-pgj	44-51	intercellular adhesion molecule 1	Homo sapiens	18-24
16413037-10	2006	The inhibition of ICAM-1 gene expression by 15d-PGJ(2) was abrogated by NAC and glutathione in IL-6-treated ECs.	15d-pgj	44-51	X-linked Kx blood group	Homo sapiens	72-75
16413037-10	2006	The inhibition of ICAM-1 gene expression by 15d-PGJ(2) was abrogated by NAC and glutathione in IL-6-treated ECs.	15d-pgj	44-51	interleukin 6	Homo sapiens	95-99
16413037-11	2006	Taken together, these results suggest that 15d-PGJ(2) inhibits IL-6-stimulated phosphorylation on tyr705 of STAT3 dependent on its own electrophilic reactivity in ECs.	15d-pgj	43-50	interleukin 6	Homo sapiens	63-67
16413037-11	2006	Taken together, these results suggest that 15d-PGJ(2) inhibits IL-6-stimulated phosphorylation on tyr705 of STAT3 dependent on its own electrophilic reactivity in ECs.	15d-pgj	43-50	signal transducer and activator of transcription 3	Homo sapiens	108-113
16647637-0	2006	Effects of 15d-PGJ(2) on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells.	15d-pgj	11-18	vascular endothelial growth factor A	Homo sapiens	25-29
16647637-2	2006	We found that 15d-PGJ(2) (1-10muM) attenuated all VEGF-induced angiogenic activities in human umbilical vein endothelial cells (HUVEC).	15d-pgj	14-21	vascular endothelial growth factor A	Homo sapiens	50-54
16647637-4	2006	15d-PGJ(2) inhibited expression of VEGFR-1 and VEGFR-2 receptors both at mRNA and protein levels.	15d-pgj	0-7	fms related receptor tyrosine kinase 1	Homo sapiens	35-42
16647637-4	2006	15d-PGJ(2) inhibited expression of VEGFR-1 and VEGFR-2 receptors both at mRNA and protein levels.	15d-pgj	0-7	kinase insert domain receptor	Homo sapiens	47-54
16647637-6	2006	Accordingly, proliferation was inhibited when 15d-PGJ(2) was added 24h after VEGF or in cells stimulated with basic fibroblast growth factor.	15d-pgj	46-53	vascular endothelial growth factor A	Homo sapiens	77-81
16256979-5	2005	This is the first report showing the evidence for direct binding of ramatroban to CRTH2, revealing its competitive inhibitory effects and another interesting finding that PGD(2), indomethacin and 15d-PGJ(2) share the same binding site with ramatroban on CRTH2.	15d-pgj	196-203	prostaglandin D2 receptor 2	Homo sapiens	82-87
16601291-9	2006	15d-PGJ(2) significantly inhibited estrogen-mediated proliferation of MCF-7 cells, and caused accumulation of p21 and p27 protein.	15d-pgj	0-7	H3 histone pseudogene 16	Homo sapiens	110-113
16601291-9	2006	15d-PGJ(2) significantly inhibited estrogen-mediated proliferation of MCF-7 cells, and caused accumulation of p21 and p27 protein.	15d-pgj	0-7	interferon alpha inducible protein 27	Homo sapiens	118-121
17183189-13	2006	Both 15d-PGJ(2) and ciglitazone decreased the expression of CD40 mRNA and ICAM-1 protein.	15d-pgj	5-12	CD40 molecule	Rattus norvegicus	60-64
17183189-13	2006	Both 15d-PGJ(2) and ciglitazone decreased the expression of CD40 mRNA and ICAM-1 protein.	15d-pgj	5-12	intercellular adhesion molecule 1	Rattus norvegicus	74-80
16256979-5	2005	This is the first report showing the evidence for direct binding of ramatroban to CRTH2, revealing its competitive inhibitory effects and another interesting finding that PGD(2), indomethacin and 15d-PGJ(2) share the same binding site with ramatroban on CRTH2.	15d-pgj	196-203	prostaglandin D2 receptor 2	Homo sapiens	254-259
16000871-2	2005	Recent studies have shown that 15d-PGJ(2) is the potent anti-inflammatory agent functioning via PPARgamma-dependent and -independent mechanisms.	15d-pgj	31-38	peroxisome proliferator activated receptor gamma	Homo sapiens	96-105
15821150-5	2005	At low concentrations (<0.1 microM), 15d-PGJ(2) inhibited IL-1beta-stimulated prostaglandin E(2) (PGE(2)) but not cytokine (IL-6/IL-8) production or cyclooxygenase-2 (COX-2) expression.	15d-pgj	40-47	interleukin 1 beta	Homo sapiens	61-69
15821150-5	2005	At low concentrations (<0.1 microM), 15d-PGJ(2) inhibited IL-1beta-stimulated prostaglandin E(2) (PGE(2)) but not cytokine (IL-6/IL-8) production or cyclooxygenase-2 (COX-2) expression.	15d-pgj	40-47	C-X-C motif chemokine ligand 8	Homo sapiens	132-136
15821150-5	2005	At low concentrations (<0.1 microM), 15d-PGJ(2) inhibited IL-1beta-stimulated prostaglandin E(2) (PGE(2)) but not cytokine (IL-6/IL-8) production or cyclooxygenase-2 (COX-2) expression.	15d-pgj	40-47	prostaglandin-endoperoxide synthase 2	Homo sapiens	152-168
15821150-5	2005	At low concentrations (<0.1 microM), 15d-PGJ(2) inhibited IL-1beta-stimulated prostaglandin E(2) (PGE(2)) but not cytokine (IL-6/IL-8) production or cyclooxygenase-2 (COX-2) expression.	15d-pgj	40-47	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	170-175
15908479-6	2005	To this end, we studied the effects of the PPARgamma ligands 15d-PGJ(2), rosiglitazone (BRL49653), and troglitazone on Fn expression in NSCLC cells and found that they were able to inhibit Fn gene transcription.	15d-pgj	61-68	fibronectin 1	Homo sapiens	119-121
15821150-7	2005	At higher concentrations (1-10 microM), 15d-PGJ(2) inhibited IL-1beta-stimulated PGE(2) and cytokine production and COX-2 expression, and this effect was not blocked by GW9662.	15d-pgj	40-47	interleukin 1 beta	Homo sapiens	61-69
15821150-7	2005	At higher concentrations (1-10 microM), 15d-PGJ(2) inhibited IL-1beta-stimulated PGE(2) and cytokine production and COX-2 expression, and this effect was not blocked by GW9662.	15d-pgj	40-47	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	116-121
15821150-10	2005	IL-1beta-induced nuclear factor-kappaB (NF-kappaB) DNA binding activity was significantly inhibited by 15d-PGJ(2) (10 microM) and GW501516 (1 microM) but increased with 10 microM rosiglitazone.	15d-pgj	103-110	interleukin 1 beta	Homo sapiens	0-8
15821150-10	2005	IL-1beta-induced nuclear factor-kappaB (NF-kappaB) DNA binding activity was significantly inhibited by 15d-PGJ(2) (10 microM) and GW501516 (1 microM) but increased with 10 microM rosiglitazone.	15d-pgj	103-110	nuclear factor kappa B subunit 1	Homo sapiens	40-49
15821150-11	2005	We conclude that 1) at low concentrations, 15d-PGJ(2) acts through a PPAR-gamma signaling pathway; b) at higher concentrations, its actions are mediated most likely through other pathways such as activation of PPAR-delta and/or inhibition of NF-kappaB; and 3) rosiglitazone exerts PPAR-independent effects at high concentrations (>1 microM).	15d-pgj	43-50	peroxisome proliferator activated receptor gamma	Homo sapiens	69-79
15821150-11	2005	We conclude that 1) at low concentrations, 15d-PGJ(2) acts through a PPAR-gamma signaling pathway; b) at higher concentrations, its actions are mediated most likely through other pathways such as activation of PPAR-delta and/or inhibition of NF-kappaB; and 3) rosiglitazone exerts PPAR-independent effects at high concentrations (>1 microM).	15d-pgj	43-50	peroxisome proliferator activated receptor delta	Homo sapiens	210-220
15821150-11	2005	We conclude that 1) at low concentrations, 15d-PGJ(2) acts through a PPAR-gamma signaling pathway; b) at higher concentrations, its actions are mediated most likely through other pathways such as activation of PPAR-delta and/or inhibition of NF-kappaB; and 3) rosiglitazone exerts PPAR-independent effects at high concentrations (>1 microM).	15d-pgj	43-50	nuclear factor kappa B subunit 1	Homo sapiens	242-258
15821150-11	2005	We conclude that 1) at low concentrations, 15d-PGJ(2) acts through a PPAR-gamma signaling pathway; b) at higher concentrations, its actions are mediated most likely through other pathways such as activation of PPAR-delta and/or inhibition of NF-kappaB; and 3) rosiglitazone exerts PPAR-independent effects at high concentrations (>1 microM).	15d-pgj	43-50	peroxisome proliferator activated receptor alpha	Homo sapiens	69-73
16000871-4	2005	We examined the possibility that IL-6 signaling via the Jak-Stat pathway is modulated by 15d-PGJ(2) in lymphocytes and also examined whether the inhibition of IL-6 signaling is dependent of PPARgamma.	15d-pgj	89-96	interleukin 6	Homo sapiens	33-37
16000871-5	2005	15d-PGJ(2) blocked IL-6 induced Stat1 and Stat3 activation in primary human lymphocytes, Jurkat cells and immortalized rheumatoid arthritis B cells.	15d-pgj	0-7	interleukin 6	Homo sapiens	19-23
16000871-5	2005	15d-PGJ(2) blocked IL-6 induced Stat1 and Stat3 activation in primary human lymphocytes, Jurkat cells and immortalized rheumatoid arthritis B cells.	15d-pgj	0-7	signal transducer and activator of transcription 1	Homo sapiens	32-37
16000871-5	2005	15d-PGJ(2) blocked IL-6 induced Stat1 and Stat3 activation in primary human lymphocytes, Jurkat cells and immortalized rheumatoid arthritis B cells.	15d-pgj	0-7	signal transducer and activator of transcription 3	Homo sapiens	42-47
16000871-6	2005	Inhibition of IL-6 signaling was induced rapidly within 15 min after treatment of 15d-PGJ(2).	15d-pgj	82-89	interleukin 6	Homo sapiens	14-18
16000871-7	2005	Other PPARgamma-agonists, such as troglitazone and ciglitazone, did not inhibit IL-6 signaling, indicating that 15d-PGJ(2) affect the IL-6-induced Jak-Stat signaling pathway via PPARgamma-independent mechanism.	15d-pgj	112-119	interleukin 6	Homo sapiens	134-138
16000871-8	2005	Although cycloheximide reversed 15d-PGJ(2)-mediated inhibition of Stat3 activation, actinomycin D had no effect on 15d-PGJ(2)-mediated inhibition of IL-6 signaling, indicating that inhibition of IL-6 signaling occur independent of de novo gene expression.	15d-pgj	32-39	signal transducer and activator of transcription 3	Homo sapiens	66-71
15755849-5	2005	15d-PGJ(2) inhibited NF-kappaB activity and COX-2 expression in both cell types.	15d-pgj	0-7	nuclear factor kappa B subunit 1	Homo sapiens	21-30
15755849-5	2005	15d-PGJ(2) inhibited NF-kappaB activity and COX-2 expression in both cell types.	15d-pgj	0-7	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	44-49
15755849-7	2005	This shows that, in amnion and myometrium, inhibition of NF-kappaB activity and COX-2 expression by 15d-PGJ(2) is independent of PPARs and requires the cyclopentenone ring.	15d-pgj	100-107	nuclear factor kappa B subunit 1	Homo sapiens	57-66
15755849-7	2005	This shows that, in amnion and myometrium, inhibition of NF-kappaB activity and COX-2 expression by 15d-PGJ(2) is independent of PPARs and requires the cyclopentenone ring.	15d-pgj	100-107	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	80-85
15850670-6	2005	Previously, we and others demonstrated that PPAR-gamma agonists including 15d-PGJ(2) are effective in the treatment of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. PPAR-gamma modulation of EAE may occur, at least in part, by inhibition of microglial cell activation.	15d-pgj	74-81	peroxisome proliferator activated receptor gamma	Homo sapiens	44-54
15850670-6	2005	Previously, we and others demonstrated that PPAR-gamma agonists including 15d-PGJ(2) are effective in the treatment of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. PPAR-gamma modulation of EAE may occur, at least in part, by inhibition of microglial cell activation.	15d-pgj	74-81	peroxisome proliferator activated receptor gamma	Homo sapiens	191-201
15850670-8	2005	Furthermore, 15d-PGJ(2) acts cooperatively with 9-cis retinoic acid, the ligand for the retinoid X receptor (RXR), in inhibiting microglial cell activation.	15d-pgj	13-20	retinoid X receptor alpha	Homo sapiens	88-107
15850670-8	2005	Furthermore, 15d-PGJ(2) acts cooperatively with 9-cis retinoic acid, the ligand for the retinoid X receptor (RXR), in inhibiting microglial cell activation.	15d-pgj	13-20	retinoid X receptor alpha	Homo sapiens	109-112
15850670-9	2005	This suggests that 15d-PGJ(2) and 9-cis RA inhibit cell activation through the formation of PPAR-gamma/RXR heterodimers.	15d-pgj	19-26	peroxisome proliferator activated receptor gamma	Homo sapiens	92-102
15850670-9	2005	This suggests that 15d-PGJ(2) and 9-cis RA inhibit cell activation through the formation of PPAR-gamma/RXR heterodimers.	15d-pgj	19-26	retinoid X receptor alpha	Homo sapiens	103-106
15850670-11	2005	Collectively, these studies suggest that 15d-PGJ(2) inhibits microglial cell activation by PPAR-gamma-dependent as well as PPAR-gamma-independent mechanisms.	15d-pgj	41-48	peroxisome proliferator activated receptor gamma	Homo sapiens	91-101
15850670-11	2005	Collectively, these studies suggest that 15d-PGJ(2) inhibits microglial cell activation by PPAR-gamma-dependent as well as PPAR-gamma-independent mechanisms.	15d-pgj	41-48	peroxisome proliferator activated receptor gamma	Homo sapiens	123-133
15850670-12	2005	The studies further suggest that the PPAR-gamma agonist 15d-PGJ(2) in combination with retinoids may be effective in the treatment of MS.	15d-pgj	56-63	peroxisome proliferator activated receptor gamma	Homo sapiens	37-47
15748950-3	2005	The results show that TZDs and 15d-PGJ(2) are effective in inhibiting production of nitric oxide, the pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6, and the chemokine MCP-1 from microglia and astrocytes.	15d-pgj	31-38	tumor necrosis factor	Mus musculus	129-138
15748950-3	2005	The results show that TZDs and 15d-PGJ(2) are effective in inhibiting production of nitric oxide, the pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6, and the chemokine MCP-1 from microglia and astrocytes.	15d-pgj	31-38	interleukin 1 beta	Mus musculus	140-148
15748950-3	2005	The results show that TZDs and 15d-PGJ(2) are effective in inhibiting production of nitric oxide, the pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6, and the chemokine MCP-1 from microglia and astrocytes.	15d-pgj	31-38	interleukin 6	Mus musculus	154-158
15748950-3	2005	The results show that TZDs and 15d-PGJ(2) are effective in inhibiting production of nitric oxide, the pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6, and the chemokine MCP-1 from microglia and astrocytes.	15d-pgj	31-38	mast cell protease 1	Mus musculus	178-183
15641079-8	2005	Troglitazone, a selective peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, enhanced COX-2 expression, while GW9662, a specific PPARgamma antagonist, relieved the suppressive effect of 15d-PGJ(2).	15d-pgj	204-211	peroxisome proliferator activated receptor gamma	Homo sapiens	147-156
15694358-1	2005	We previously reported that 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), the most potent agonist for peroxisome proliferator-activated receptor gamma (PPAR gamma), induces apoptosis of human chondrosarcoma cell line OUMS-27.	15d-pgj	70-77	peroxisome proliferator activated receptor gamma	Homo sapiens	111-159
15694358-1	2005	We previously reported that 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), the most potent agonist for peroxisome proliferator-activated receptor gamma (PPAR gamma), induces apoptosis of human chondrosarcoma cell line OUMS-27.	15d-pgj	70-77	peroxisome proliferator activated receptor gamma	Homo sapiens	161-171
15694358-5	2005	Among cyclin-dependent kinase inhibitors, p21 was induced and up-regulated by 15d-PGJ(2), but p16 and p27 were not changed, suggesting that the involvement of p21 in inhibition of cell proliferation.	15d-pgj	78-85	H3 histone pseudogene 16	Homo sapiens	42-45
15694358-6	2005	Activation of caspase-3 by 15d-PGJ(2) was partly, but not completely, blocked by PPAR gamma antagonist (GW9662) suggesting the 15d-PGJ(2) exerted its effect by PPAR gamma-dependent and -independent pathways.	15d-pgj	27-34	caspase 3	Homo sapiens	14-23
15694358-6	2005	Activation of caspase-3 by 15d-PGJ(2) was partly, but not completely, blocked by PPAR gamma antagonist (GW9662) suggesting the 15d-PGJ(2) exerted its effect by PPAR gamma-dependent and -independent pathways.	15d-pgj	27-34	peroxisome proliferator activated receptor gamma	Homo sapiens	160-170
15694358-6	2005	Activation of caspase-3 by 15d-PGJ(2) was partly, but not completely, blocked by PPAR gamma antagonist (GW9662) suggesting the 15d-PGJ(2) exerted its effect by PPAR gamma-dependent and -independent pathways.	15d-pgj	127-134	caspase 3	Homo sapiens	14-23
15694358-6	2005	Activation of caspase-3 by 15d-PGJ(2) was partly, but not completely, blocked by PPAR gamma antagonist (GW9662) suggesting the 15d-PGJ(2) exerted its effect by PPAR gamma-dependent and -independent pathways.	15d-pgj	127-134	peroxisome proliferator activated receptor gamma	Homo sapiens	81-91
15694358-6	2005	Activation of caspase-3 by 15d-PGJ(2) was partly, but not completely, blocked by PPAR gamma antagonist (GW9662) suggesting the 15d-PGJ(2) exerted its effect by PPAR gamma-dependent and -independent pathways.	15d-pgj	127-134	peroxisome proliferator activated receptor gamma	Homo sapiens	160-170
15498850-4	2005	15d-PGJ(2)-induced apoptosis occurs through multiple caspase activation pathways involving caspase-8 and caspase-9, and is prevented by pretreatment with the pan-caspase inhibitor ZVAD (z-Val-Ala-Asp).	15d-pgj	0-7	caspase 8	Homo sapiens	53-60
15498850-4	2005	15d-PGJ(2)-induced apoptosis occurs through multiple caspase activation pathways involving caspase-8 and caspase-9, and is prevented by pretreatment with the pan-caspase inhibitor ZVAD (z-Val-Ala-Asp).	15d-pgj	0-7	caspase 8	Homo sapiens	91-100
15498850-4	2005	15d-PGJ(2)-induced apoptosis occurs through multiple caspase activation pathways involving caspase-8 and caspase-9, and is prevented by pretreatment with the pan-caspase inhibitor ZVAD (z-Val-Ala-Asp).	15d-pgj	0-7	caspase 9	Homo sapiens	105-114
15498850-4	2005	15d-PGJ(2)-induced apoptosis occurs through multiple caspase activation pathways involving caspase-8 and caspase-9, and is prevented by pretreatment with the pan-caspase inhibitor ZVAD (z-Val-Ala-Asp).	15d-pgj	0-7	caspase 8	Homo sapiens	91-98
15531761-6	2005	Coimmunoprecipitation revealed that 15d-PGJ(2) induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol.	15d-pgj	36-43	peroxisome proliferator activated receptor gamma	Homo sapiens	93-102
15531761-6	2005	Coimmunoprecipitation revealed that 15d-PGJ(2) induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol.	15d-pgj	36-43	nuclear receptor subfamily 3 group C member 1	Homo sapiens	111-134
15531761-6	2005	Coimmunoprecipitation revealed that 15d-PGJ(2) induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol.	15d-pgj	36-43	nuclear receptor subfamily 3 group C member 1	Homo sapiens	136-138
15531761-6	2005	Coimmunoprecipitation revealed that 15d-PGJ(2) induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol.	15d-pgj	36-43	tumor necrosis factor	Homo sapiens	143-151
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	15d-pgj	0-7	tumor necrosis factor	Homo sapiens	54-62
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	15d-pgj	0-7	C-C motif chemokine ligand 11	Homo sapiens	101-108
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	15d-pgj	0-7	RELA proto-oncogene, NF-kB subunit	Homo sapiens	132-135
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	15d-pgj	0-7	C-C motif chemokine ligand 11	Homo sapiens	151-158
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	180-189
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	15d-pgj	0-7	nuclear receptor subfamily 3 group C member 1	Homo sapiens	194-196
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	15d-pgj	0-7	C-C motif chemokine ligand 11	Homo sapiens	151-158
15641079-3	2005	We undertook this study to investigate the effects of 15d-PGJ(2) on interleukin-1beta (IL-1beta)-induced COX-2 expression in human synovial fibroblasts (HSFs).	15d-pgj	54-61	interleukin 1 beta	Homo sapiens	68-85
15641079-3	2005	We undertook this study to investigate the effects of 15d-PGJ(2) on interleukin-1beta (IL-1beta)-induced COX-2 expression in human synovial fibroblasts (HSFs).	15d-pgj	54-61	interleukin 1 beta	Homo sapiens	87-95
15641079-3	2005	We undertook this study to investigate the effects of 15d-PGJ(2) on interleukin-1beta (IL-1beta)-induced COX-2 expression in human synovial fibroblasts (HSFs).	15d-pgj	54-61	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	105-110
15641079-9	2005	IL-1beta-induced histone H3 acetylation was selectively blocked by 15d-PGJ(2).	15d-pgj	67-74	interleukin 1 beta	Homo sapiens	0-8
15641079-12	2005	Furthermore, 15d-PGJ(2) blocked IL-1beta-induced recruitment of p300 to the COX-2 promoter, which may be the mechanism for decreased histone H3 acetylation and COX-2 expression.	15d-pgj	13-20	interleukin 1 beta	Homo sapiens	32-40
15641079-12	2005	Furthermore, 15d-PGJ(2) blocked IL-1beta-induced recruitment of p300 to the COX-2 promoter, which may be the mechanism for decreased histone H3 acetylation and COX-2 expression.	15d-pgj	13-20	E1A binding protein p300	Homo sapiens	64-68
15641079-12	2005	Furthermore, 15d-PGJ(2) blocked IL-1beta-induced recruitment of p300 to the COX-2 promoter, which may be the mechanism for decreased histone H3 acetylation and COX-2 expression.	15d-pgj	13-20	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	76-81
15641079-12	2005	Furthermore, 15d-PGJ(2) blocked IL-1beta-induced recruitment of p300 to the COX-2 promoter, which may be the mechanism for decreased histone H3 acetylation and COX-2 expression.	15d-pgj	13-20	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	160-165
15641079-13	2005	In accordance with this, overexpression of p300, but not of a mutant p300 lacking HAT activity, relieved the inhibitory effect of 15d-PGJ(2) on COX-2 promoter activation.	15d-pgj	130-137	E1A binding protein p300	Homo sapiens	43-47
15641079-13	2005	In accordance with this, overexpression of p300, but not of a mutant p300 lacking HAT activity, relieved the inhibitory effect of 15d-PGJ(2) on COX-2 promoter activation.	15d-pgj	130-137	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	144-149
15641079-14	2005	CONCLUSION: These data suggest that 15d-PGJ(2) can inhibit IL-1beta-induced COX-2 expression by an HDAC-independent mechanism, probably by interfering with HAT p300.	15d-pgj	36-43	interleukin 1 beta	Homo sapiens	59-67
15641079-14	2005	CONCLUSION: These data suggest that 15d-PGJ(2) can inhibit IL-1beta-induced COX-2 expression by an HDAC-independent mechanism, probably by interfering with HAT p300.	15d-pgj	36-43	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	76-81
15641079-14	2005	CONCLUSION: These data suggest that 15d-PGJ(2) can inhibit IL-1beta-induced COX-2 expression by an HDAC-independent mechanism, probably by interfering with HAT p300.	15d-pgj	36-43	E1A binding protein p300	Homo sapiens	160-164
15659834-11	2004	Thus, the induction of HO-1 expression and the activation of Akt/PKB by 15d-PGJ(2) and PGA(2) are likely to confer cytoprotective or antiapoptotic effects exerted by these cyPGs.	15d-pgj	72-79	heme oxygenase 1	Homo sapiens	23-27
15265789-4	2004	In PPARgamma-positive NK cells, PPAR-gamma activation by 15d-PGJ(2) and ciglitazone (a synthetic ligand) leads to reduction in both mRNA and protein levels of IFN-gamma.	15d-pgj	57-64	peroxisome proliferator activated receptor gamma	Homo sapiens	32-42
15265789-4	2004	In PPARgamma-positive NK cells, PPAR-gamma activation by 15d-PGJ(2) and ciglitazone (a synthetic ligand) leads to reduction in both mRNA and protein levels of IFN-gamma.	15d-pgj	57-64	interferon gamma	Homo sapiens	159-168
15265789-7	2004	In addition, 15d-PGJ(2) but not ciglitazone reduces expression of CD69 in human NK cells, whereas CD44 expression is not affected.	15d-pgj	13-20	CD69 molecule	Homo sapiens	66-70
15317873-10	2004	9,10-Dihydro-15d-PGJ(2), a 15d-PGJ(2) analog that shows the same potency as peroxisome proliferator-activated receptor (PPAR) agonist in MC but lacks the cyclopentenone moiety, displays reduced ability to modify proteins and to block 15d-PGJ(2) binding.	15d-pgj	13-20	peroxisome proliferator activated receptor alpha	Homo sapiens	76-118
15533897-7	2004	Forced expression of hPPAR-gamma1 or hPPAR-gamma2 made ECs sensitive to 15d-PGJ(2) and led to reduced cellular viability.	15d-pgj	72-79	peroxisome proliferator activated receptor alpha	Homo sapiens	21-26
15533897-7	2004	Forced expression of hPPAR-gamma1 or hPPAR-gamma2 made ECs sensitive to 15d-PGJ(2) and led to reduced cellular viability.	15d-pgj	72-79	peroxisome proliferator activated receptor alpha	Homo sapiens	37-42
15317873-10	2004	9,10-Dihydro-15d-PGJ(2), a 15d-PGJ(2) analog that shows the same potency as peroxisome proliferator-activated receptor (PPAR) agonist in MC but lacks the cyclopentenone moiety, displays reduced ability to modify proteins and to block 15d-PGJ(2) binding.	15d-pgj	13-20	peroxisome proliferator activated receptor alpha	Homo sapiens	120-124
15317873-11	2004	Micromolar concentrations of 15d-PGJ(2) inhibit cytokine-elicited levels of inducible nitricoxide synthase, cyclooxygenase-2, and intercellular adhesion molecule-1 in MC.	15d-pgj	29-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	108-163
15316561-2	2004	We recently showed that treatment with 15d-PGJ(2) induces apoptosis accompanied by downregulation of the oncogenic signal transducer and activator of transcription 3 (Stat3) signalling in human oral squamous cell carcinoma (SCC) cells.	15d-pgj	39-46	signal transducer and activator of transcription 3	Homo sapiens	115-165
15271788-9	2004	The PPARgamma activator, 15d-PGJ(2), however, inhibited IL-1beta-induced upregulation of LOX-1.	15d-pgj	25-32	peroxisome proliferator activated receptor gamma	Homo sapiens	4-13
15271788-9	2004	The PPARgamma activator, 15d-PGJ(2), however, inhibited IL-1beta-induced upregulation of LOX-1.	15d-pgj	25-32	interleukin 1 beta	Homo sapiens	56-64
15271788-9	2004	The PPARgamma activator, 15d-PGJ(2), however, inhibited IL-1beta-induced upregulation of LOX-1.	15d-pgj	25-32	oxidized low density lipoprotein receptor 1	Homo sapiens	89-94
15319433-7	2004	Preincubation with 15d-PGJ(2) rendered PC12 cells resistant to nitrosative stress induced by SIN-1.	15d-pgj	19-26	MAPK associated protein 1	Homo sapiens	93-98
15316561-2	2004	We recently showed that treatment with 15d-PGJ(2) induces apoptosis accompanied by downregulation of the oncogenic signal transducer and activator of transcription 3 (Stat3) signalling in human oral squamous cell carcinoma (SCC) cells.	15d-pgj	39-46	signal transducer and activator of transcription 3	Homo sapiens	167-172
15316561-3	2004	The current study examines the effects of 15d-PGJ(2) on the epidermal growth factor receptor (EGFR) and Janus Kinase (JAK)-mediated signalling pathways.	15d-pgj	42-49	epidermal growth factor receptor	Homo sapiens	60-92
15316561-3	2004	The current study examines the effects of 15d-PGJ(2) on the epidermal growth factor receptor (EGFR) and Janus Kinase (JAK)-mediated signalling pathways.	15d-pgj	42-49	epidermal growth factor receptor	Homo sapiens	94-98
15316561-4	2004	Inhibition of Stat3 by 15d-PGJ(2) was abolished by exogenous stimulation with transforming growth factor alpha (TGF-alpha), but not interleukin 6 (IL-6), supporting a selective effect of 15d-PGJ(2) on IL-6-mediated signalling.	15d-pgj	23-30	signal transducer and activator of transcription 3	Homo sapiens	14-19
15316561-4	2004	Inhibition of Stat3 by 15d-PGJ(2) was abolished by exogenous stimulation with transforming growth factor alpha (TGF-alpha), but not interleukin 6 (IL-6), supporting a selective effect of 15d-PGJ(2) on IL-6-mediated signalling.	15d-pgj	23-30	tumor necrosis factor	Homo sapiens	78-110
15316561-4	2004	Inhibition of Stat3 by 15d-PGJ(2) was abolished by exogenous stimulation with transforming growth factor alpha (TGF-alpha), but not interleukin 6 (IL-6), supporting a selective effect of 15d-PGJ(2) on IL-6-mediated signalling.	15d-pgj	23-30	transforming growth factor alpha	Homo sapiens	112-121
15316561-5	2004	Importantly, 15d-PGJ(2) selectively abrogated constitutive and IL-6-mediated JAK phosphorylation without affecting EGFR-activated levels.	15d-pgj	13-20	interleukin 6	Homo sapiens	63-67
15316561-8	2004	Our findings provide the first evidence for 15d-PGJ(2)-mediated downregulation of constitutive and IL-6-induced JAK signalling in cancer and support that JAK inhibition and suppression of EGFR-independent Stat3 activation by 15d-PGJ(2) represent a promising approach for induction of apoptosis in oral SCC cells.	15d-pgj	44-51	interleukin 6	Homo sapiens	99-103
15316561-8	2004	Our findings provide the first evidence for 15d-PGJ(2)-mediated downregulation of constitutive and IL-6-induced JAK signalling in cancer and support that JAK inhibition and suppression of EGFR-independent Stat3 activation by 15d-PGJ(2) represent a promising approach for induction of apoptosis in oral SCC cells.	15d-pgj	44-51	epidermal growth factor receptor	Homo sapiens	188-192
15316561-8	2004	Our findings provide the first evidence for 15d-PGJ(2)-mediated downregulation of constitutive and IL-6-induced JAK signalling in cancer and support that JAK inhibition and suppression of EGFR-independent Stat3 activation by 15d-PGJ(2) represent a promising approach for induction of apoptosis in oral SCC cells.	15d-pgj	44-51	signal transducer and activator of transcription 3	Homo sapiens	205-210
15316561-8	2004	Our findings provide the first evidence for 15d-PGJ(2)-mediated downregulation of constitutive and IL-6-induced JAK signalling in cancer and support that JAK inhibition and suppression of EGFR-independent Stat3 activation by 15d-PGJ(2) represent a promising approach for induction of apoptosis in oral SCC cells.	15d-pgj	225-232	interleukin 6	Homo sapiens	99-103
15130939-7	2004	Platelet incubation with a natural PPARgamma agonist, 15d-PGJ(2), or with a potent synthetic PPARgamma ligand, rosiglitazone, prevented thrombin-induced CD40L surface expression and release of CD40L and thromboxane B(2) (TXB(2)).	15d-pgj	54-61	coagulation factor II, thrombin	Homo sapiens	136-144
15130939-7	2004	Platelet incubation with a natural PPARgamma agonist, 15d-PGJ(2), or with a potent synthetic PPARgamma ligand, rosiglitazone, prevented thrombin-induced CD40L surface expression and release of CD40L and thromboxane B(2) (TXB(2)).	15d-pgj	54-61	CD40 ligand	Homo sapiens	153-158
15130939-7	2004	Platelet incubation with a natural PPARgamma agonist, 15d-PGJ(2), or with a potent synthetic PPARgamma ligand, rosiglitazone, prevented thrombin-induced CD40L surface expression and release of CD40L and thromboxane B(2) (TXB(2)).	15d-pgj	54-61	peroxisome proliferator activated receptor gamma	Homo sapiens	35-44
15130939-7	2004	Platelet incubation with a natural PPARgamma agonist, 15d-PGJ(2), or with a potent synthetic PPARgamma ligand, rosiglitazone, prevented thrombin-induced CD40L surface expression and release of CD40L and thromboxane B(2) (TXB(2)).	15d-pgj	54-61	CD40 ligand	Homo sapiens	193-198
15322215-3	2004	15d-PGJ(2) potently inhibited the expression of microglial cytokines (IL-1, TNF-alpha, and IL-6).	15d-pgj	0-7	interleukin 1 beta	Homo sapiens	70-74
15322215-3	2004	15d-PGJ(2) potently inhibited the expression of microglial cytokines (IL-1, TNF-alpha, and IL-6).	15d-pgj	0-7	tumor necrosis factor	Homo sapiens	76-85
15322215-3	2004	15d-PGJ(2) potently inhibited the expression of microglial cytokines (IL-1, TNF-alpha, and IL-6).	15d-pgj	0-7	interleukin 6	Homo sapiens	91-95
15450387-7	2004	Treatment of amnion and choriodecidual tissues with SASP concentrations greater than 5 mM, 15 mM NAC, 30 microM 15d-PGJ(2) and 30 microM troglitazone significantly reduced the release of PTHrP (p < 0.05).	15d-pgj	112-119	aspartic peptidase retroviral like 1	Homo sapiens	52-56
15450387-7	2004	Treatment of amnion and choriodecidual tissues with SASP concentrations greater than 5 mM, 15 mM NAC, 30 microM 15d-PGJ(2) and 30 microM troglitazone significantly reduced the release of PTHrP (p < 0.05).	15d-pgj	112-119	parathyroid hormone like hormone	Homo sapiens	187-192
15199053-8	2004	We concluded that 15d-PGJ(2) may help to control NF-kappaB signaling and normal intestinal homeostasis to the enteric microflora by modulating RelA phosphorylation in IEC through altered protein phosphatase 2A activity.	15d-pgj	18-25	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	143-147
15322177-10	2004	These data demonstrate that environmental phthalates can cooperate with an endogenous ligand, 15d-PGJ(2), to inhibit proliferation of and induce apoptosis in developing bone marrow B cells, potentially via PPARgamma activation.	15d-pgj	94-101	peroxisome proliferator activated receptor gamma	Homo sapiens	206-215
15199053-5	2004	In addition, 15d-PGJ(2) but not the synthetic high affinity PPARgamma ligand rosiglitazone triggered ERK1/2 phosphorylation in IEC, and most importantly, MEK1 inhibitor PD98059 reversed the inhibitory effect of 15dPGJ(2) on LPS-induced RelA phosphorylation and interleukin-6 gene expression.	15d-pgj	13-20	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	236-240
15289320-4	2004	15d-PGJ(2) interfered with at least two steps within the signaling pathway leading to AP-1 activation.	15d-pgj	0-7	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-90
15304320-3	2004	We previously demonstrated that 15d-PGJ(2) was more potent than troglitazone to counteract IL-1beta effects on chondrocytes.	15d-pgj	32-39	interleukin 1 beta	Rattus norvegicus	91-99
15304320-4	2004	Here, we studied the action of 15d-PGJ(2) on intracellular targets in nuclear factor-kappaB (NF-kappaB) signalling pathway in IL-1beta treated rat chondrocytes.	15d-pgj	31-38	interleukin 1 beta	Rattus norvegicus	126-134
15304320-5	2004	We found that 15d-PGJ(2) decreased inhibitor kappaBalpha (IkappaBalpha) degradation but not its phosphorylation by specifically inhibiting IkappaB kinase beta (IKKbeta), but not IKKalpha, enzymatic activity.	15d-pgj	14-21	NFKB inhibitor alpha	Rattus norvegicus	58-70
15304320-5	2004	We found that 15d-PGJ(2) decreased inhibitor kappaBalpha (IkappaBalpha) degradation but not its phosphorylation by specifically inhibiting IkappaB kinase beta (IKKbeta), but not IKKalpha, enzymatic activity.	15d-pgj	14-21	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	139-158
15304320-5	2004	We found that 15d-PGJ(2) decreased inhibitor kappaBalpha (IkappaBalpha) degradation but not its phosphorylation by specifically inhibiting IkappaB kinase beta (IKKbeta), but not IKKalpha, enzymatic activity.	15d-pgj	14-21	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	160-167
15304320-9	2004	15d-PGJ(2) exhibited the same effect in chondrocytes overexpressing mutated PPARgamma protein.	15d-pgj	0-7	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	76-85
15266333-9	2004	In addition, 15d-PGJ(2) suppressed tumour necrosis factor-alpha-induced-COX-2 expression, confirming the reciprocal correlation between COX-2 and PPARgamma.	15d-pgj	13-20	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	72-77
15266333-9	2004	In addition, 15d-PGJ(2) suppressed tumour necrosis factor-alpha-induced-COX-2 expression, confirming the reciprocal correlation between COX-2 and PPARgamma.	15d-pgj	13-20	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	136-141
15266333-9	2004	In addition, 15d-PGJ(2) suppressed tumour necrosis factor-alpha-induced-COX-2 expression, confirming the reciprocal correlation between COX-2 and PPARgamma.	15d-pgj	13-20	peroxisome proliferator activated receptor gamma	Homo sapiens	146-155
15289320-6	2004	Second, 15d-PGJ(2) selectively inhibited c-Jun NH(2) terminal kinase (JNK) but not extracellular signal-regulated kinase or p38 mitogen-activated protein kinase activation induced by PMA.	15d-pgj	8-15	mitogen-activated protein kinase 8	Homo sapiens	41-68
15289320-6	2004	Second, 15d-PGJ(2) selectively inhibited c-Jun NH(2) terminal kinase (JNK) but not extracellular signal-regulated kinase or p38 mitogen-activated protein kinase activation induced by PMA.	15d-pgj	8-15	mitogen-activated protein kinase 8	Homo sapiens	70-73
15289320-10	2004	The antioxidant N-acetylcysteine significantly reversed the inhibition by 15d-PGJ(2) of AP-1 activity and COX-2 or VEGF transcriptional induction.	15d-pgj	74-81	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	88-92
14715242-4	2004	Regardless of the oxygen concentration, 15d-PGJ(2) inhibited activity of hypoxia inducible factor-1 (HIF-1), the major hypoxic regulator of VEGF.	15d-pgj	40-47	hypoxia inducible factor 1 subunit alpha	Homo sapiens	73-99
15187150-8	2004	Finally, 15d-PGJ(2)-induced decreases in glucocorticoid binding to GR resulted in parallel decreases in the ability of GR to activate the transcription of a glucocorticoid-inducible reporter gene and to reduce the expression of monocyte chemoattractant protein-1.	15d-pgj	9-16	C-C motif chemokine ligand 2	Homo sapiens	228-262
15187150-9	2004	Together these data suggest that 15d-PGJ(2) limits glucocorticoid binding and signaling in monocytes/macrophages through a PPARgamma-independent and cyclopentenone-dependent mechanism.	15d-pgj	33-40	peroxisome proliferator activated receptor gamma	Homo sapiens	123-132
14741709-7	2004	The suppression of GM-CSF promoter activity by 15d-PGJ(2) and 2-cyclopenten-1-one was mediated through reduction of NF-kappaB binding to GM-CSF promoter.	15d-pgj	47-54	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	19-25
14741709-7	2004	The suppression of GM-CSF promoter activity by 15d-PGJ(2) and 2-cyclopenten-1-one was mediated through reduction of NF-kappaB binding to GM-CSF promoter.	15d-pgj	47-54	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	137-143
15158456-5	2004	Moreover, addition of an anti-clusterin antibody completely inhibited the nodule formation induced by 15d-PGJ(2) and induced apoptosis.	15d-pgj	102-109	clusterin	Homo sapiens	30-39
15023995-5	2004	15d-PGJ(2) and TRO suppressed IL-1beta-induced activation of the mPGES-1 promoter.	15d-pgj	0-7	interleukin 1 beta	Homo sapiens	30-38
15023995-5	2004	15d-PGJ(2) and TRO suppressed IL-1beta-induced activation of the mPGES-1 promoter.	15d-pgj	0-7	prostaglandin E synthase	Mus musculus	65-72
15013841-7	2004	Cell death induced by PGJ(2) and 15d-PGJ(2) was the result of apoptotic processes, since RBL-2H3 cells treated with 30 microM of the prostaglandins had condensed nuclei, DNA fragmentation and increase in activities of caspase-3 and -9.	15d-pgj	33-40	caspase 3	Rattus norvegicus	218-234
14998722-6	2004	Although 15d-PGJ(2) significantly activated the MAPKs of JNK and ERK, the activation of JNK and ERK did not contribute to the induction of HO-1 as determined using transfection of dominant-negative plasmids and MAPKs inhibitors.	15d-pgj	9-16	mitogen-activated protein kinase 8	Homo sapiens	57-60
14998722-6	2004	Although 15d-PGJ(2) significantly activated the MAPKs of JNK and ERK, the activation of JNK and ERK did not contribute to the induction of HO-1 as determined using transfection of dominant-negative plasmids and MAPKs inhibitors.	15d-pgj	9-16	mitogen-activated protein kinase 1	Homo sapiens	65-68
14998722-8	2004	15d-PGJ(2) significantly decreased the intracellular level of reduced glutathione; and the thiol antioxidant, N-acetyl-L-cysteine (NAC), and the thiol-reducing agent, dithiothreitol (DTT), inhibited the induction of HO-1 by 15d-PGJ(2).	15d-pgj	0-7	X-linked Kx blood group	Homo sapiens	131-134
14998722-8	2004	15d-PGJ(2) significantly decreased the intracellular level of reduced glutathione; and the thiol antioxidant, N-acetyl-L-cysteine (NAC), and the thiol-reducing agent, dithiothreitol (DTT), inhibited the induction of HO-1 by 15d-PGJ(2).	15d-pgj	0-7	heme oxygenase 1	Homo sapiens	216-220
14998722-9	2004	Finally, NAC and DTT exhibited significant inhibition of HO-1 mRNA and HO-1 promoter reporter activity induced by 15d-PGJ(2).	15d-pgj	114-121	X-linked Kx blood group	Homo sapiens	9-12
14998722-9	2004	Finally, NAC and DTT exhibited significant inhibition of HO-1 mRNA and HO-1 promoter reporter activity induced by 15d-PGJ(2).	15d-pgj	114-121	heme oxygenase 1	Homo sapiens	57-61
14998722-9	2004	Finally, NAC and DTT exhibited significant inhibition of HO-1 mRNA and HO-1 promoter reporter activity induced by 15d-PGJ(2).	15d-pgj	114-121	heme oxygenase 1	Homo sapiens	71-75
14998722-10	2004	These results suggest that thiol antioxidant and reducing agents attenuate the expression of HO-1 induced by 15d-PGJ(2), and that the cellular thiol-disulfide redox status may be linked to HO-1 activation.	15d-pgj	109-116	heme oxygenase 1	Homo sapiens	93-97
14715242-4	2004	Regardless of the oxygen concentration, 15d-PGJ(2) inhibited activity of hypoxia inducible factor-1 (HIF-1), the major hypoxic regulator of VEGF.	15d-pgj	40-47	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-106
14715242-4	2004	Regardless of the oxygen concentration, 15d-PGJ(2) inhibited activity of hypoxia inducible factor-1 (HIF-1), the major hypoxic regulator of VEGF.	15d-pgj	40-47	vascular endothelial growth factor A	Homo sapiens	140-144
14715242-9	2004	We conclude that induction of HO-1 by 15d-PGJ(2) results in augmentation of VEGF synthesis in normoxia.	15d-pgj	38-45	heme oxygenase 1	Homo sapiens	30-34
14715242-9	2004	We conclude that induction of HO-1 by 15d-PGJ(2) results in augmentation of VEGF synthesis in normoxia.	15d-pgj	38-45	vascular endothelial growth factor A	Homo sapiens	76-80
14715242-10	2004	In hypoxia, however, the stimulatory effect of HO-1 is outweighed by 15d-PGJ(2)-mediated inhibition of the HIF-1 pathway.	15d-pgj	69-76	hypoxia inducible factor 1 subunit alpha	Homo sapiens	107-112
14636064-2	2003	We have previously shown that 15d-PGJ(2) potently induces apoptosis of SH-SY5Y human neuroblastoma cells via accumulation of the tumor suppressor gene product p53.	15d-pgj	30-37	tumor protein p53	Homo sapiens	159-162
15720836-13	2004	The concentration of TBARS and MPO activity in the gastric mucosa were both significantly increased after I/R, and pretreatment with 15d-PGJ(2) significantly reduced these increases.	15d-pgj	133-140	myeloperoxidase	Rattus norvegicus	31-34
15720836-15	2004	However, the increase in TNF-alpha was significantly inhibited by pretreatment with 15d-PGJ(2).	15d-pgj	84-91	tumor necrosis factor	Rattus norvegicus	25-34
15720836-16	2004	CONCLUSIONS: 15d-PGJ(2) significantly inhibited the severity of acute gastric mucosal injury induced by I/R in rats through PPAR-gamma-dependent mechanisms.	15d-pgj	13-20	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	124-134
14693716-8	2004	15d-PGJ(2) inhibited the TGF-beta 1-induced MAPK activation.	15d-pgj	0-7	transforming growth factor, beta 1	Mus musculus	25-35
14693716-9	2004	Dominant-negative PPAR-gamma (Delta PPAR-gamma) completely abrogated the inhibitory effect of pioglitazone and incompletely blocked its effect of 15d-PGJ(2) on TGF-beta 1-induced AP-1 reporter activity.	15d-pgj	146-153	peroxisome proliferator activated receptor gamma	Mus musculus	18-28
14693716-9	2004	Dominant-negative PPAR-gamma (Delta PPAR-gamma) completely abrogated the inhibitory effect of pioglitazone and incompletely blocked its effect of 15d-PGJ(2) on TGF-beta 1-induced AP-1 reporter activity.	15d-pgj	146-153	peroxisome proliferator activated receptor gamma	Mus musculus	36-46
14693716-9	2004	Dominant-negative PPAR-gamma (Delta PPAR-gamma) completely abrogated the inhibitory effect of pioglitazone and incompletely blocked its effect of 15d-PGJ(2) on TGF-beta 1-induced AP-1 reporter activity.	15d-pgj	146-153	transforming growth factor, beta 1	Mus musculus	160-170
14693716-9	2004	Dominant-negative PPAR-gamma (Delta PPAR-gamma) completely abrogated the inhibitory effect of pioglitazone and incompletely blocked its effect of 15d-PGJ(2) on TGF-beta 1-induced AP-1 reporter activity.	15d-pgj	146-153	jun proto-oncogene	Mus musculus	179-183
14673141-6	2004	Administration of the cyclooxygenase 2 inhibitor NS-398 to mice with carrageenan-induced pleurisy caused persistence of neutrophil recruitment and, in macrophages, attenuated the 15d-PGJ(2) accumulation and PrxI expression.	15d-pgj	179-186	prostaglandin-endoperoxide synthase 2	Mus musculus	22-38
14673141-7	2004	Administration of 15d-PGJ(2) into the pleural space of NS-398-treated wild-type mice largely counteracted both the decrease in PrxI and persistence of neutrophil recruitment.	15d-pgj	18-25	peroxiredoxin 1	Mus musculus	127-131
14636064-5	2003	In addition, exposure of the cells to 15d-PGJ(2) resulted in an accumulation of ubiquitinated proteins and in a significant inhibition of proteasome activities, suggesting that 15d-PGJ(2) acted on the ubiquitin-proteasome pathway, a regulatory mechanism of p53 turnover.	15d-pgj	38-45	tumor protein p53	Homo sapiens	257-260
14636064-5	2003	In addition, exposure of the cells to 15d-PGJ(2) resulted in an accumulation of ubiquitinated proteins and in a significant inhibition of proteasome activities, suggesting that 15d-PGJ(2) acted on the ubiquitin-proteasome pathway, a regulatory mechanism of p53 turnover.	15d-pgj	177-184	tumor protein p53	Homo sapiens	257-260
14636064-7	2003	These data suggest that the modulation of proteasome activity may be involved in the mechanism responsible for the accumulation of p53 and subsequent induction of apoptotic cell death induced by 15d-PGJ(2).	15d-pgj	195-202	tumor protein p53	Homo sapiens	131-134
14563954-3	2003	15d-PGJ(2) induced apoptosis in SK-Hep1 and HepG2 cells at a 50 micro M concentration.	15d-pgj	0-7	DNL-type zinc finger	Homo sapiens	35-39
14607914-6	2003	Conversely, overexpression of Bcl-2 or Bcl-x(L) completely inhibits the initiation of apoptosis, indicating that 15d-PGJ(2)-mediated apoptosis involves activation of the mitochondrial pathway.	15d-pgj	113-120	BCL2 apoptosis regulator	Homo sapiens	30-35
14607914-6	2003	Conversely, overexpression of Bcl-2 or Bcl-x(L) completely inhibits the initiation of apoptosis, indicating that 15d-PGJ(2)-mediated apoptosis involves activation of the mitochondrial pathway.	15d-pgj	113-120	BCL2 like 1	Homo sapiens	39-47
14607914-7	2003	In line with these results, 15d-PGJ(2) induces mitochondria disassemblage as demonstrated by dissipation of mitochondrial transmembrane potential (Deltapsi(m)) and cytochrome c release.	15d-pgj	28-35	cytochrome c, somatic	Homo sapiens	164-176
14580366-5	2003	We examined the effect of 15d-PGJ(2) on the expression of ENA-78 in cultured endothelial cells stimulated with IL-1beta.	15d-pgj	26-33	C-X-C motif chemokine ligand 5	Homo sapiens	58-64
14580366-5	2003	We examined the effect of 15d-PGJ(2) on the expression of ENA-78 in cultured endothelial cells stimulated with IL-1beta.	15d-pgj	26-33	interleukin 1 beta	Homo sapiens	111-119
14580366-6	2003	15d-PGJ(2) inhibited the IL-1beta-induced expression of ENA-78, but not the expression of IL-8 or GRO-alpha in response to IL-1.	15d-pgj	0-7	interleukin 1 beta	Homo sapiens	25-33
14580366-6	2003	15d-PGJ(2) inhibited the IL-1beta-induced expression of ENA-78, but not the expression of IL-8 or GRO-alpha in response to IL-1.	15d-pgj	0-7	C-X-C motif chemokine ligand 5	Homo sapiens	56-62
14580366-6	2003	15d-PGJ(2) inhibited the IL-1beta-induced expression of ENA-78, but not the expression of IL-8 or GRO-alpha in response to IL-1.	15d-pgj	0-7	interleukin 1 beta	Homo sapiens	25-29
14555212-10	2003	This commentary focuses on dual effects of the typical PPARgamma agonist 15d-PGJ(2) on cell proliferation and growth, and its possible involvement in the NSAID-induced COX-2 expression and apoptosis.	15d-pgj	73-80	peroxisome proliferator activated receptor gamma	Homo sapiens	55-64
14563954-5	2003	This indicated that 15d-PGJ(2) induction of apoptosis was associated with a caspase-3-independent pathway.	15d-pgj	20-27	caspase 3	Homo sapiens	76-85
14563954-6	2003	15d-PGJ(2) also induced down-regulation of the X chromosome-linked inhibitor of apoptosis (XIAP), Bclx, and apoptotic protease-activating factor-1 in SK-Hep1 cells but not in HepG2 cells.	15d-pgj	0-7	X-linked inhibitor of apoptosis	Homo sapiens	47-89
14563954-6	2003	15d-PGJ(2) also induced down-regulation of the X chromosome-linked inhibitor of apoptosis (XIAP), Bclx, and apoptotic protease-activating factor-1 in SK-Hep1 cells but not in HepG2 cells.	15d-pgj	0-7	X-linked inhibitor of apoptosis	Homo sapiens	91-95
14563954-6	2003	15d-PGJ(2) also induced down-regulation of the X chromosome-linked inhibitor of apoptosis (XIAP), Bclx, and apoptotic protease-activating factor-1 in SK-Hep1 cells but not in HepG2 cells.	15d-pgj	0-7	BCL2 like 1	Homo sapiens	98-102
14563954-6	2003	15d-PGJ(2) also induced down-regulation of the X chromosome-linked inhibitor of apoptosis (XIAP), Bclx, and apoptotic protease-activating factor-1 in SK-Hep1 cells but not in HepG2 cells.	15d-pgj	0-7	apoptotic peptidase activating factor 1	Homo sapiens	108-146
14563954-6	2003	15d-PGJ(2) also induced down-regulation of the X chromosome-linked inhibitor of apoptosis (XIAP), Bclx, and apoptotic protease-activating factor-1 in SK-Hep1 cells but not in HepG2 cells.	15d-pgj	0-7	DNL-type zinc finger	Homo sapiens	153-157
14563954-9	2003	These results suggest that the effect of 15d-PGJ(2) was through a PPARgamma-independent mechanism.	15d-pgj	41-48	peroxisome proliferator activated receptor gamma	Homo sapiens	66-75
14563954-12	2003	In SK-Hep1 cells, the ability of 15d-PGJ(2) to induce cell toxicity, NF-kappaB suppression, or XIAP down-regulation seemed to occur via a PPARgamma-independent mechanism, but in HepG2 cells, NF-kappaB suppression by 15d-PGJ(2) was dependent on PPARgamma.	15d-pgj	33-40	DNL-type zinc finger	Homo sapiens	6-10
14563954-12	2003	In SK-Hep1 cells, the ability of 15d-PGJ(2) to induce cell toxicity, NF-kappaB suppression, or XIAP down-regulation seemed to occur via a PPARgamma-independent mechanism, but in HepG2 cells, NF-kappaB suppression by 15d-PGJ(2) was dependent on PPARgamma.	15d-pgj	33-40	X-linked inhibitor of apoptosis	Homo sapiens	95-99
14563954-12	2003	In SK-Hep1 cells, the ability of 15d-PGJ(2) to induce cell toxicity, NF-kappaB suppression, or XIAP down-regulation seemed to occur via a PPARgamma-independent mechanism, but in HepG2 cells, NF-kappaB suppression by 15d-PGJ(2) was dependent on PPARgamma.	15d-pgj	33-40	peroxisome proliferator activated receptor gamma	Homo sapiens	138-147
14563954-12	2003	In SK-Hep1 cells, the ability of 15d-PGJ(2) to induce cell toxicity, NF-kappaB suppression, or XIAP down-regulation seemed to occur via a PPARgamma-independent mechanism, but in HepG2 cells, NF-kappaB suppression by 15d-PGJ(2) was dependent on PPARgamma.	15d-pgj	33-40	peroxisome proliferator activated receptor gamma	Homo sapiens	244-253
12947319-4	2003	AsPC-1 cells were treated with nontoxic doses of PPARgamma ligands (15d-PGJ(2), troglitazone, or rosiglitazone) and Matrigel Invasion chambers were used to assess invasion in vitro.	15d-pgj	68-75	peroxisome proliferator activated receptor gamma	Homo sapiens	49-58
14499870-9	2003	In addition, 15d-PGJ(2) and PIO treatment suppressed the proliferative response and interferon-gamma production of T cell-enriched splenocytes from rats with EAM.	15d-pgj	13-20	interferon gamma	Rattus norvegicus	84-100
12829999-8	2003	Consistent with these findings, both 15d-PGJ(2) and troglitazone significantly inhibited the G2/M cyclin-dependent kinase (CDK) Cdc2 activity.	15d-pgj	37-44	cyclin dependent kinase 1	Homo sapiens	128-132
12921638-7	2003	The expression rate of bax were (9,2 +/- 1.5)%, (63 +/- 10)%, and (31 +/- 6)% respectively in the control, 15d-PGJ(2), and ciglitazone groups with a very significant difference between ant 2 groups (all P < 0.01).	15d-pgj	107-114	BCL2 associated X, apoptosis regulator	Homo sapiens	23-26
12921638-8	2003	he expression rate of bcl-2 were (18 +/- 3)%, (36 +/- 9)%, and (33 +/- 7)% respectively in the control, 15d-PGJ(2), and ciglitazone groups with a very significant difference between the control group and any of the agonist-treated groups (all P < 0.01) and without significant difference between the two treated groups.	15d-pgj	104-111	BCL2 apoptosis regulator	Homo sapiens	22-27
12921638-9	2003	The expression rates of caspase-3 were (6.5 +/- 1.0)%, (65 +/- 11)%, and (40 +/- 7)% respectively in the control, 15d-PGJ(2), and ciglitazone groups with a significant difference between any 2 group (all P < 0.01).	15d-pgj	114-121	caspase 3	Homo sapiens	24-33
12829999-9	2003	Furthermore, cells treated with 15d-PGJ(2) and troglitazone showed elevated expression of p53 and two p53-controlled downstream genes, GADD45 and p21(WAF1/Cip1).	15d-pgj	32-39	tumor protein p53	Homo sapiens	90-93
12829999-9	2003	Furthermore, cells treated with 15d-PGJ(2) and troglitazone showed elevated expression of p53 and two p53-controlled downstream genes, GADD45 and p21(WAF1/Cip1).	15d-pgj	32-39	tumor protein p53	Homo sapiens	102-105
12829999-9	2003	Furthermore, cells treated with 15d-PGJ(2) and troglitazone showed elevated expression of p53 and two p53-controlled downstream genes, GADD45 and p21(WAF1/Cip1).	15d-pgj	32-39	growth arrest and DNA damage inducible alpha	Homo sapiens	135-141
12829999-9	2003	Furthermore, cells treated with 15d-PGJ(2) and troglitazone showed elevated expression of p53 and two p53-controlled downstream genes, GADD45 and p21(WAF1/Cip1).	15d-pgj	32-39	cyclin dependent kinase inhibitor 1A	Homo sapiens	146-149
12829999-9	2003	Furthermore, cells treated with 15d-PGJ(2) and troglitazone showed elevated expression of p53 and two p53-controlled downstream genes, GADD45 and p21(WAF1/Cip1).	15d-pgj	32-39	cyclin dependent kinase inhibitor 1A	Homo sapiens	150-154
12829999-9	2003	Furthermore, cells treated with 15d-PGJ(2) and troglitazone showed elevated expression of p53 and two p53-controlled downstream genes, GADD45 and p21(WAF1/Cip1).	15d-pgj	32-39	cyclin dependent kinase inhibitor 1A	Homo sapiens	155-159
12829999-10	2003	Dominant negative inhibition of p53 in SG231 cells significantly blocked the 15d-PGJ(2) and troglitazone-induced growth inhibition, G2/M arrest, and GADD45/p21 induction.	15d-pgj	77-84	tumor protein p53	Homo sapiens	32-35
12759491-3	2003	METHODS: We have studied the effect of 15d-PGJ(2) on the IFN-gamma-induced galectin-9 expression in human umbilical vein endothelial cells (HUVEC) in culture.	15d-pgj	39-46	interferon gamma	Homo sapiens	57-66
12759491-5	2003	15d-PGJ(2) partially inhibited IFN-gamma-induced phosphorylation of STAT-1 in HUVEC.	15d-pgj	0-7	interferon gamma	Homo sapiens	31-40
12734337-6	2003	Moreover, PGD(2) and 15d-PGJ(2) strongly reduce the secretion of the Th1 promoting cytokine IL-12 and affect the synthesis of chemokines involved in Th1 cell chemotaxis, particularly CXCL10.	15d-pgj	21-28	C-X-C motif chemokine ligand 10	Homo sapiens	183-189
12759491-3	2003	METHODS: We have studied the effect of 15d-PGJ(2) on the IFN-gamma-induced galectin-9 expression in human umbilical vein endothelial cells (HUVEC) in culture.	15d-pgj	39-46	galectin 9	Homo sapiens	75-85
12759491-5	2003	15d-PGJ(2) partially inhibited IFN-gamma-induced phosphorylation of STAT-1 in HUVEC.	15d-pgj	0-7	signal transducer and activator of transcription 1	Homo sapiens	68-74
12759491-4	2003	RESULTS: 15d-PGJ(2) inhibited the IFN-gamma-induced galectin-9 expression in a PPAR-gamma-independent manner, and also inhibited the adhesion of EoL-1 cells to an HUVEC monolayer treated with IFN-gamma.	15d-pgj	9-16	interferon gamma	Homo sapiens	34-43
12759491-4	2003	RESULTS: 15d-PGJ(2) inhibited the IFN-gamma-induced galectin-9 expression in a PPAR-gamma-independent manner, and also inhibited the adhesion of EoL-1 cells to an HUVEC monolayer treated with IFN-gamma.	15d-pgj	9-16	galectin 9	Homo sapiens	52-62
12759491-4	2003	RESULTS: 15d-PGJ(2) inhibited the IFN-gamma-induced galectin-9 expression in a PPAR-gamma-independent manner, and also inhibited the adhesion of EoL-1 cells to an HUVEC monolayer treated with IFN-gamma.	15d-pgj	9-16	peroxisome proliferator activated receptor gamma	Homo sapiens	79-89
12759491-4	2003	RESULTS: 15d-PGJ(2) inhibited the IFN-gamma-induced galectin-9 expression in a PPAR-gamma-independent manner, and also inhibited the adhesion of EoL-1 cells to an HUVEC monolayer treated with IFN-gamma.	15d-pgj	9-16	interferon gamma	Homo sapiens	192-201
12707336-6	2003	In this study we describe the effect of 15d-PGJ(2) on the activation of the fas-L gene in T lymphocytes.	15d-pgj	40-47	Fas ligand	Homo sapiens	76-81
12707336-9	2003	In addition, the activation/expression of the heat shock response genes HSF-1 and HSP70 is not directly involved in the repression, and the electrophilic molecule cyclopentenone (2-cyclopenten-1-one) may reproduce the effects mediated by 15d-PGJ(2).	15d-pgj	238-245	heat shock transcription factor 1	Homo sapiens	72-77
12584205-7	2003	15d-PGJ(2) and rosiglitazone rapidly induce the transcription of suppressor of cytokine signaling (SOCS) 1 and 3, which in turn inhibit JAK activity in activated glial cells.	15d-pgj	0-7	suppressor of cytokine signaling 1	Homo sapiens	65-112
12720296-4	2003	Moreover, 15d-PGJ(2) and PGA(1) activated the c-jun N-terminal kinase (JNK) and caspase-3 activity in dose- and time-dependent manners.	15d-pgj	10-17	mitogen-activated protein kinase 8	Homo sapiens	46-69
12720296-4	2003	Moreover, 15d-PGJ(2) and PGA(1) activated the c-jun N-terminal kinase (JNK) and caspase-3 activity in dose- and time-dependent manners.	15d-pgj	10-17	mitogen-activated protein kinase 8	Homo sapiens	71-74
12720296-4	2003	Moreover, 15d-PGJ(2) and PGA(1) activated the c-jun N-terminal kinase (JNK) and caspase-3 activity in dose- and time-dependent manners.	15d-pgj	10-17	caspase 3	Homo sapiens	80-89
12720296-6	2003	Overexpression of DN-JNK significantly repressed both endogenous JNK and caspase-3 activity, and subsequently decreased apoptosis induced by 15d-PGJ(2) and PGA(1).	15d-pgj	141-148	mitogen-activated protein kinase 8	Homo sapiens	21-24
12720296-7	2003	These results suggested that CyPGs, such as 15d-PGJ(2) and PGA(1), activated JNK signaling pathway, and that JNK activation may be involved in 15d-PGJ(2)- and PGA(1)-induced apoptosis.	15d-pgj	44-51	mitogen-activated protein kinase 8	Homo sapiens	77-80
12720296-7	2003	These results suggested that CyPGs, such as 15d-PGJ(2) and PGA(1), activated JNK signaling pathway, and that JNK activation may be involved in 15d-PGJ(2)- and PGA(1)-induced apoptosis.	15d-pgj	143-150	mitogen-activated protein kinase 8	Homo sapiens	109-112
12604364-6	2003	Stimulation of monocytes with LPS resulted in an 88% inhibition of PPAR-gamma mRNA expression that was fully restored by 15d-PGJ(2) but only to a partial extent by ciglitazone and WY-14,643.	15d-pgj	121-128	peroxisome proliferator activated receptor gamma	Homo sapiens	67-77
12435328-3	2002	The addition of 15d-PGJ(2) completely blocked (by 93%) the IL-1beta-induced PGE(2) synthesis, whereas COX-2 level was only partially reduced (by 72%).	15d-pgj	16-23	interleukin 1 beta	Homo sapiens	59-67
12566244-2	2003	We reported previously that staurosporine, cycloheximide, actinomycin D, as well as more physiological apoptotic agents (lactosylceramide, 15d-PGJ(2)) increase prostaglandin release in parallel with induction of apoptosis in WISH and amnion epithelial cells.	15d-pgj	139-146	NCK interacting protein with SH3 domain	Homo sapiens	225-229
12604364-4	2003	Treatment of cells with 15d-PGJ(2) (10 microM) was associated with a nearly complete inhibition of the expression of all genes that remained unaltered in the presence of the PPAR-gamma antagonist bisphenol A diglycidyl ether (BADGE; 100 microM).	15d-pgj	24-31	peroxisome proliferator activated receptor gamma	Homo sapiens	174-184
12598422-12	2003	15d-PGJ(2) also caused a substantial reduction of (i) the degree of colonic injury, (ii) the rise in myeloperoxidase (MPO) activity (mucosa), (iii) the increase in the tissue levels of malondialdehyde (MDA) and (iv) of the pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta).	15d-pgj	0-7	myeloperoxidase	Rattus norvegicus	101-116
12598422-12	2003	15d-PGJ(2) also caused a substantial reduction of (i) the degree of colonic injury, (ii) the rise in myeloperoxidase (MPO) activity (mucosa), (iii) the increase in the tissue levels of malondialdehyde (MDA) and (iv) of the pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta).	15d-pgj	0-7	myeloperoxidase	Rattus norvegicus	118-121
12598422-12	2003	15d-PGJ(2) also caused a substantial reduction of (i) the degree of colonic injury, (ii) the rise in myeloperoxidase (MPO) activity (mucosa), (iii) the increase in the tissue levels of malondialdehyde (MDA) and (iv) of the pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta).	15d-pgj	0-7	tumor necrosis factor	Rattus norvegicus	280-289
12598422-12	2003	15d-PGJ(2) also caused a substantial reduction of (i) the degree of colonic injury, (ii) the rise in myeloperoxidase (MPO) activity (mucosa), (iii) the increase in the tissue levels of malondialdehyde (MDA) and (iv) of the pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta).	15d-pgj	0-7	interleukin 1 beta	Rattus norvegicus	295-312
12598422-12	2003	15d-PGJ(2) also caused a substantial reduction of (i) the degree of colonic injury, (ii) the rise in myeloperoxidase (MPO) activity (mucosa), (iii) the increase in the tissue levels of malondialdehyde (MDA) and (iv) of the pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta).	15d-pgj	0-7	interleukin 1 beta	Rattus norvegicus	314-322
12598422-17	2003	Furthermore, 15d-PGJ(2) stimulates the activation of heat shock protein 72 (hsp72) in the inflamed colon, as assessed by Western blot analysis.	15d-pgj	13-20	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	76-81
14515149-9	2003	In contrast, 15d-PGJ(2) very potently inhibited the synthesis of uPA.	15d-pgj	13-20	plasminogen activator, urokinase	Homo sapiens	65-68
12455057-2	2003	The purpose of our study was to examine the relationship between COX-2 (with the resulting prostaglandins E(2), PGE(2)) and PPARgamma (and its natural endogenous ligand 15-Deoxy-Delta(12,14)-prostaglandin J(2), 15d-PGJ(2)) at various stages during the development of human breast cancer and its progression to metastasis.	15d-pgj	211-218	prostaglandin-endoperoxide synthase 2	Homo sapiens	65-70
12455057-2	2003	The purpose of our study was to examine the relationship between COX-2 (with the resulting prostaglandins E(2), PGE(2)) and PPARgamma (and its natural endogenous ligand 15-Deoxy-Delta(12,14)-prostaglandin J(2), 15d-PGJ(2)) at various stages during the development of human breast cancer and its progression to metastasis.	15d-pgj	211-218	peroxisome proliferator activated receptor gamma	Homo sapiens	124-133
12435328-5	2002	This study showed that the PPARgamma agonist, 15d-PGJ(2), exerts a dual effect on COX-2 production.	15d-pgj	46-53	peroxisome proliferator activated receptor gamma	Homo sapiens	27-36
12435328-5	2002	This study showed that the PPARgamma agonist, 15d-PGJ(2), exerts a dual effect on COX-2 production.	15d-pgj	46-53	prostaglandin-endoperoxide synthase 2	Homo sapiens	82-87
12237101-6	2002	Treatment with PGA(1) or 15d-PGJ(2) separately also reduced histamine release from KU812 cells in response to cross-linkage of Fc epsilon RI.	15d-pgj	25-32	Fc epsilon receptor Ia	Homo sapiens	127-140
12379230-3	2002	We hypothesized that 15d-PGJ(2) might affect PDGF expression in endothelial cells through activating PPARgamma.	15d-pgj	21-28	peroxisome proliferator activated receptor gamma	Homo sapiens	101-110
12364456-7	2002	Treatment of placental, amnion, and choriodecidual tissues with both 15d-PGJ(2) and troglitazone significantly reduced the release of lipopolysaccharide-stimulated IL-6, IL-8, and TNF-alpha (t test, P < 0.05).	15d-pgj	69-76	interleukin 6	Homo sapiens	164-168
12364456-7	2002	Treatment of placental, amnion, and choriodecidual tissues with both 15d-PGJ(2) and troglitazone significantly reduced the release of lipopolysaccharide-stimulated IL-6, IL-8, and TNF-alpha (t test, P < 0.05).	15d-pgj	69-76	C-X-C motif chemokine ligand 8	Homo sapiens	170-174
12364456-7	2002	Treatment of placental, amnion, and choriodecidual tissues with both 15d-PGJ(2) and troglitazone significantly reduced the release of lipopolysaccharide-stimulated IL-6, IL-8, and TNF-alpha (t test, P < 0.05).	15d-pgj	69-76	tumor necrosis factor	Homo sapiens	180-189
12237101-8	2002	Cells treated with 15d-PGJ(2) expressed lower levels of Fc epsilon RI alpha and gamma mRNA, and PGA(1) treatment decreased the level of Fc epsilon RI gamma mRNA.	15d-pgj	19-26	Fc epsilon receptor Ia	Homo sapiens	56-75
12237101-8	2002	Cells treated with 15d-PGJ(2) expressed lower levels of Fc epsilon RI alpha and gamma mRNA, and PGA(1) treatment decreased the level of Fc epsilon RI gamma mRNA.	15d-pgj	19-26	Fc epsilon receptor Ig	Homo sapiens	136-155
12230869-8	2002	Activation of HO-1 with hemin or ectopic overexpression of HO-1 in HMEC-1 perfectly mimicked the effect of 15d-PGJ(2) and led to increased VEGF production.	15d-pgj	107-114	heme oxygenase 1	Homo sapiens	14-18
12354750-4	2002	Treatment of MCF-7 cells with 15d-PGJ(2) leads to a rapid increase in the phosphorylation of protein synthesis initiation factor eukaryotic initiation factor 2alpha (eIF-2alpha) and a shift of cyclin D1 mRNA from the polysome-associated to free mRNA fraction, indicating that 15d-PGJ(2) inhibits the initiation of cyclin D1 mRNA translation.	15d-pgj	30-37	eukaryotic translation initiation factor 2A	Homo sapiens	166-176
12354750-4	2002	Treatment of MCF-7 cells with 15d-PGJ(2) leads to a rapid increase in the phosphorylation of protein synthesis initiation factor eukaryotic initiation factor 2alpha (eIF-2alpha) and a shift of cyclin D1 mRNA from the polysome-associated to free mRNA fraction, indicating that 15d-PGJ(2) inhibits the initiation of cyclin D1 mRNA translation.	15d-pgj	30-37	cyclin D1	Homo sapiens	193-202
12354750-4	2002	Treatment of MCF-7 cells with 15d-PGJ(2) leads to a rapid increase in the phosphorylation of protein synthesis initiation factor eukaryotic initiation factor 2alpha (eIF-2alpha) and a shift of cyclin D1 mRNA from the polysome-associated to free mRNA fraction, indicating that 15d-PGJ(2) inhibits the initiation of cyclin D1 mRNA translation.	15d-pgj	30-37	cyclin D1	Homo sapiens	314-323
12354750-8	2002	15d-PGJ(2) strongly stimulates eIF-2alpha phosphorylation and down-regulates cyclin D1 expression in a cell line derived from wild-type mouse embryo fibroblasts but has an attenuated effect in PKR-null cells, providing evidence that PKR is involved in mediating the effect of 15d-PGJ(2) on eIF-2alpha phosphorylation and cyclin D1 expression.	15d-pgj	0-7	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	31-41
12354750-8	2002	15d-PGJ(2) strongly stimulates eIF-2alpha phosphorylation and down-regulates cyclin D1 expression in a cell line derived from wild-type mouse embryo fibroblasts but has an attenuated effect in PKR-null cells, providing evidence that PKR is involved in mediating the effect of 15d-PGJ(2) on eIF-2alpha phosphorylation and cyclin D1 expression.	15d-pgj	0-7	cyclin D1	Mus musculus	77-86
12354750-8	2002	15d-PGJ(2) strongly stimulates eIF-2alpha phosphorylation and down-regulates cyclin D1 expression in a cell line derived from wild-type mouse embryo fibroblasts but has an attenuated effect in PKR-null cells, providing evidence that PKR is involved in mediating the effect of 15d-PGJ(2) on eIF-2alpha phosphorylation and cyclin D1 expression.	15d-pgj	0-7	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	193-196
12354750-8	2002	15d-PGJ(2) strongly stimulates eIF-2alpha phosphorylation and down-regulates cyclin D1 expression in a cell line derived from wild-type mouse embryo fibroblasts but has an attenuated effect in PKR-null cells, providing evidence that PKR is involved in mediating the effect of 15d-PGJ(2) on eIF-2alpha phosphorylation and cyclin D1 expression.	15d-pgj	0-7	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	233-236
12354750-8	2002	15d-PGJ(2) strongly stimulates eIF-2alpha phosphorylation and down-regulates cyclin D1 expression in a cell line derived from wild-type mouse embryo fibroblasts but has an attenuated effect in PKR-null cells, providing evidence that PKR is involved in mediating the effect of 15d-PGJ(2) on eIF-2alpha phosphorylation and cyclin D1 expression.	15d-pgj	0-7	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	290-300
12354750-8	2002	15d-PGJ(2) strongly stimulates eIF-2alpha phosphorylation and down-regulates cyclin D1 expression in a cell line derived from wild-type mouse embryo fibroblasts but has an attenuated effect in PKR-null cells, providing evidence that PKR is involved in mediating the effect of 15d-PGJ(2) on eIF-2alpha phosphorylation and cyclin D1 expression.	15d-pgj	0-7	cyclin D1	Mus musculus	321-330
12202119-7	2002	PPAR agonists 15d-PGJ(2) and GI262570 (10 microM) inhibited IL-1beta- and TNFalpha-induced proteoglycan degradation measured both before and after addition of APMA.	15d-pgj	14-21	peroxisome proliferator activated receptor alpha	Rattus norvegicus	0-4
12202119-7	2002	PPAR agonists 15d-PGJ(2) and GI262570 (10 microM) inhibited IL-1beta- and TNFalpha-induced proteoglycan degradation measured both before and after addition of APMA.	15d-pgj	14-21	interleukin 1 beta	Rattus norvegicus	60-68
12202119-7	2002	PPAR agonists 15d-PGJ(2) and GI262570 (10 microM) inhibited IL-1beta- and TNFalpha-induced proteoglycan degradation measured both before and after addition of APMA.	15d-pgj	14-21	tumor necrosis factor	Rattus norvegicus	74-82
12230869-8	2002	Activation of HO-1 with hemin or ectopic overexpression of HO-1 in HMEC-1 perfectly mimicked the effect of 15d-PGJ(2) and led to increased VEGF production.	15d-pgj	107-114	heme oxygenase 1	Homo sapiens	59-63
12230869-9	2002	Importantly, the inhibition of the HO-1 pathway by tin protoporphyrin-IX significantly reduced the stimulatory effect of 15d-PGJ(2) on VEGF synthesis.	15d-pgj	121-128	heme oxygenase 1	Homo sapiens	35-39
12230869-9	2002	Importantly, the inhibition of the HO-1 pathway by tin protoporphyrin-IX significantly reduced the stimulatory effect of 15d-PGJ(2) on VEGF synthesis.	15d-pgj	121-128	vascular endothelial growth factor A	Homo sapiens	135-139
12006176-7	2002	Similarly, a dominant-negative mutant of Nrf2, but not of c-Jun or c-Fos, abrogated 15d-PGJ(2)-stimulated E1 transcription activity.	15d-pgj	84-91	nuclear factor, erythroid derived 2, like 2	Mus musculus	41-45
12150985-6	2002	We also demonstrated that 1 microM 15d-PGJ(2) was able to suppress the IL-4-induced phosphorylation of the Signal Transducer and Activator of Transcription 6 (STAT6), which is a transcription factor essential for epsilon GT expression.	15d-pgj	35-42	interleukin 4	Homo sapiens	71-75
12150985-6	2002	We also demonstrated that 1 microM 15d-PGJ(2) was able to suppress the IL-4-induced phosphorylation of the Signal Transducer and Activator of Transcription 6 (STAT6), which is a transcription factor essential for epsilon GT expression.	15d-pgj	35-42	signal transducer and activator of transcription 6	Homo sapiens	107-157
12150985-6	2002	We also demonstrated that 1 microM 15d-PGJ(2) was able to suppress the IL-4-induced phosphorylation of the Signal Transducer and Activator of Transcription 6 (STAT6), which is a transcription factor essential for epsilon GT expression.	15d-pgj	35-42	signal transducer and activator of transcription 6	Homo sapiens	159-164
12150985-7	2002	Therefore, the suppression of STAT6 phosphorylation by 15d-PGJ(2) is thought to participate in the inhibition of epsilon GT expression.	15d-pgj	55-62	signal transducer and activator of transcription 6	Homo sapiens	30-35
12031542-5	2002	PPAR-gamma agonists such as 15d-PGJ(2), ciglitazone and troglitazone prevented LPS-induced neuronal death and abolished LPS-induced NO and PGE(2) release, however PPAR-alpha agonists such as clofibrate and WY14,643 did not produce the same results.	15d-pgj	28-35	peroxisome proliferator activated receptor gamma	Homo sapiens	0-10
12031542-5	2002	PPAR-gamma agonists such as 15d-PGJ(2), ciglitazone and troglitazone prevented LPS-induced neuronal death and abolished LPS-induced NO and PGE(2) release, however PPAR-alpha agonists such as clofibrate and WY14,643 did not produce the same results.	15d-pgj	28-35	peroxisome proliferator activated receptor alpha	Homo sapiens	163-173
11971025-7	2002	15d-PGJ(2) suppressed COX-2 induction in human astrocytes.	15d-pgj	0-7	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-27
11890746-7	2002	15d-PGJ(2) 10(-5)M inhibits cNOS and iNOS activity both in control and diabetic islets (P < 0.05).	15d-pgj	0-7	nitric oxide synthase 3	Rattus norvegicus	28-32
11786541-7	2002	In addition, the immunostaining of lipopolysaccharide-stimulated RAW264.7 macrophages with mAb11G2 demonstrated an enhanced intracellular accumulation of 15d-PGJ(2), suggesting that the PGD(2) metabolic pathway, generating the anti-inflammatory PGs, is indeed utilized in the cells during inflammation.	15d-pgj	154-161	phosphoglycerate dehydrogenase	Homo sapiens	186-189
11786541-8	2002	The activation of macrophages also resulted in the extracellular production of PGD(2), which was associated with a significant increase in the extracellular 15d-PGJ(2) levels, and the extracellular 15d-PGJ(2) production was reproduced by incubating PGD(2) in a cell-free medium and in phosphate-buffered saline.	15d-pgj	157-164	phosphoglycerate dehydrogenase	Homo sapiens	79-82
11786541-8	2002	The activation of macrophages also resulted in the extracellular production of PGD(2), which was associated with a significant increase in the extracellular 15d-PGJ(2) levels, and the extracellular 15d-PGJ(2) production was reproduced by incubating PGD(2) in a cell-free medium and in phosphate-buffered saline.	15d-pgj	198-205	phosphoglycerate dehydrogenase	Homo sapiens	79-82
11786541-8	2002	The activation of macrophages also resulted in the extracellular production of PGD(2), which was associated with a significant increase in the extracellular 15d-PGJ(2) levels, and the extracellular 15d-PGJ(2) production was reproduced by incubating PGD(2) in a cell-free medium and in phosphate-buffered saline.	15d-pgj	198-205	phosphoglycerate dehydrogenase	Homo sapiens	249-252
11890746-7	2002	15d-PGJ(2) 10(-5)M inhibits cNOS and iNOS activity both in control and diabetic islets (P < 0.05).	15d-pgj	0-7	nitric oxide synthase 2	Rattus norvegicus	37-41
11869069-7	2002	PPARgamma activators (15d-PGJ(2) and BRL 49653) inhibited IL-1beta-induced MMP-1 synthesis in a dose-dependent manner.	15d-pgj	22-29	peroxisome proliferator activated receptor gamma	Homo sapiens	0-9
11869069-7	2002	PPARgamma activators (15d-PGJ(2) and BRL 49653) inhibited IL-1beta-induced MMP-1 synthesis in a dose-dependent manner.	15d-pgj	22-29	interleukin 1 beta	Homo sapiens	58-66
11869069-7	2002	PPARgamma activators (15d-PGJ(2) and BRL 49653) inhibited IL-1beta-induced MMP-1 synthesis in a dose-dependent manner.	15d-pgj	22-29	matrix metallopeptidase 1	Homo sapiens	75-80
11742805-8	2002	15d-PGJ(2) and troglitazone modulated the expression of LPS-induced iNOS, COX-2, and proinflammatory cytokines differently.	15d-pgj	0-7	nitric oxide synthase 2	Rattus norvegicus	68-72
11869069-9	2002	Activation of the human MMP-1 promoter was also attenuated by 15d-PGJ(2), indicating that the inhibitory effect of 15d-PGJ(2) occurs at the transcriptional level.	15d-pgj	62-69	matrix metallopeptidase 1	Homo sapiens	24-29
11869069-9	2002	Activation of the human MMP-1 promoter was also attenuated by 15d-PGJ(2), indicating that the inhibitory effect of 15d-PGJ(2) occurs at the transcriptional level.	15d-pgj	115-122	matrix metallopeptidase 1	Homo sapiens	24-29
11869069-10	2002	Interestingly, 15d-PGJ(2) reduced both basal and IL-1beta-induced AP-1 binding activity.	15d-pgj	15-22	interleukin 1 beta	Homo sapiens	49-57
11869069-10	2002	Interestingly, 15d-PGJ(2) reduced both basal and IL-1beta-induced AP-1 binding activity.	15d-pgj	15-22	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-70
11742805-8	2002	15d-PGJ(2) and troglitazone modulated the expression of LPS-induced iNOS, COX-2, and proinflammatory cytokines differently.	15d-pgj	0-7	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	74-79
11466314-6	2001	The covalent modification of p50 by 15d-PGJ(2) was demonstrated by reverse-phase high pressure liquid chromatography and mass spectrometry analysis that showed an increase in retention time and in the molecular mass of 15d-PGJ(2)-treated p50, respectively.	15d-pgj	36-43	nuclear factor kappa B subunit 1	Homo sapiens	29-32
11581147-7	2001	An increase in [(3)H]leucine uptake induced by angiotensin II or phenylephrine was significantly inhibited by troglitazone and 15d-PGJ(2).	15d-pgj	127-134	angiotensinogen	Rattus norvegicus	47-61
11712859-6	2001	Both troglitazone and 15d-PGJ(2)markedly inhibited TNF-alpha-induced NF-kappaB activation at 30 microM.	15d-pgj	22-29	tumor necrosis factor	Homo sapiens	51-60
11466314-6	2001	The covalent modification of p50 by 15d-PGJ(2) was demonstrated by reverse-phase high pressure liquid chromatography and mass spectrometry analysis that showed an increase in retention time and in the molecular mass of 15d-PGJ(2)-treated p50, respectively.	15d-pgj	36-43	nuclear factor kappa B subunit 1	Homo sapiens	238-241
11466314-8	2001	15d-PGJ(2) effectively inhibited cytokine-elicited NF-kappaB activity in HeLa without reducing IkappaBalpha degradation or nuclear translocation of NF-kappaB subunits.	15d-pgj	0-7	nuclear factor kappa B subunit 1	Homo sapiens	51-60
11466314-9	2001	15d-PGJ(2) reduced NF-kappaB DNA binding activity in isolated nuclear extracts, suggesting a direct effect on NF-kappaB proteins.	15d-pgj	0-7	nuclear factor kappa B subunit 1	Homo sapiens	19-28
11466314-9	2001	15d-PGJ(2) reduced NF-kappaB DNA binding activity in isolated nuclear extracts, suggesting a direct effect on NF-kappaB proteins.	15d-pgj	0-7	nuclear factor kappa B subunit 1	Homo sapiens	110-119
10999955-5	2000	15d-PGJ(2) was found to inhibit the phosphatidylinositol 3-kinase/protein kinase B signaling pathway, which mediates cyclin D1 expression.	15d-pgj	0-7	cyclin D1	Homo sapiens	117-126
11511093-5	2001	LOX-1 expression induced by phorbol 12-myristrate 13-acetate was also inhibited by 15d-PGJ(2).	15d-pgj	83-90	oxidized low density lipoprotein receptor 1	Bos taurus	0-5
11287611-6	2001	Herein PPARgamma, liganded by either natural (15d-PGJ(2) and PGD(2)) or synthetic ligands (BRL49653 and troglitazone), selectively inhibited expression of the cyclin D1 gene.	15d-pgj	46-53	peroxisome proliferator activated receptor gamma	Homo sapiens	7-16
11287611-7	2001	The inhibition of S-phase entry and activity of the cyclin D1-dependent serine-threonine kinase (Cdk) by 15d-PGJ(2) was not observed in PPARgamma-deficient cells.	15d-pgj	105-112	cyclin D1	Homo sapiens	52-61
11287611-8	2001	Cyclin D1 overexpression reversed the S-phase inhibition by 15d-PGJ(2).	15d-pgj	60-67	cyclin D1	Homo sapiens	0-9
11287611-11	2001	15d-PGJ(2) enhanced recruitment of p300 to PPARgamma but reduced binding to c-Fos.	15d-pgj	0-7	E1A binding protein p300	Homo sapiens	35-39
11287611-11	2001	15d-PGJ(2) enhanced recruitment of p300 to PPARgamma but reduced binding to c-Fos.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	43-52
11287611-11	2001	15d-PGJ(2) enhanced recruitment of p300 to PPARgamma but reduced binding to c-Fos.	15d-pgj	0-7	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	76-81
10903334-8	2000	These findings suggest that PPAR-gamma may be an important immunoinflammatory mediator and its ligands, especially 15d-PGJ(2), may be useful in the treatment of RA.	15d-pgj	115-122	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	28-38
10873632-7	2000	Prostaglandin E(1) (PGE(1)) and 15-deoxy-Delta(12,14)-PGJ(2) (a potent PPARgamma ligand, 15d-PGJ(2)) dramatically increased VEGF production.	15d-pgj	89-96	peroxisome proliferator activated receptor gamma	Homo sapiens	71-80
10873632-7	2000	Prostaglandin E(1) (PGE(1)) and 15-deoxy-Delta(12,14)-PGJ(2) (a potent PPARgamma ligand, 15d-PGJ(2)) dramatically increased VEGF production.	15d-pgj	89-96	vascular endothelial growth factor A	Homo sapiens	124-128
10873632-8	2000	The combination of PGE(1) and 15d-PGJ(2) additively increased VEGF production.	15d-pgj	30-37	vascular endothelial growth factor A	Homo sapiens	62-66
10873632-11	2000	Unexpectedly, 15d-PGJ(2) also drastically increased IL-1beta production, an indicator of macrophage activation, although PGE(1) only mildly increased it.	15d-pgj	14-21	interleukin 1 beta	Homo sapiens	52-60
10873632-12	2000	Additional enhancement of IL-1beta production was observed in the combination of PGE(1) and 15d-PGJ(2).	15d-pgj	92-99	interleukin 1 beta	Homo sapiens	26-34
10827178-4	2000	Here, we show that 15d-PGJ(2) suppresses the lipopolysaccharide (LPS)-induced expression of COX-2 in the macrophage-like differentiated U937 cells but not in vascular endothelial cells.	15d-pgj	19-26	prostaglandin-endoperoxide synthase 2	Homo sapiens	92-97
10801895-9	2000	15d-PGJ(2) and PD98059 inhibited both the degradation of p27(kip1) and the induction of cyclin D1 in response to mitogens.	15d-pgj	0-7	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	57-60
10801895-9	2000	15d-PGJ(2) and PD98059 inhibited both the degradation of p27(kip1) and the induction of cyclin D1 in response to mitogens.	15d-pgj	0-7	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	61-65
10801895-9	2000	15d-PGJ(2) and PD98059 inhibited both the degradation of p27(kip1) and the induction of cyclin D1 in response to mitogens.	15d-pgj	0-7	cyclin D1	Rattus norvegicus	88-97
10837804-7	2000	Concomitantly, 15d-PGJ(2) itself up-regulates the production of the antioxidant enzyme heme oxygenase-1 (HO-1) and increases intracellular total glutathione levels.	15d-pgj	15-22	heme oxygenase 1	Mus musculus	87-103
10837804-6	2000	We report here that in addition to suppressing iNOS production, 15d-PGJ(2) also decreases the production of tumor necrosis factor alpha (TNFalpha), interleukin-1 beta (IL-1beta) and cyclooxygenase-2 (COX-2) in LPS-stimulated BV-2 microglial cells, thereby acting as a general inhibitor of microglial activation.	15d-pgj	64-71	nitric oxide synthase 2, inducible	Mus musculus	47-51
10837804-7	2000	Concomitantly, 15d-PGJ(2) itself up-regulates the production of the antioxidant enzyme heme oxygenase-1 (HO-1) and increases intracellular total glutathione levels.	15d-pgj	15-22	heme oxygenase 1	Mus musculus	105-109
10837804-6	2000	We report here that in addition to suppressing iNOS production, 15d-PGJ(2) also decreases the production of tumor necrosis factor alpha (TNFalpha), interleukin-1 beta (IL-1beta) and cyclooxygenase-2 (COX-2) in LPS-stimulated BV-2 microglial cells, thereby acting as a general inhibitor of microglial activation.	15d-pgj	64-71	tumor necrosis factor	Mus musculus	108-135
10837804-10	2000	These results suggest that HO-1 upregulation by 15d-PGJ(2) is not the primary pathway responsible for the anti-inflammatory action of 15d-PGJ(2) in microglial cells.	15d-pgj	48-55	heme oxygenase 1	Mus musculus	27-31
10837804-6	2000	We report here that in addition to suppressing iNOS production, 15d-PGJ(2) also decreases the production of tumor necrosis factor alpha (TNFalpha), interleukin-1 beta (IL-1beta) and cyclooxygenase-2 (COX-2) in LPS-stimulated BV-2 microglial cells, thereby acting as a general inhibitor of microglial activation.	15d-pgj	64-71	tumor necrosis factor	Mus musculus	137-145
10781090-2	2000	15d-PGJ(2) is a high-affinity ligand for the peroxisome proliferator-activated receptor gamma (PPARgamma) and has been demonstrated to inhibit the induction of inflammatory response genes, including inducible NO synthase and tumor necrosis factor alpha, in a PPARgamma-dependent manner.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	45-93
10837804-6	2000	We report here that in addition to suppressing iNOS production, 15d-PGJ(2) also decreases the production of tumor necrosis factor alpha (TNFalpha), interleukin-1 beta (IL-1beta) and cyclooxygenase-2 (COX-2) in LPS-stimulated BV-2 microglial cells, thereby acting as a general inhibitor of microglial activation.	15d-pgj	64-71	interleukin 1 beta	Mus musculus	148-166
10837804-6	2000	We report here that in addition to suppressing iNOS production, 15d-PGJ(2) also decreases the production of tumor necrosis factor alpha (TNFalpha), interleukin-1 beta (IL-1beta) and cyclooxygenase-2 (COX-2) in LPS-stimulated BV-2 microglial cells, thereby acting as a general inhibitor of microglial activation.	15d-pgj	64-71	interleukin 1 beta	Mus musculus	168-176
10837804-6	2000	We report here that in addition to suppressing iNOS production, 15d-PGJ(2) also decreases the production of tumor necrosis factor alpha (TNFalpha), interleukin-1 beta (IL-1beta) and cyclooxygenase-2 (COX-2) in LPS-stimulated BV-2 microglial cells, thereby acting as a general inhibitor of microglial activation.	15d-pgj	64-71	prostaglandin-endoperoxide synthase 2	Mus musculus	182-198
10837804-6	2000	We report here that in addition to suppressing iNOS production, 15d-PGJ(2) also decreases the production of tumor necrosis factor alpha (TNFalpha), interleukin-1 beta (IL-1beta) and cyclooxygenase-2 (COX-2) in LPS-stimulated BV-2 microglial cells, thereby acting as a general inhibitor of microglial activation.	15d-pgj	64-71	prostaglandin-endoperoxide synthase 2	Mus musculus	200-205
10787429-8	2000	PKC inhibitors reduced basal expression of CD36 and blocked induction of CD36 mRNA by 15d-PGJ(2), OxLDL and IL-4.	15d-pgj	86-93	protein kinase C alpha	Homo sapiens	0-3
10807869-8	2000	In parallel with the increase in the expression level of L-PGDS, endothelial cells released PGD(2) and 15d-PGJ(2) into culture medium.	15d-pgj	103-110	prostaglandin D2 synthase	Homo sapiens	57-63
10781090-2	2000	15d-PGJ(2) is a high-affinity ligand for the peroxisome proliferator-activated receptor gamma (PPARgamma) and has been demonstrated to inhibit the induction of inflammatory response genes, including inducible NO synthase and tumor necrosis factor alpha, in a PPARgamma-dependent manner.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	95-104
10781090-2	2000	15d-PGJ(2) is a high-affinity ligand for the peroxisome proliferator-activated receptor gamma (PPARgamma) and has been demonstrated to inhibit the induction of inflammatory response genes, including inducible NO synthase and tumor necrosis factor alpha, in a PPARgamma-dependent manner.	15d-pgj	0-7	nitric oxide synthase 2	Homo sapiens	199-220
10781090-2	2000	15d-PGJ(2) is a high-affinity ligand for the peroxisome proliferator-activated receptor gamma (PPARgamma) and has been demonstrated to inhibit the induction of inflammatory response genes, including inducible NO synthase and tumor necrosis factor alpha, in a PPARgamma-dependent manner.	15d-pgj	0-7	tumor necrosis factor	Homo sapiens	225-252
10781090-2	2000	15d-PGJ(2) is a high-affinity ligand for the peroxisome proliferator-activated receptor gamma (PPARgamma) and has been demonstrated to inhibit the induction of inflammatory response genes, including inducible NO synthase and tumor necrosis factor alpha, in a PPARgamma-dependent manner.	15d-pgj	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	259-268
10781090-3	2000	We report here that 15d-PGJ(2) potently inhibits NF-kappaB-dependent transcription by two additional PPARgamma-independent mechanisms.	15d-pgj	20-27	peroxisome proliferator activated receptor gamma	Homo sapiens	101-110